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Chapter I Introduction 
Introduction 
1.1 Steroid Hormones 
Endocrinology is the science, which describes how cells communicate via the sending of 
chemical messengers termed hormones. There are three classes of hormones based on 
their chemical structure: peptide or protein hormones, steroid hormones and amino acid- 
related hormones. 
There are six families of steroid hormones. They are oestrogens, androgens, progestins, - 
mineralocorticoids, glucocorticoids and vitamin D. Bile acids are structurally related to 
cholesterol and therefore constitute a seventh member of the steroid family. All of these 
steroids are derived from cholesterol. 
Figure M: Structure of Cholesterol 
Cholestane the fully saturated ring structure of cholesterol gives rise to the parent ring 
structures of mammalian steroid hormones oestrane, androstane, pregnane and cholane. 
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The principal tissues of synthesis of the five classical steroid hormones (oestrogens, 
androgens, progestins, glucocorticoids and mineralocorticoids) are the adrenal cortex, 
ovaries and the testis. The metabolic pathway for the conversion of cholesterol into 
steroid hormones is outlined below. 
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Figure 1.2: Steroid Metabolism 
The critical step in the formation of steroids is the conversion of cholesterol to 
pregnenolone, which is under control of adrenocorticotrophin hormone (ACTM in the 
adrenal and luteinising hormone in the gonads. Pregnenolone can either be converted to 
progesterone and via this intermediate to glucocorticoids, androgens or oestrogens. 
Alternatively 17-hydroxyprogesterone is formed from pregnenolone. This constitutes an 
alternative pathway formation of androgens or oestrogens (Norman et al. 1997). 
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The estrogens are 18-carbon steroids produced in the ovaries and fetal-placental unit. 
Oestrone and oestradiol are also produced from androstenedione, and testosterone 
respectively in adipose tissue, muscle and breast turnours by the cytochrome p450 
aromatase enzymes. 
The adrenal cortex is divided into three zones that produce the different classes of the 
adrenal steroids. These are the zona glomerulosa (mineralocorticoids), zonafasciculata 
(glucocorticoids) and zona reticularis (androgens). 
The androgens are all steroids with 19 carbons. The major naturally occurring steroids 
with androgenic activity are Rx -dihydrotestosterone (5cc-DHT), testosterone, 5- 
androstene-30,170-diol (Adiol), androstenedione, dehydroepiandrosterone sulphate 
(DIHEAS) and dehydroepiandrosterone (DHEA) . 
1.2 Androgen receptor structure and functional domains 
The androgen receptor is a member of the nuclear receptor superfamily of transcription 
factors. These proteins act as transcription factors in many different species and can be 
classified according to the type of ligand they bind: steroids (glucocorticoids, progestins, 
mineralocorticoids, androgens and oestrogens), steroid derivatives (vitamin D3) or non- 
steroids (thyroid hormones, retinoids, prostoglandins) (Tenbaum et aL 1997). 
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Nuclear receptors are related in structure and organization of their functional domains. 
They contain a highly conserved DNA binding region, a variable amino (N-) terminal and 
conserved carboxy (C-) terminal, suggesting that nuclear receptors are derived from a 
common ancestral form (Parker 1993). 
Andrggen receptor functional domains 
NB CD E/F 
NH2 COOH 
DNA binding 
E-- -_--) 
Ligand binding 
Dimerisation Dimedsation 
AH AF5 AF2 
Nudear localisation 
HSP 90 
I-- 
Figure 1.3: Androgen receptor functional domains 
The highly conserved DNA binding domain is rich in cysteme residues and contains the 
zinc-finger motif required for binding to hormone response elements in target genes 
(Evans et al. 1988). This region also contains sequences responsible for dimerisation. 
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The C-terminus contains the hormone binding domain and amino acid residues 
responsible for interaction with the 90kD heat shock protein Hsp90 (Pratt et al. 1988) and 
a region involved in hormone dependent nuclear translocation of the androgen receptor 
(Picard et al. 1987). 
In their inactive state, steroid hormone receptors are bound to chaperon proteins such as 
Hsp90, which maintain them in a conformation where ligand binding can occur. 
Following ligand binding dissociation from Hsp90 and dimerisation occurs allowing the 
ligand-bound receptor to bind to promoter and enhancer sequences in target genes. 
Ligand 
Cell membrane 
Ligand binding 
and dissociation 
Hsp90 trom hsp90 
Dimeriscrfion 
DNA 
T ipti binding ranscr on 
Target gene 
Figure 1.4: Ligand dependent activation of the androgen receptor 
The involvement of additional trans-activation domains located on the C-terminus and N- 
terminus are required for full transcriptional activity of the steroid receptor. The trans- 
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activation function 2 (AF2) located on the C-terminus is activated on binding of ligand 
(Kumar el aL 1987). Point mutations in the AF2 domain have no effect on the binding of 
ligand, dimerisation or DNA-binding but abolish transcriptional activation. 
Another trans-activation function AM is located on the N-terminus and is essential for 
transactivation activity in the full-length receptor (Jenster et aL 199 1). More recently a 
third trans-activation function AF5, which is involved in the transactivation capacity of 
the constitutively active C-terininus truncated androgen receptor has been identified on 
the N-tenninus (Jenster et al. 1995). 
Recent evidence suggests an interaction between the ligand binding domain of the C- 
terminus and the AF functions of the N-terminus. By this mechanism the trans-activation 
function AF I is inhibited by the ligand-binding domain in the absence of ligand and the 
trans-activation function AF5 is inhibited by the ligand-binding domain in the presence of 
ligand (Brinkman 1999). 
1.3 Androgen receptor is a ligand-dependent transcription factor 
The trans-activation domains of the androgen receptor interact with components of the 
basal transcription complex to initiate transcription. The basal transcription complex is 
composed of RNA polymerase 11 and various transcriptional factors such as TFIIB and 
TFIID, which assemble at the gene promoter and are essential for transcription to occur 
(Latchman 1997). It has become apparent, more recently, that another layer of proteins 
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called co-activators and co-repressors regulate transcriptional activity of honnone 
receptors by interacting with the basal transcriptional complex and the trans-activation 
function AF2 on the C-terminus of the hormone receptor. 
The observations that steroid receptors could interfere with each other's function (Meyer 
et aL 1989) and possess a conserved region required for ligand-dependent transcriptional 
activity provided initial evidence of the existence of coactivator proteins that mediate 
AF2 function. 
A large number of co-activator proteins have now been identified. Two families of co- 
activators are paramount in terms of ability to potentiate transcriptional activity of the 
nuclear receptor: the p 160 family of co-activators including steroid receptor co-activator 
I/ nuclear receptor co-activator I (SRCI/N-CoAl), p300/CBP co-integrator associate 
protein/ amplified in breast cancer I (p/CIF/AIB I) and transcriptional intermediary factor 
2/ glucocorticoid receptor interacting protein I (TIF2/GRIPI) and the CREB binding 
protein/p300 (CBP/p300) fwnily (Glass et aL 1997). 
Studies demonstrated that overexpression of SRCl/N-CoAI stimulated the transcriptional 
activities of steroid hormone receptors in response to their ligands (Onate et aL 1995). 
Subsequently, further proteins termed TIF2/GRIPI and p/CIF/AIB I, highly homologous 
to SRCI/N-CoAl were identified with a similar ability to potentiate the transcriptional 
activity of steroid hormone receptors (Voegel et aL 1996) (Anzick et aL 1997). 
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Overexpression of CBPJp300 also potentiates ligand-dependent transcriptional responses 
of nuclear receptors (Kamei et aL 1996). The CBP/p300 family of co-activators has been 
shown to act as essential co-activators for a large number of transcription factors 
including steroid receptors. It has been postulated that CBP/p300 may therefore act as an 
integrator of multiple signal transduction pathways, and competition for CBP/p300 may 
serve as a mechanism for antagonistic interactions between signaling pathways (Glass et 
aL 1997). 
Shang et al have proposed the formation of an androgen receptor transcription complex in 
which agonist-bound androgen receptors, bound to promoter and enhancer DNA 
sequences, are linked by a coactivator complex containing p 160 proteins, CBP/p300 and 
p300/CBP associated factor (pCAF) to the basal transcription machinery (Shang et aL 
2002). PCAF is a coactivator known to possess separate sites for interaction with nuclear 
receptors, p160 proteins and CBPJp300 (Blanco et aL 1998). By this mechanism enhancer 
and promoter sequences are brought in close proximity, and communication occurs 
between enhancer and promoter via the coactivator complex. 
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Androaen rece or transcdotion con-plex 
Enhancer 
DNA 
AR 
PI 60 
CBP/p 300 
P160 TFIIB 
Promoter 
AR ý A, agonist bound androgen receptor :p 160 
CBPjp 300 coactivator complex : RNA potyn-erase 
TAID TFIIB basal transcription machinery 
Figure 1.5: Coactivator Complex 
A large number of nuclear hormone receptor coactivators that do not form part of this 
pl60/p3OO/CBP/pCAF complex have now been identified including BRCAI (Park el al. 
2000), ARA70 (Yeh et al. 1996) and TIP60 (Brady et al. 1999). The roles of these 
proteins are unknown. It has been postulated that they may be specifically required for 
different target genes; they may be restricted to certain tissues or they may be selectively 
involved in some but not all, nuclear receptors. 
In addition to proteins, which interact with nuclear receptors to enhance transcription, 
proteins, terined corepressors, have been discovered which repress transcription. Nuclear 
receptor corepressor (NcoR) and silencing mediator of retinold and thyroid hormone 
receptor (SMRT) were originally identified to interact With retinoic acid and thyroid 
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hormone receptors in the inactive state (Chen et aL 1995). Subsequently it has been found 
that they are recruited by antagonist bound oestrogen receptors (Lavinsky et al. 1998). 
Chromatin structure presents a physical obstacle for gene transcription, presumably by 
limiting the access of transcription factors and RNA polymerase Il to the target DNA 
(Struht 1998). Nuclear receptors modulate transcription via alterations in the state of 
chromatin structure at the promoter of target genes (Lemon et aL 1999). Histone 
acetylation results in decreased affinity between histone subunits and DNA and correlates 
with transcriptional activity. It has been found that coactivator proteins have histone 
acetylase (HAT) activity and corepressors have histone deacetylase (HDAQ activity. The 
balance between histone acetylation and deacetylation determines the outcome of ligand 
binding to nuclear receptor. Ligands act as switches to recruit HATs with the dismissal of 
HDACs (Xu et aL 1999). 
A mechanism of ligand-dependent transcriptional activation can therefore be proposed. In 
the absence of ligand, steroid hormone receptors exist as inactive complexes with 
chaperone proteins such as Hsp90. Following hormone binding the complex dissociates, 
dimerisation occurs and the hormone receptor acts as a transcription factor by binding to 
DNA in the vicinity of target genes. Transcription is mediated by interaction of the trans- 
activation functions with the basal transcription complex. This process is modulated co- 
activator and co-repressor proteins, which act by adding or removing acetyl groups to 
chromatin, thereby altering the accessibility of target DNA to transcriptional factors and 
RNA polymerase. 
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1.4 Androgen receptor expression in breast cancer 
Although measurement of oestrogen receptor is well established as prognostic and 
predictive factors in the management of breast cancer (Hawkins et aL 1980) the role of 
androgen receptors is less well defined. 
Early studies measuring androgen receptor expression in breast cancer used ligand- 
binding assays. Androgen receptor expression was reported as being 35% (Miller et aL 
1985), 84% (Lea el aL 1989) and 9 1.1 % (Soreide et al. 1992). However, ligand-binding 
assays had technical limitations and did not provide any information about cellular 
distribution of the receptor. 
More recently, following development of a monoclonal antibody to AR, 
immunohistochemical studies have been described and androgen receptors were reported 
to be present in 76% (Kuenen-Boumeester et al. 1996) (Kuenen-Boumeester et aL 1992) 
and 79% (Isola 1993). Indeed androgen receptor is reported as the most frequently 
expressed steroid receptor in breast cancer (Lea et al. 1989). 
Kuenen-Boulmeester et al reported that 53% of breast cancers expressed AR, ER and PR 
(Kuenen-Boumeester et aL 1992). Several other groups have also found a significant 
association between AR and ER, PR expression in breast cancer (Lea et al. 1989) (Isola 
1993) (Soreide et aL 1992). Only one study did not find any correlation between 
androgen receptor and oestrogen receptor expression, though they did report a correlation 
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between androgen receptor and progesterone receptor levels in breast cancer (Langer et 
al. 1990). 
Whereas several studies have investigated the level of androgen receptor expression in 
breast cancer, none have hitherto looked at the variability of androgen receptor 
expression within individual turnours. However, androgen receptor, expressed as the sole 
hormone receptor, has been reported to occur 9% of breast cancers (Kuenen-Boumeester 
et aL 1992) and is better preserved during the process of metastasis than either oestrogen 
or progesterone receptor expression. Lea et al found that androgen receptors were present 
in 76% of metastatic breast cancer compared to 86% of primary breast tumours, and that 
25% of metastatic breast cancers have the AR+ER-PR- phenotype (Lea et aL 1989). In a 
multi-step model for the progression of breast cancer from a hormone-sensitive 
ER+PR+AR+ phenotype to a hormone-insensitive ER-PR-AR- phenotype, androgen 
receptor appears to be the last receptor to be lost. 
In a study of 1026 patients with primary and recurrent breast cancer Lea et al found that 
androgen receptor concentration increased with age of the patient (Lea et al. 1989). 
Oestrogen receptor expression in breast cancer similarly increases with age of the patient. 
This is presumably an adaptation by up-regulation of the receptor apparatus to declining 
supply of circulating sex steroids found in postmenopausal women. 
Several lines of evidence suggest that androgen receptor expression is a marker of good 
prognosis in breast cancer. In a large study of 1371 women with primary and recurrent 
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breast cancer, Bryan et al reported that patients with androgen receptor negative tumours 
had a significantly poorer response to hornional therapy and a significant trend towards 
shorter overall survival, than those with androgen receptor-positive tumors (Bryan et al. 
1984). Furthermore, androgen receptor expression was an independent prognostic factor 
for response to hormonal therapy and survival. Other groups have reported a positive 
correlation between androgen receptor expression, overall survival (Langer et aL 1990) 
and disease-free survival (Kuenen-Boumeester et aL 1996). 
Studies investigating the relationship between androgen receptor and turnour grade have 
shown that androgen receptor expression is inversely correlated to histological grade 
(Kuenen-Boumeester et aL 1996) (Isola 1993) and S-phase fraction (Isola 1993). 
In keeping with the observation that androgen receptor expression correlated with 
markers of good prognosis, it would have been expected that androgen receptor 
expression coffelated inversely with lymph node metastases in breast cancer. However, 
the data on androgen receptor expression and lymph node status has been conflicting. 
Kuenen-Boumeester et al failed to show any significant association between 
immunohistochemically detected androgen receptor status and lymph node status 
(Kuenen-Boumeester et al. 1996). Indeed one group found a positive correlation between 
androgen receptor expression and the presence of axillary metastasis with multivariate 
analysis showing that androgen receptor content was an independent predictor of the 
likelihood of axillary metastases (Soreide et aL 1992). 
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There has only been one published report investigating a relationship between the levels 
of androgen receptor expression in breast cancer and circulating androgen levels. Langer 
et al in a study of 61 women with operable breast cancer found no significant correlation 
between serum testosterone, dehydroepiandrosterone sulphate (DHEAS) and tumour 
androgen receptor expression. However, they did find a significant positive association 
between serum androstenedione levels and androgen receptor expression (Langer el aL 
1990). 
1.5 Serum androgens levels In breast cancer 
Several epidemiological studies have reported elevated adrenal androgen levels in the 
serum of postmenopausal women who subsequently developed breast cancer compared to 
controls (Cauley 1999) (Dorgan 1997) (Gordan 1990) (Zeleniuch-Jacqotte 1997). In a 
study comparing 97 postmenopausal women and 244 controls Cauley et al found 
significantly elevated serum androstenedione, DHEAS, and testosterone levels in women 
who subsequently developed breast cancer. However, in a statistical model that included 
bioavailable testosterone and oestradiol only bioavailable oestradiol was significantly 
related to breast cancer risk. This suggested that DHEAS and androstenedione contribute 
to the risk of breast cancer by acting as precursors to oestrogens (Cauley 1999). 
Dorgan et al reported significantly elevated levels of DHEA, DBEAS and androstenediol 
in 71 postmenopausal women who subsequently developed breast cancer (Dorgan 1997). 
Gordon et al in a study of 30 postmenopausal women who developed breast cancer and 
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59 controls reported a significant association between DHEA and breast cancer risk and a 
non-significant association between DBEAS levels and breast cancer risk (Gordan 1990). 
Zeleniuch-Jacquotte et al likewise reported that DBEAS were non-significantly elevated 
in 85 postmenopausal women who developed breast cancer compared to 163 controls 
(Zeleniuch-Jacqotte 1997). However, Barrett-Connor et al found no difference in 
DBEAS levels between women who developed breast cancer and controls (Barrett- 
Connor 1990). 
Fewer studies have measured serum androgens in women with confirmed breast cancer. 
Secreto et al found that the risk of breast cancer was positively associated with serum 
levels of testosterone, DHEAS, androstenedione, and dihydrotestosterone in 75 women 
with breast cancer compared to 15 0 controls (Secreto 199 1). Likewise, Zumoff et al 
reported supra-normal levels of DBEA and DBEA in postmenopausal women with 
primary operable breast cancer (Zumoff 1981). In this study, DHEA and DBEAS levels 
were found to be age invariant in women with breast cancer in contrast to a marked 
decline in levels of these androgens with age in controls. 
Studies of adrenal androgen levels in premenopausal women who develop breast cancer 
have been less numerous. Several have reported subnormal levels of adrenal androgens in 
women with breast cancer compared to controls (HeIzIsouer 1992) (Bulbrook 1986) 
(Zumoff 1981). 
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Helzlsouer et al measured serum DHEA and DHEAS in 15 premenopausal women who 
subsequently developed breast cancer. They reported that serum DHEA levels were lower 
in women who developed breast cancer, though there was no difference in DBEAS levels 
between cases and controls (Helzlsouer 1992). Zumoff et al reported subnormal levels of 
both DHEA and DHEAS in premenopausal women with breast cancer (Zumoff 1981). In 
a study of premenopausal women on the island of Guernsey, Bulbrook measured urinary 
metabolites of DBEAS (etiocholanolone and androsterone) in I 10 women who developed 
breast cancer. Women who developed the disease in premenopausal years had 
significantly lower levels of these metabolites than age-matched controls (Bulbrook 
1986). 
In a review of the association between abnormal androgen production and breast cancer, 
Secreto and Zumoff summarize the evidence implicating excessive androgen production 
of ovarian origin in the aetiology of breast cancer (Secreto 1994). Polycystic ovarian 
syndrome, a condition characterised by anovulatory hyperplasia of the endometrium and 
elevated testosterone secretion is a risk factor for breast cancer (Coulam 1983). In 
addition elevated testosterone levels are found in women with abdominal obesity; such 
women are also at increased risk for breast cancer (Schapira et aL 1990). 
Several investigators have found circulating levels of testosterone to be elevated in 
women with breast cancer (Malarkey 1977) (Zeleniuch-Jacqotte 1997) (Secreto 1991) 
(Sauter 2002) (Hill 1985) (Thomas 1997) (McFayden 1976) (Cauley 1999). 
16 
Chapter I Introduction 
Five studies have found elevated circulating testosterone levels in postmenopausal 
women with breast cancer (Zeleniuch-Jacqotte 1997) (Cauley 1999) (Hill 1985) (Secreto 
199 1) (Thomas 1997). Only two measured serum testosterone in premenopausal women 
with breast cancer and found levels to be elevated compared to controls (Malarkey 1977) 
(Sauter 2002). 
Whether circulating testosterone levels are independently associated with breast cancer 
risk is not established. Two studies have reported that the association of circulating 
testosterone levels to breast cancer risk is not independent of bioavailable oestrogen 
(Thomas 1997) (Zeleniuch-Jacqotte 1997). Whereas, only one has found that testosterone 
levels are an independent risk factor for breast cancer (Cauley 1999). 
Several mechanisms have been proposed by which androgens may increase the risk of 
breast cancer, either directly or indirectly. We discuss in the next section mechanisms by 
which androgens may stimulate the proliferation of breast cancer cell lines via the 
oestrogen receptor, and these are well documented in the literature (Rochefort et aL 
1984). On the other hand, androgens have been shown to inhibit oestrogen-induced 
proliferation of breast cancer cell lines by an androgen receptor-mediated mechanism 
(Poulin 1988) (Maclndoe 1981) (Rochefort et aL 1984). 
Androgens may indirectly affect the growth of breast cancer by two mechanisms. They 
may be converted to oestrogens by the aromatization of testosterone and androstenedione 
(Longcope 1978). In addition, both oestradiol and testosterone are both bound in the 
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circulation to sex hormone-binding globulin (SHBG), however testosterone binds sex 
hormone-binding globulin with greater affinity than oestradiol (Brooks 1984). Elevated 
testosterone levels therefore indirectly increase bioavailable oestrogens by displacing 
oestradiol from sex hormone-binding globulin (Siiteri et aL 1982). 
Recently, in a review of the role of adrenal androgens in breast cancer, Adams proposed 
that women who develop breast cancer in premenopausal years tend to have subnormal 
serum levels of adrenal androgens. Women who develop the disease in postmenopausal 
years have supranormal levels of these hormones. This he argues is due to androgens, 
acting via the androgen receptor, opposing oestrogen-stimulated growth in 
premenopausal years and stimulating growth via the oestrogen receptor in 
postmenopausal women (Adams 1998). 
In contrast to adrenal androgens testosterone has been reported to be elevated in both pre 
and postmenopausal women with breast cancer (Secreto 1994). The reason for this is 
unknown. The major metabolite of testosterone, 5a-dihydrotestosterone, appears to 
inhibit the growth of breast cancer cell lines (Poulin 1988), though some groups have 
found that it can stimulate or inhibit the proliferation of breast cancer cell lines (Birrell 
1995). 
Testosterone may affect the proliferation of breast cancer by one of the mechanisms 
described above. In addition, Secreto and Zumoff have proposed that testosterone may 
stimulate the secretion of peptide growth factors such as epidermal growth factor which 
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act in a autocrine or paracrine loop to stimulate proliferation of breast cancer (Secreto 
1994). 
1.6 Growth actions of androgens on breast cancer cell lines 
Biffell et al showed that androgens can both stimulate and inhibit growth of breast cancer 
cell lines (Birrell 1995). This effect appeared to be independent of the level androgen 
receptor expression by the breast cancer cell line. However, androgen receptor expression 
was necessary for the growth regulatory effects of androgens to be observed, as the 
growth of the two androgen receptor negative cell lines BT-20 and MDA-MB-231 was 
unaffected by androgens. 
On investigating the effect of the naturally occurring androgen 5ec-dihydrotestosterone 
(5a-DHT) and the synthetic, non-metabolized androgen mibolerone on six breast cancer 
cell lines, Biffell et al found that T47-D and ZR-75-1 were growth inhibited by 
androgens, while the growth of MCF-7 and MDA-MB-453 was stimulated by the 
presence of androgens. Co-incubation of 5cc-DHT with the anti-androgen 
hydroxyflutamide resulted in reversal of inhibitory and stimulatory effects of 5a-DHT on 
T47-D, MCF-7 and MDA-MB-453 cell proliferation suggesting an androgen receptor 
mediated mechanism. 
Birrell et al reported that stimulatory or inhibitory effects on growth were only observed 
after 6 days incubation with 5cc-DHT, an observation that has been confirmed by other 
groups (Poulin et aL 1988). This is considerably longer than the time required by 170- 
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oestradiol to exert its effects on cell proliferation, again suggesting different pathways for 
the action of androgens and estrogens on cell proliferation. 
Two breast cancer cell lines MDA-MB453 (Hall et al. 1994) and NEFM-223 
(Hackenberg et aL 1991) are unique in that they express high levels of androgen receptors 
in the absence of estrogen and progesterone receptors. However, although they have 
similar steroid receptor profiles they differ markedly in their response to androgens, 
MDA-MB453 being growth stimulated and MEFM-223 growth inhibited. 
Why 5cc-dihydrotestosterone can stimulate or inhibit the growth of cell lines with similar 
receptor profiles is unclear. Metabolism to oestrogenic substrates, which interact with the 
oestrogen receptor, is one possibility. This may explain the stimulatory action of 5cc- 
dihydrotestosterone on MCF-7 cell line. MCF-7 cells possess glucuronyltransferase 
activity enabling 5(x-DHT to be metabolized to compounds such as androstanediol (Roy 
1992). Furthermore, androstanediol has been shown to stimulate the proliferation of 
MCF7 cells via interaction with the oestrogen receptor (Hackenberg 1993). 
However, both MFM-223 and MDA-MB-453 cell lines do not express oestrogen 
receptors, and the growth effects of 5a-dihydrotestosterone can be inhibited by 
antiandrogens, suggesting an androgen receptor mediated mechanism. Clearly, there is a 
need for a more detailed understanding of the mechanisms of androgenic growth control 
in human breast cancer. 
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In a 12-day incubation of physiological doses of 5cc-DHT with the ZR-75-1 breast cancer 
cell line, Poulin et al found that 5cc-DHT inhibited cell prolifemtion and that the 
mitogenic effect of 170-oestradiol on ZR-75-1 cells was completely inhibited by 
increasing concentrations of androgens (Poulin 1988). This anti-proliferative action was 
reversed by addition of the antiandrogen hydroxyflutamide suggesting that the effect was 
mediated by the androgen receptor and not by competition for binding with the oestrogen 
receptor. 
In a study of the MCF7 breast cancer cell line, MacIndoe demonstrated that 5a-DHT 
inhibited oestrogenic induction and ongoing stimulation of progesterone receptor 
synthesis. Again this inhibitory activity of 5a-DHT was blocked by the addition of 
several anti-androgens, supporting the concept that the anti-oestrogenic effect of 
androgens is mediated by an androgen receptor mechanism (Maclndoe 1981). 
In 1976 Lippman showed that 5a-DHT stimulated the growth of MCF7 breast cancer cell 
line. However, the concentration of 5cc-DHT required to saturate the androgen receptor in 
vitro, was 1000 times lower than that which maximally stimulated MCF7 proliferation 
(Lippman 1976). If the mechanism of androgen action on the MCF7 cell line was due to 
androgens binding to the androgen receptor, then maximal stimulation would have 
occurred at 5a-DHT concentration sufficient to saturate the androgen receptor i. e. 
1/1000'h of that observed. 
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There are two explanations of this anomaly. Firstly, 5ct-dihydrotestosterone was 
metabolized to androstanediol by MCF7 cells, which stimulates proliferation via the 
oestrogen receptor, as discussed above, or 5a-dihydrotestosterone interacted directly with 
the oestrogen receptor. 
While Zava et al also showed that 5a-DHT stimulated the growth of MCF7 cells at 
pharmacological doses (1076M) they found no effect on cell growth at physiological doses 
(I 0-"M), despite 5a-DHT translocating the androgen receptor to the cell nucleus at this 
lower concentration. In contrast to Lippman's group, Zava et al found that 10-, 6M 5a- 
DHT competed with oestradiol for binding to the oestrogen receptor, translocated 
oestrogen receptor to the cell nucleus and stimulated progesterone synthesis. 
These findings suggested that the growth effects of 10'6M 5a-DHT on MCF7 cells were 
mediated by direct interaction of 5 cc-DHT with the oestrogen receptor. The effects of 10- 
6M 5a-DHT on cell growth, receptor depletion and progesterone synthesis was almost 
comparable to 10-8M 170-oestradiol and the affinity of 5cc-DHT for the oestrogen 
receptor was estimated as approximately I 000-fold less than oestradiol (Zava 1978; Zava 
1978). The above discussion has been restricted to 5ct-dihydrotestosterone, an androgen 
with a high affinity for the androgen receptor. However, as discussed elsewhere, there are 
a large number of metabolically related androgens with a variety of androgenic and 
oestrogenic activities (Rocliefort et aL 1984). The metabolism of androgens and 
interactions with the androgen and oestrogen receptors are illustrated below. 
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Dehydroepiandrosterone Sulphate 
Dehydroepiandrosterone lo 4-Androstenedione 
Oestrone 
5-Androstene-30,170-diol Testosterone 
Oestradiol 
Oestrogen Androgen 
Receptor 5a-Dihydrotestosteronf- Receptor 
30-Androstanediol 3ec-Androstanediol 
Figure 1.6: Androgen Metabolism in peripheral tissues 
Rochefort and Garcia (Rochefort et aL 1984) divide androgens into three groups: 
Oestradiol 
Oestrogen Androgen 
Receptor 5a-Dihydrotestosteronf- Receptor 
30-Androstanediol 3ec-Androstanediol 
Figure 1.6: Androgen Metabolism in peripheral tissues 
1) Androgens, such as 5(x-dihydrotestosterone and testosterone, with a high affinity for 
the androgen receptor 
2) Androgens, such androstenedione and testosterone which are converted to oestrogens 
by aromatization 
3) Androgens of adrenal origin such as dihydroepiandrosterone sulphate (DHEAS), 
androstenediol and androstanediol which have some affmity for the oestrogen 
receptor 
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While 5a-dihydrotestosterone stimulates proliferation and induces progesterone receptor 
expression at pharmacological concentrations (Zava 1978), adrenal androgens produce 
similar effects at physiological concentrations. 
5-androstene-30,170-diol a metabolite of DBEA has been shown to stimulate the 
proliferation of hormone dependent breast cancer cell lines at physiological 
concentrations via interaction with the oestrogen receptor (Adams et aL 198 1) (Poulin et 
al. 1986) (Hackenberg 1993). 
Similarly, DBEAS has oestrogen-like actions on MCF-7 and T47D breast cancer cell 
lines at physiological concentrations (LeBail et aL 1998) (Poulin et aL 1986) and DHEA 
stimulates MCF-7 breast cancer cell lines by a similar mechanism (Boccuzzi et at 1992) 
(Poulin et aL 1986). 
In a recent study of the oestrogenic activity of androgens LeBail et al found that DHEA, 
DHEAS, androstenediol, androstanediol, androstenedione, 5alpha dihydrotestosterone 
and testosterone were all able to elicit oestrogen-like actions on MCF-7 and T47D breast 
cancer cell. However, only DHEAS demonstrated oestrogenic activity at physiological 
concentrations (LeBail et aL 1998). This is in disagreement with other groups who have 
found that androstenediol not DBEAS has oestrogenic activity at physiological 
concentrations (Poulin et aL 1986). 
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Adrenal androgens have been shown to inhibit the growth of the NIFM-223 breast cancer 
cell line, by an androgen receptor mediated mechanism (Hackenberg: 1993). 5- 
Androstene-3 P, I 7p-diol and DBEA bave likewise been sbown to inbibit oestrogen- 
stimulated growth of MCF7 cells by an androgen receptor mediated mechanism 
(Boccuzzi et aL 1993) (Boccuzzi et aL 1994). 
The action of adrenal androgens depends on the endocrine environment: adrenal 
androgens stimulate the growth of hormone dependent breast cancer in the absence of 
oestrogens,, and inhibit growth in the presence of oestrogens. These actions occur by the 
oestrogen and androgen receptor respectively and may underlie the findings of several 
studies that prediagnostic levels of adrenal androgens are elevated in postmenopausal 
women with breast cancer and reduced in premenopausal women with breast cancer 
(Adams 1998). 
1.7 Insulin-like growth factor system in breast cancer 
Insulin growth factor receptor I (IGFRI) is a member of the tyrosine kinase receptor 
superfamily and shares 70% homology with the insulin receptor (IR) (Ullrich et aL 1986). 
It is ubiquitously expressed in human tissues and has been implicated in mitogenesis, 
cellular transformation, survival and differentiation (Rubin et aL 1995). 
IGFRI expression is elevated in breast cancer compared with non-malignant tumours or 
normal breast epithelium (Peyrat et aL 1992) and the ligands for IGFRI (IGFI and lGFH) 
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are potent mitogens for human breast cancer cell lines (Furlanetto et aL 1984). A 
substantial body of evidence implicates the IGF system as a key growth regulatory 
pathway in human breast cancer, which may be a therapeutic target for novel breast 
cancer therapy (Lee et al. 1998). 
Oestradiol has been shown to upregulate the expression of IGFRl mRNA in MCF7 breast 
cancer cell line (Stewart et aL 1990) as well as downstream molecules in the IGF 
pathway such as insulin receptor substrate- I (IRS- 1) (Lee et aL 1999). These results 
suggest that an important mechanism, by which oestrogens stimulate the proliferation of 
hormone-dependent breast cancer involve sensitization to the proliferative effects of 
IGFs. Oestadiol and IGFs have been shown to act synergistically to stimulate the 
proliferation of breast cancer cell lines (Stewart et al. 1992). 
Activation of IGFRI results in oligomerization, autophosphorylation and activation of 
tyrosine kinase (Ullrich et aL 1986). IGFRI is coupled to downstream signaling 
molecules insulin receptor substrate -1 (IRS-1) and Src homology 2 containing sequence, 
which are phosphorylated by activated tyrosine kinases and interact with multiple signal 
pathways including the MAPkinase pathway (Myers et al. 1994) (Pelicci et aL 1992). 
Thus providing a pathway for the interaction between IGFRI and steroid hormone 
receptors, to be discussed later. 
Several large studies have reported no significant associations between IGFRI expression 
and a variety of prognostic parameters including tumour grade, lymph node status, and 
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disease-free and overall survival (Surmacz et aL 1998). However, it is established that 
IGFRI is co-expressed with oestrogen receptor in human breast cancer (Peyrat et al. 
1988) (Pekonen 1988). Despite ongoing investigations, the exact role of the IGF system 
in the progression of human breast cancer remains obscure. 
1.8 Epidermal growth factor system In breast cancer 
Epidermal growth factor receptor (EGFR) is a cell surface receptor with tyrosine kinase 
activity, which has shown to be the cellular homologue of the v-erbB2 oncogene 
(Downward el aL 1984). Like the IGF system an interaction between the EGF system and 
steroid hormone receptors occurs. EGF activates the oestrogen receptor via the 
MAPKinase pathway resulting in phosphorylation of the ser' in the transactivation 
domain AFI located in the N-terminus (Bunone et aL 1996). 
EGFR is important in the growth regulation of normal breast and can be detected in all 
samples of normal breast (Dittardi et aL 1993). However, it can be identified only in 
approximately one third of human breast carcinomas, where it is associated with high 
tumour grade (Walker et al. 1999), poor response to endocrine therapy (Nicholson et aL 
1989), and is inversely associated with oestrogen receptor (Sainsbury et aL 1985) 
(Pekonen 1988) (Walker et al. 1999). 
EGFR has been implicated in the progression of human breast cancer to hormone 
independence. Oestrogen has been shown to have a biphasic effect on EGFR expression 
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in breast cancer cell lines. In the presence of oestrogen, there is a rapid and transient up- 
regulation of EGFR expression, followed by a down-regulation to basal levels, which is 
dependent on protein synthesis. This suggests that hormone-dependent breast cancer cells 
possess active mechanisms to maintain low levels of EGFR (Yarden et aL 1996). 
WalkerRA et al have proposed that in a proportion of patients lacking oestrogen receptors 
this regulation is lost, leading to an upregulation of EGFR. Overexpression. of EGFR is 
therefore a result, not a cause of hormone independence (Walker et al. 1999). 
Chrysogelos et al proposed a multistep model for the progression of breast cancer from a 
hormone dependent ER+/EGFR- phenotype to a hormone independent ER-/EGFR+ 
phenotype (Chrysogelos et al. 1994). 
1.9 Cross-talk between steroid hormone and growth factor signal 
transduction pathways In cancer 
The evidence from a large number of studies has established that growth factor signal 
transduction and steroid hormone pathways interact. This interaction is termed 
"crosstalkr. Power el al first showed that dopamine, an extracellular ligand was able to 
stimulate transcriptional enhancement of oestrogen receptor (Power el aL 1991). 
Subsequently it was shown that epidermal growth factor (EGF) induced oetrogen-like 
effects on mouse reproductive tract, which were attenuated by administration of an 
oestrogen receptor antagonist (Ignar-Trowbridge el aL 1992). 
28 
Chapter I Introduction 
These results suggested that EGF induced these effects by an interaction between the 
EGF signaling pathway and the oestrogen receptor. More recently it has been confirmed 
that the oestrogen-like effects of EGF in the mouse uterus require the oestrogen receptor. 
Curtis et al showed that EGF treatment induced DNA synthesis and progesterone 
receptor mRNA in wildtype but not oestrogen receptor knockout (ERKO) mice (Curtis et 
al, 1996). 
EGF was also shown to modulate the transcriptional activity of oestrogen responsive 
elements (EREs) in endometrial and ovarian carcinoma cells. In this study, it was 
demonstrated by the use of truncated steroid hormone receptors, that EGF interacted with 
the N-terminus of the oestrogen receptor (Ignar-Trowbridge et aL 1993). 
Crosstalk between peptide growth factors and oestrogen. receptor is not restricted to EGF. 
Insulin-like growth factor-I OGF-1) has also been shown to mediate oestrogen receptor- 
mediated transcription in the rat uterus (Aronica et aL 1993) and the MCF7 human breast 
cancer cell line (Katzenellenbogen et aL 1990). 
In addition agents, which increase cyclic adenosine monophosphate (cAND), are able to 
stimulate oestrogen receptor-mediated transactivation in the rat uterus (Aronica et aL 
1993) and protein kinase activators act synergistically with oestradiol to increase 
oestrogen-receptor mediated transcription (Cho et aL 1993). 
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Synergy exists between growth factor and oestrogen-mediated proliferation of breast 
cancer cells. Oestradiol was shown to increase the proliferative effects of a number of 
growth factors in MCF7 cells (Stewart et aL 1992). IGF-binding protein-I (IGF-BP-1) an 
inhibitor of IGF- I action, inhibits not only IGF- I mediated activation of oestrogen 
receptor, but also oestradiol mediated action in MCF7 cells (Lee 1997). Similarly, anti- 
oestrogens partially inhibited IGF-I mediated growth of MCF7 cells in addition to 
completely inhibiting oestradiol mediated growth (Wakeling et aL 1988). Several reports 
have provided evidence that oestrogen can affect EGF and IGF action in vitro and in vivo 
(Dickson et aL 1987). 
The growth factor and oestrogen-mediated growth factor pathways are interrelated in 
breast cancer. The mechanism of crosstalk appears to be bi-directional, with each 
signaling pathway positively influencing the other, resulting in reinforcement of both 
signaling pathways. The insulin-like growth factor pathway is required for maximal 
oestrogen-mediated stimulation of growth and vice versa (Yee et al. 2000). 
In prostate cancer, there is evidence supporting a similar interaction of growth factor and 
androgen receptor pathways in the control of prostate cancer growth. IGF-I, EGF and 
keratinocyte growth factor (KGF) have been shown to activate androgen receptor- 
mediated transcription in the absence of androgens in the prostate cancer cell line DU- 
. 145 transfected with androgen receptor (Culig 1994). Again, a mitogen activated protein 
kinase (MAPK) pathway has been identified which phosphorlates ser5l 3 on the N- 
terminus of the androgen receptor activating androgen receptor mediated transcription in 
30 
Chapter I Introduction 
response to peptide growth factors (Abreu-Martin et aL 1999). Like the oestrogen 
receptor the androgen receptor can also be activated by agents, which increase 
intracellular cAMP levels, in the absence of androgens. This effect was inhibited by 
protein kinase A inhibitor and anti-androgen, suggesting that activation of androgen 
receptor may occur through a protein kinase A signaling pathway in prostate carcinoma 
(Nazareth et aL 1996) 
Further studies were undertaken to investigate the mechanism of signal transduction 
pathway responsible for ligand-independent activation of the oestrogen receptor. These 
showed that IGF-l elicited only weak transcriptional activation in the presence of a 
deletion mutant that lacked the N-terminus. This suggested that ligand-independent 
activation of oestrogen receptor transcription by peptide growth factors is mediated 
through AFI by a mechanism distinct from oestradiol and protein kinase C (Ignar- 
Trowbridge et al. 1996). It has subsequently been shown that transcriptional activation of 
the oestrogen receptor by EGF and IGF is mediated through the membrane- associated 
receptor tyrosine kinase-Ras-Raf-MAPK cascade, which enhances the activity of 
oestrogen receptor AF I by phosphorylating Ser' 18 residue located in the N-terminus 
(Kato et aL 1995). 
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Figure 1.7: Ligand independent activation of the androgen receptor 
1.10 Tumour Markers in Breast Cancer 
The term "tumour marker" embraces a spectrum of molecules of widely divergent 
characteristics, but sharing an association with malignancy that facilitate their application 
in the clinical detection (diagnosis, screening) and management (monitoring, prognosis) 
of cancer patients (Sturgeon el al. 1999). 
A large number of tumour markers exist for breast cancer, including the glycoprotein 
encoded by the MUCI gene; carcinoembryonic antigen (CEA); tissue polypeptide 
antigen (TPA) and tissue polypeptide specific JPS) antigen, which are soluble markers 
of cytokeratin 18; and oncoproteins such as HER-2. 
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MUCI antigen and CEA, in combination (Cheung et aL 2000), are the most useful sennn 
markers in patients with advanced breast cancer. Serial determinations of these markers 
may detect recurrence following primary treatment, and be useful in monitoring response 
to therapy (Steams et aL 1998). However, the clinical benefit of their use is not 
established and present data regarding MUCI and CEA were insufficient for them to be 
recommended for routine use by the American Society of Clinical Oncology (Bast et al. 
1996). 
Although a tumour marker that distinguishes benign from malignant breast disease would 
be very useful, no tumour marker is sufficiently sensitive to be recommended for the 
diagnosis and screening of breast cancer (Sturgeon et aL 1999). The detection of elevated 
serum BER-2 is unlikely to be useful as a tool for the diagnosis of breast cancer as it is 
only elevated in a subgroup of patients who over-express IHER-2 at the tissue level 
(Breuer et al. 1993). 
Serum HER-2 may be useful for the monitoring of tumour recurrence in patients with 
HER-2 over-expressing primary tumours (Isola et aL 1994) and predicting resistance to 
hormonal therapy (Harris et aL 1999). However, the most promising use of serum HER-2 
would appear to be in monitoring response to herceptin therapy, the recombinant 
humanized monoclonal antibody against HER-2. Though further studies are needed to 
fully evaluate the role of serum HER-2 for this purpose (Cheung et aL 2000). 
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1.11 Retroviruses, proto-oncogenes and oncogenes 
One common feature of all types of cancer, regardless of tissue of origin, is a loss of 
normal growth control mechanisms. This results in unchecked proliferation of neoplastic 
cells, which contributes to tumour formation. Rous first hypothesized the existence of an 
infectious agent, which could cause tumour formation in chickens this led to the 
discovery of the Rous sarcoma virus, a transforming retrovirus (McKenzie 199 1). 
During the life cycle of a retrovirus genetic material from the host is incorporated into its 
genome, in some cases modifying the gene and creating an oncogene. Retroviruses that 
can induce tumours in infected animals carry sequences responsible for their oncogenesis. 
These nucleotide sequences are called oncogenes and are derived from normal cellular 
genes called proto-oncogenes. These precursors to oncogenes, termed proto-oncogenes, 
are intimately involved in the control of cellular proliferation and differentiation and 
encode growth factors, growth factor receptors, signal transducers or nuclear receptors 
(McKenzie 1991). 
Genetic mutations acquired en route from proto-oncogene to oncogene, which release the 
gene product from its normal cellular control mechanisms maybe responsible for the 
transforming activity of oncogenes (Bishop 1987). Avian erythroblastosis virus a 
retrovirus that induces erythroid. leukaemia and sarcomas in infected chickens contains 
the v-erbB oncogene responsible for its transforming activity (Graf et aL 1978). 
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1.12 HER-2 proto-oncogene and protein In breast cancer 
Comparison of the structure of the AEV transforming gene v-erbB with the human 
epidermal growth factor receptor revealed close sequence homology (Yamamoto et aL 
1983). The predicted v-erbB transforming protein is a truncated form of the epidermal 
growth factor receptor, which contains the transmembrane and cytoplasmic domains, but 
lacks the extracellular EGF binding domain. It is postulated that the absence of the EGF 
binding domain might remove the control generated by ligand binding and results in the 
continuous generation of a signal (or constitutive activation) equivalent to that produced 
by EGF, causing the cells to proliferate rapidly (Downward et aL 1984). 
Another proto-oncogene, termed neu, identified originally in ethinyInitrosurea-induced 
rats (Shih et aL 198 1) is also related to v-erbB. Using v-erbB as a screening probe 
(Coussens et aL 1985) a gene on q21 of chromosome 17 has been isolated which encodes 
a cell surface receptor with tyrosine kinase activity, now known to be the human 
counterpart of neu, termed HER-2 (human ppidermal growth factor receptor 2) or cerbB- 
2 (cellular erbB2). 
IHER-2 encodes a transmembrane receptor of 185kDa with intrinsic tyrosine kinase 
activity termed p185 (Stem et al. 1986), which is highly homologous but distinct from 
the EGFR (Bargmann et aL 1986) (Yamamoto et aL 1986). We now know that IHER-2 
belongs to a family of closely related growth factor receptors including EGFR, HER-3 
and IHER4, identified through their homology with the transforming gene v-erbB. This 
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family encodes receptor tyrosine kinases possessing a cysteine-rich extracellular domain, 
a transmembrane domain and an intracellular domain possessing tyrosine kinase activity 
(Sahin 2000). 
A point mutation in the transmembrane domain of rat neu gene has been identified which 
results in activation of the gene. This results in an amino acid substitution, which 
presumably alters the protein confirmation such that the tyrosine kinase becomes 
constitutively active (Bargmann et aL 1986). No such mutation has been reported in its 
human counterpart BER-2. 
Activated HER-2, as well as interacting with other members of the epidermal growth 
factor fwnily to form homodimers, or heterodimers (Dougall et aL 1994), interacts with a 
variety of downstream substrates. These downstream molecules include mitogen- 
activated protein (MAP) kinase, Src and PI 3-kinase. MAP kinase is a pathway involved 
in the growth and transformation of many cell systems, which is overexpressed in 
malignant breast tissue: Src a nonreceptor tyrosine kinase which has also been implicated 
in mammary tumorigenesis; and PI 3-kinase a pathway that regulates cell death 
machinery (Hung et al. 1999). 
One of the mechanisms implicated in the multistep process of tumorigenesis involves the 
amplification of one or more proto-oncogenes and the concomitant over-expression of its 
protein product (Weinberg 1989). Amplification of a normal HER-2 gene rather than 
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mutation to an abnormal gene appears to activate BER-2 in human breast cancer (Slamon 
et aL 1989). 
King et al first identified HER-2 amplification in a breast cancer cell line (King et aL 
1985). Subsequently, Slamon et al reported that HER-2 was amplified in 25-30% of 
human breast cancers. Amplification of HER-2 was found have prognostic significance 
for disease-free and overall survival in the lymph node positive group in this study 
(Slamon et aL 1987). Review of data from studies Published to date, suggest that HER-2 
is amplified or over-expressed in 10-34% of human breast cancers (Ross et al. 1999). 
Following reports of the amplification of HER-2, several groups investigated the 
significance of HER-2 protein product expression in breast cancer. Amplification of 
HER-2 and over-expression of the HER-2 protein-product are significantly correlated in 
breast cancer (Venter et aL 1987). However some tumours, which contain only a single 
copy of the HER-2 gene were found to express high levels of the HER-2 protein product, 
suggesting that mechanisms other than gene amplification may lead to enhanced gene 
expression (Tandon et aL 1989). 
HER-2 over-expression in breast cancer has been found to be an important independent 
prognostic factor in breast cancer, only lymph node status being a greater predictor of 
disease-free and overall survival (Paik et aL 1990) (Wright et aL 1989). Like HER-2 
amplification, a large number of studies have reported a significant correlation between 
HER-2 over-expression and reduced disease-free and overall survival in lymph node 
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positive patients (Sahin 2000). However, although some have reported similar fmdings in 
lymph node negative patients (Guterson et aL 1992), the most studies have found no 
correlation between HER-2 status and outcome in this group (Slamon. et aL 1989; Tandon 
et aL 1989; Clark et aL 199 1). 
In studies of an association with biomarkers of poor differentiation IHER-2 over- 
expression has been shown to correlate with lack of oestrogen and progesterone receptors 
and high nuclear grade in human breast cancer (Berger et aL 1988) (Tandon et aL 1989) 
(Pa& et aL 1990) (Wright et aL 1989). 
Review of studies implicating HER-2 as a predictive marker of response to breast cancer 
therapy suggest that HER-2 over-expression may be linked to resistance to CNff-based 
(cytoxan, methotrexate, 5-fluorouracil) therapy and an enhanced response to high-dose 
doxorubicin regimens. More studies are required to confirm these findings before clinical 
decisions based on HER-2 status can be made regarding adjuvant chemotherapy (Pegram 
et aL 1998). 
In contrast, several studies have shown that BER-2 over-expression predicts poor 
response to hormonal therapy (i. e. tamoxifen) (Pegrarn et aL 1998). The mechanism of 
hormone resistance in BER-2 over-expressing breast cancer has been the subject of 
intense laboratory investigation. Data from these studies suggest that overexpression or 
ligand activation of BER-2 results in functional signaling between BER-2 receptor 
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tyrosine kinase and oestrogen receptor (Pietras et aL 1995). However, to date no ligands 
that directly bind to IHER-2 protein have been clearly identified (Hung et aL 1999). 
IHER-2 receptor protein is an ideal therapeutic target as it is expressed in primary and 
metastatic tumours, and its expression is low in normal tissues (Press et aL 1990). The 
anti-HER2 antibody, which is directed against the extracellular domain of IHER-2 was 
humanised by inserting its murine antigen-binding region into the framework of a human 
immunoglobulin molecule (Carter et aL 1992). 
The recombinant humanised monoclonal antibody, called trastuzumab or herceptin, 
inhibits growth in breast cancer cell lines that over-express IHER-2 (Hudziak et aL 1989) 
and increases the response rate when given alone (Cobleigh et aL 1998) or in 
combination with chemotherapy (Slamon et aL 1998) in HER-2 positive advanced breast 
cancer. 
1.13 Serum cerbB-2 
Zabrecky et al detected, using two monoclonal antibodies specific for the extra-cellular 
domain of the BER-2 protein product, a protein of molecular mass 105kDa in 
conditioned media from cultures of SK-BR-3 cells (a breast cancer cell line known to 
express BER-2). They proposed that this molecule was the extra-cellular domain of BER- 
2 and SK-BR-3 cells release this portion of the receptor into its growth medium, and its 
detection could prove useful as a tumour marker (Zabrecky et aL 199 1). 
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Growth signal transduction by HER-2 appears to involve receptor dimerisation and 
increased tyrosine kinase activity (DOugall et aL 1994). This is accompanied by release of 
extra-cellular domain of HER-2 and its accumulation in the extra-cellular environment 
Thus accumulation of the extra-cellular domain of HER-2 in the extra-cellular 
environment represents a potential marker of uncontrolled growth signal transduction at 
the cellular level (Brandt-Rauf 1995). The mechanism of release of the soluble extra- 
cellular domain of HER-2 is believed to involve proteolytic cleavage from the surface of 
tumour cells. The release of the extra-cellular domain generates a truncated membrane 
receptor, which is constitutively activated (Pupa et aL 1993). 
It was subsequently shown that a similar antigen is shed into the serum of nude mice 
bearing tumours that over-express BER-2. In addition, increasing antigen levels 
correlated with over-expression of IEER-2 and increasing tumour volume. The utility of 
such an assay to detect IHER-2 for the diagnosis and monitoring of patients with breast 
cancer was therefore proposed (Langton et aL 1991). 
Studies of serum IHER-2 levels in human breast cancer have shown that they are elevated 
in 23% of patients with locally advanced or metastatic disease (Leitzel et at 1992). 
Other groups have confirmed that serum HER-2 levels are higher among patients with 
recurrent or metastatic breast cancer who have an increased tumour burden (Yasasever et 
at 2000) (Isola et at 1994). Though results from other groups have been conflicting 
(Brandt-Rauf 1995) suggesting that there is no association between tumour stage and 
serum HER-2 (Harris et at 1999). 
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Elevated serum HER-2 levels were found almost exclusively among patients whose 
tumours expressed BER-2 (Isola et aL 1994). In addition serum BER-2 levels were found 
to return to normal values following removal of the tumour (Breuer et aL 1993), strongly 
suggesting that the source of the increased serum HER-2 was the tumour. It was therefore 
suggested that serum HER-2 might prove useful as a tumour marker in the monitoring of 
patients with HER-2 over-expressing primary tumours for recurrence (Isola et aL 1994) 
(Harris et aL 1999). 
Commercially available kits are now available to measure serum BER-2. They are 
enzyme linked immunosorbent assays (ELISAs) using the two-site double antibody 
sandwich principle, i. e. they employ an antibody to the extracellular domain of IHER-2 to 
capture the molecule from the serum and another antibody, directed to a different epitope 
on the ECD of HER-2, as a marker. This second antibody is usually conjugated to an 
enzyme, such as horseradish peroxidase which catalyses a colour change in a substrate. 
Chiron@ and Oncogene Science@ manufacture such kits. 
In the present study an assay, which measures glycoconjugates present on the surface of 
the cerbB-2 glycoprotein present in the serum of women with breast cancer has been 
described. This assay used the lectin enzyme-linked immunoassay (ELISA) format This 
employed an antibody against cerbB-2 in the solid phase to capture antigen and a protein, 
which binds carbohydrate, termed a lectin, in the liquid phase, to detect glycoconjugate 
groups expressed by the cerbB-2 antigen. The rational for using the lectin ELISA format 
was that glycoconjugates are altered in malignancy. Measuring altered glycoforms of the 
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cerbB-2 glycoprotein present in the serum of women with breast cancer might therefore 
form the basis of a more specific test for breast cancer. 
In the following sections the classification of glycoproteins and the changes in 
glycoconjugate strusture that accompany malignancy are described. The properties of 
lectins and the results of histochemical studies investigating lectin binding in breast 
cancer sections have then been summarized. 
1.14 Glycoproteins 
Glycoproteins are proteins that have oligosaccharide or glycan chains attached to their 
polypeptide backbone. Almost all plasma proteins, with the exception of albumin are 
glycoproteins. Glycoconjugate and complex carbohydrate are equivalent terms to 
denote molecules containing one or more carbohydrate chains covalently linked to either 
protein or lipid. Glycoproteins, glycosylphosphatidylinositol anchors and glycolipids are 
all glycoconjugates. In addition proteoglycans (formerly called mucopolysaccha ride) 
are a particular type of glycoprotein consisting of a complex of glycosaminoglycans 
covalently attached to protein. Glycoproteins can be divided into two major classes based 
on the nature of the linkage between the polypeptide and oligosacharride chains. Those 
co ntaining a serine or threonine 0-acetylgalactosamine linkage are termed O-linked 
glycoproteins and those containing asparagine N-acetylglucosamine linkage N-linked 
glycoproteins (Murray 1993). 
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Although about two hundred monosaccharides are found in nature, only about seven are 
commonly found in the oligosaccharide chains of glycoprotems. Each N-linked 
glycoprotem contains a common pentasaccharide core consisting of mannose (Man), N- 
acetylglucosamine (GIcNac) and glucose (GIc) but differs in its outer branches to form 
three classes of glycoconjugate complex, hybrid and high-mannose. These terminal 
elaborations consist of sugars associated with adhesion and recognition functions such as 
N-acetylneuraminic acid (NeuAc), galactose (Gal) and N-acetylgalactosamine (Gal-Nac) 
(Drickamer el al. 1998). 
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Figure 1.8: N-linked and 0-linked glycoproteins 63 GaINAc; M GlcNAc; ..., galactose, - 
mannose; L, fticose, 0 SA; - polypeptide chain (Durand, 2000) 
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Figure 1.9: Processing of N-linked glycoproteins 13 GaINAc; 0 GlcNAc; galactose, 
mannose; L fticose; 0 SA; - polypeptide chain, Doi Dolichol, P phosphate (Durand, 
2000) 
Biosynthesis of N-linked ofigosaccharide chains begins in the endoplasi-nic reticulurn 
(ER) with a large precursor molecule containing 14 sugar residues. This precursor is 
linked to dolichol pyrophosphate, which acts as a carrier molecule, and transferred en 
bloc to an asparagiine residue on the growing polypeptide chain. Transfer to the Golgi 
complex follows and the action of glycosidases and glycosyltransferases, which remove 
and add sugar molecules, completes the maturation process. During this pathway the 
inner five residues, which constitute the common pentasaccharide core are conserved. 
High-mannose and hybrid oligosaccharides appear as intermediates along this pathway, 
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while the complex type is the mature form of N-linked oligosaccharide (Drickamer et al. 
1998). 
Glycan structure affects the overall conformation of the glycoprotein and as a 
consequence its molecular properties such as localisation, half-life and biological activity. 
In addition the cell surface location and three-dimensional structure allow the glycan to 
be recognised by receptors and to mediate events such as cell trafficking and cell 
adhesion (Murray 1993). 
The structural diversity of glycans is dictated by tissue-specific regulation of 
glycosyltransferase genes, availability of sugar nucleotides in the Golgi and competition 
between enzymes for acceptor intermediates during glycan elongation. Wild-type 
glycoproteins consist of mixtures of glycosylated variants known as glycoforms, in 
which the same peptide sequence is associated with different glycans at the same 
glycosylation site. This phenomenon is termed micoheterogeneity (Hakomori 1989). 
The potential structural diversity of glycans attached to proteins is enormous given the 
number of monosaccharides, linkages, branches and variable lengths of glycan chains, 
and has presented a considerable obstacle to the analysis of glycan structure. Analytical 
techniques of glycoconjugates such as sequential removal of oligosaccharides followed 
by mass spectometry or nuclear magnetic resonance analysis are time-consuming and 
expensive (Dwek et aL 1993). This has led to many laboratories using lectin-based 
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methods for the analysis of glycosylation, though they have their limitations. These 
lectin-based methods will be discussed in a later section. 
The lysosome, which contains an array of glycosidases and proteases, constitutes the 
major catabolic organelle for glycoproteins. A variety of inherited diseases result from 
defects in glycoconjugate synthesis or catabolism and are reviewed by Durand et al 
(Durand et aL 2000). In addition glycan structure is altered in both benign and malignant 
acquired disease. The latter will be discussed in more detail in the following section. 
1.15 Altered Glycosylation In Cancer Cells 
Malignant transformation is associated with changes in glycosylation of cell surface 
proteins (Hakomori 1989) (Kim et aL 1997) (Fukuda 1996) (Dennis et aL 1999). 
Interest in the pathophysiological role of glycosylation in cancer arose from findings that 
malignant transformation was associated with an increase in the size of membrane 
glycoproteins. This is known as the "Warren-Glick" phenomenon and it is now known 
that this is due to an increase in tri- and tetra-antennary branched chains in malignancy 
(Kobata 1998). 
The cellular location of cell surface glycoconjugates suggests that they are involved in 
cell social functions such as cell to cell and cell to matrix interactions. Whereas the early 
stages of tumour formation are dependent on aberrant cell housekeeping functions, 
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regulated mainly by phosphorylation, the later stages of invasion and metastasis are due 
to aberrant cell social function, which are regulated by cell surface glycosylation 
(flakomori 1996). 
A number of different aberrations of glycosylation have been identified which are 
associated with malignancy. These can be due to increased branching of glycans or 
changes in terminal oligosaccharides. Several lines of evidence have implicated N- 
acetylglucosaminyltransferase V (GIcNAc-TV). This enzyme initiates a specific 01,6 
branch to the trimannosyl core of the glycan during cancer progression (Dennis et aL 
1999). 
In a histochemical study of sections of breast and colon tissue Fernandes et al found a 
significant increase in binding of the lectin Phaseolus vulgaris leukoagglutinin (L-PHA), 
a plant lectin which specifically binds 0 1,6 branched structures, in sections of carcinoma 
compared to benign breast tissue (Fernandes et aL 1991). Demetriou et al showed that 
expression of GlcNAc-TV in an immortalised lung epithelial cell line MvLu, results in 
loss of contact inhibition of growth and increased cell motility (Demetriou et aL 1995). 
Futhermore Lu et al showed that NIH3T3 cells transfected with a H-ras oncogene with 
reduced GIcNAc-TV expression showed reduced ability to from lung metastases after tail 
vein injection in nude mice (Lu et aL 1994). 
These and other studies suggest that increased GlcNAc-TV expression is a major factor in 
metastasis formation and is responsible for the increased glycan branching observed by 
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Waffen and Glick (Kobata 1998). Of interest, it has been shown that NIH3T3 cells 
transfected with HER-2 oncogene showed increased GLcNAc-TV expression and 01,6 
branching (Chen el aL 1998). This suggests a mechanism by which HER-2 a proto- 
oncogene associated with aggressive turnour behaviour may form metastasis. 
In addition, changes in expression of terminal oligosacchides have been observed to be 
associated with malignancy. These have been identified by the use of monoclonal 
antibodies and are reviewed by Hakamori (Hakomori 1989). They include an increased 
expression of Lewis antigens. These are antigens carried on glycan chains, which 
normally express the blood group ABH determinants. Lewie, sialyl Lewis, Lewisy and 
sialyl Lewi? are over-expressed in human carcinomas (Itzkowitz et aL 1986) (Dennis et 
al. 1999) and may be important in the later stages of metastasis, as they have been shown 
to mediate attachment tumour cells to selectins in vitro (Mannori et aL 1995). 
Selectins are endogenous adhesion molecules, which appear at the onset of inflammation 
and bind to neutrophils and monocytes slowing their movement and aiding extravasation 
through capillary endothelium and recruitment to the sites of inflammation. It has been 
hypothesized that as tumour cells express sialyl Lewie they use the same selectin- 
carbohydrate interaction as neutrophils in inflammation during the process of metastasis 
(Fukuda. 1996) (Kim et aL 1997). 
An increase in terminal sialic acid (NeuAc) has been associated with the transformed 
phenotype and metastatic potential. In addition, Santer et al showed that in NIH3T3 
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fibroblasts transfected with the H-ras oncogene, tenninal cc-Gal residues of N-linked 
oligosaccharides were replaced by NeuNAc suggesting that sialic acid was necessary for 
the complete expression of the transformed phenotype (Santer et al. 1989). 
Other changes in glycosylation which have been reported to be associated with 
malignancy, and which will only be mentioned in passing are expression of 0-linked 
oligosaccharides T, Tn and sialyl. Tn by mucins and loss of normal ABH blood group 
expression, reviewed by Hakamori (Hakomori 1989). 
1.16 Altered glycosylation of serum glycoproteins In cancer 
Altered glycosylation of serum glycoproteins in serum of patients with cancer and other 
disorders such as liver and inflammatory disorders has been reported in several studies, 
and has been proposed as the basis for more discriminative tumour markers for the 
diagnosis and monitoring of disease (Turner 1992). 
Cancer sera have been investigated by crossed affmo-immunoelectrophoresis with 
Concanavalin A by a number of groups. However, results have been conflicting (Turner 
1992). Another area, which has received particular attention, is the fucosylation and 
sialylation of serum glycoproteins in sera of cancer patients. 
Measurements of serum concentrations of fucose and sialic acid have been reported to be 
elevated in patients with cancer. The concentrations of both fucose and sialic acid were 
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correlated with a number of acute phase proteins including al-anti trypsin, at-acid 
glycoprotein and haptoglobin in cancer sera. The reported sialic acid content of these 
proteins suggesting that the elevated levels of this sugar are due to the acute phase 
response (rumer et aL 1985). 
Subsequent work has identified an abnormally fucosylated haptoglobin in sera of patients 
with ovarian (Thompson et aL 1987) and breast cancer (Thompson et aL 199 1), levels of 
which correlated with tumour burden. An abnonnally fucosylated form of aI -anti trypsin 
has been identified in patients with ovarian cancer that predicted unresponsiveness to 
chemotherapy (Thompson et aL 1988). In addition, the sialic acid content of another 
acute phase protein aI -acid glycoprotein was found to be elevated in cancer sera 
compared to sera from healthy controls and patients with other diseases (Moule et aL 
1987). The source of both fucosylated acute phase proteins was suggested to be the liver, 
rather than the tumour. 
Pekelharing was first to modify the enzyme-linked immunosorbent assay (ELISA) to 
study protein glycosylation. By replacing the enzyme-linked antibody of the conventional 
ELISA with a lectin he developed the lectin ELISA system. The sandwich, which 
consists of two monoclonal antibodies in the conventional ELISA, consists of one 
monoclonal antibody and one lectin in the lectin ELISA. Only glycoprotein meeting two 
conditions is therefore measured, it must be the right protein to bind the antibody and 
have the right glycan structures to bind the lectin. The specificity achieved is therefore 
greater than that by simply measuring the protein (Pekelharing et al. 1987). 
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Since then several groups have applied the lectin ELISA to the serum of cancer patients. 
Madiyalakan et al compared a lectin ELISA for the determination of CAI 25 antigen in 
ovarian cancer patients with conventional ELISA and found that it could detect 88% of 
ovarian cancer patients without compromising the specificity compared to 60-80% with 
the conventional assay (Madiyalakan et al. 1996). 
Parker et al applied a lectin ELISA for CA19-9 to the sera of 79 patients with pancreatic 
cancer and reported a specificity of 76% and sensitivity of 78% for the diagnosis of 
pancreatic cancer (Parker et al. 1992). 
1.17 Lectins 
Lectins are proteins and glycoproteins extracted predominantly from plants, which have 
the capacity to bind sugars specifically (Walker 1989). Although extracted from plants, in 
which they are primarily found in seeds, lectins are present ubiquitously in animals and 
microorganisms. The biological role of lectins in plants is not clear, though it has been 
proposed that they act as mediators of symbiosis between plants and microorganisms, and 
protect plants against phytopathogens. Bacterial lectins are involved in the initiation of 
infection by mediating bacterial adherence to epithelial cells such as the urinary and 
gastrointestinal tract (Lis et aL 1986). 
Lectins are isolated by their ability to agglutinate erythrocytes (haemagglutination) and 
are purified by affmity chromatography on immobilised carbohydrates. They are 
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classified according to the monosaccharide, (e. g. Man, Gal, GlcNAc, GaINAc, L-Fuc or 
NeuAc) which most effectively inhibits their haemagglutination, or by other techniques 
such as affinity chromatography or electrophoresis. Usually a particular plant source 
contains (a) lectin(s) belonging to a single specificity group. However, in some cases two 
or more lectins that differ in specificity are found in the same plant: for example, Ulex 
Europeus I has specificity for L-Fuc and Ulex Europeus II for GIcNAc (Lis et al. 1986). 
Lectin I Source Sugar Specificify 
Concanavalin A (Con A) Jackbean Mannose/Glucose 
Lens Culinaris (LCA) Lentil Mannose/Glucose 
Ulex Europeus (UEA 1) Gorse Fucose 
Triticum Vulgaris (WGA) Wheat gerin N-acetyl glucosamine / sialic; acid 
Helix Pomatia (HPA) Snail N-acetyl galactosamine 
Peanut agglutinin (PNA) Peanut Galactose / N-acetyl galactosamine 
Ricinus Communis (RCA) Rice Galactose 
Maakia Amurensis (MA) Sialic, acid 
Table 1.1: Lectin carbohydrate specificity 
Lectins, have specificity for oligosaccharides defined by inhibition of haemagglutination. 
Some e. g. Arachis hypogaea react only with terminal non-reducing sugars, others e. g. 
Concanavalin A bind to monosaccharides which are external or internal constituents of 
glycan chains (Gallagher 1984). Some lectins bind to several different monosaccharides 
e. g. wheat germ agglutinin binds to both NeuAC and GICNAc. Some lectins react with 
oligosaccharides rather than monosaccharides e. g. Phaseolus vulgaris leucagglutinin a 
lectin associated with metastatic potential (Fernandes et aL 199 1) reco i 
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es internally situated 0 1,6 branched structures. 
It would therefore be apparent that the use of lectins for the analysis of glycan structures 
has limitations. In addition, Debray et al reports that the binding of lectins to their 
monosaccharide is influenced by neighbouring saccharides on the glycan chain. This may 
result in differences in binding of lectins with identical sugar specificities between 
samples. He concludes that the results of studies with lectins on cell surface 
carbohydrates should therefore be interpreted with caution (Debray et aL 1981). 
The carbohydrate specificities of lectins have led to their utilisation as reagents for the 
study of glycoconjugates in solution and on cell surfaces, and the identification and 
separation of cells. Lectins were discovered due to their ability to agglutinate cells 
bearing appropriate carbohydrate groups; hence they frequently carry the term 
"agglutinin" as their common name. This ability is due to the fact that lectins are 
polyvalent and they have multiple carbohydrate binding sites. This property has enables 
lectins to be used routinely for the determination of ABO, and other blood group 
expression (McCoy 1987). 
Some lectins such as Phaseolus vulgaris leucagglutinin have the ability to stimulate blast 
formation in lymphocytes by a process known as mitogenic stimulation. This is used 
clinically to assess the integrity of the immune system in patients with suspected immune 
deficiency (McCoy 1987). 
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Lectins have been used to investigate glycoprotein glycosylation by incorporating them 
into existing technologies: affinity chromatography, electrophoresis, ELISA, Western 
Blotting and histochernistry. Crossed afrmo-immunoelectrophoresis is a technique 
which involves separation of serum proteins on an agarose gel containing lectin, followed 
by separation at 90' in a second agarose gel containing antibody and a sugar, which 
displaces the lectin from the protein and allows protein to react with antibody. Lectin 
blotting is an extension of Western blotting, in which proteins separated by 
electrophoresis are transferred to a nitrocellulose membrane and a lectin is used to detect 
glycans on the bound glycoproteins (Turner 1992). Affinity chromatography is a 
technique, which involves passing a specimen down a column containing lectin coupled 
to Sepharose beads, the bound glycoproteins are collected by eluting with a sugar that 
competes with the glycoprotein. for the lectin-binding sites (Cummings 1994). 
Lectins have been used extensively as probes in histochemistry (Walker 1989) and 
immunoassays for serum glycoproteins (Pekelharing et aL 1987). These latter two 
applications are discussed in more detail in the following sections. 
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1.18 Lectin binding In histochernical sections of breast turnours 
Franklin undertook a systematic examination of the lectin binding characteristics of 
twenty benign and malignant breast lesions. He reported that the pattern of staining 
differed between benign and malignant breast turnours. Wheat germ agglutinin gave the 
strongest and most consistent staining in malignant tissue, suggesting that a large 
proportion of glycans consist of GlcNAc and NeuAc in malignant breast turnours. Ricin 
communis agglutinin and Arachis hypogaea (peanut agglutinin) also showed strong 
staining suggesting a high proportion of galactosyl residues in malignant turnours, 
(Franklin 1983). However, benign breast tissue also stained positively with wheat germ 
agglutinin, Ricin communis agglutinin and peanut agglutinin. 
Walker in a study of the effect of fixation of tissue sections on lectin binding also 
reported that wheat germ agglutinin and peanut agglutinin consistently stained benign 
breast tissue. In addition this study showed that wheat germ agglutinin was binding to 
GlcNAc rather than NeuAc in these sections (Walker 1984). It would appear therefore 
that wheat germ agglutinin would have limited use in differentiating benign from 
malignant breast tissue. 
In a study of the binding of two fucose specific lectins Ulex europeus I and Lotus 
tetrogonolobus in eighty frozen breast tissue sections, Walker reported a variable loss of 
binding of Lotus tetrogonolobus within carcinomas compared to benign breast tissue. 
This suggested breast malignancy is accompanied by alteration of fucosylation of 
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glycoconjugates (Walker 1984). In this study Ulex europeus I showed inconsistent 
binding to both benign and malignant breast tissue. However, when these sections were 
re-assessed to evaluate the use of Ulex europeus I to determine vascular invasion, it was 
found that Ulex europeus I binding could be useful in differentiating vascular from 
lymphatic invasion (Walker 1985). 
A lot of attention has surrounded Helix pomatia agglutinin, a lectin extracted from snails, 
which binds terminal non-reducing GaINAc residues on glycoconjugates (Gallagher 
1984). Helix pomatia agglutinin has been shown to be of prognostic value in 
adenocarcinomas of the breast, colon and stomach and is the subject of a review by 
Mitchell and Schumacher (Mitchell et al. 1999). 
It was demonstrated that Helix pomatia agglutinin binds to both benign and malignant 
breast tissue, however, in primary breast cancer Brooks and Leathern first demonstrated a 
strong association between Helix pomatia agglutinin staining and the presence of lymph 
node metastasis (Brooks et al. 1991). Similar findings have been reported by other studies 
(Fenlon et al. 1987) (Thomas et al. 1993). Both of these studies found that Helix pomatia 
agglutinin staining correlated with lymph node stage, disease-free and overall survival. In 
addition Thomas et al showed that Helix pomatia agglutinin staining correlated with 
IHER-2 status in primary breast cancer (Thomas et al. 1993). 
Other groups were unable to reproduce these results and have disputed the prognostic 
value of Helix pomatia agglutinin staining in breast cancer Qvfitchell et al. 1999). 
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However, Brooks subsequently showed that methodological differences could account for 
the discrepancy in findings, as considerable dffferences in lectin binding patterns were 
found between direct and indirect lectin histochernical techniques (Brooks et aL 1996). 
The relationship between Helix pomatia agglutinin staining and metastasis in human 
breast cancer are supported by experimental work. Kjonniksen et al have shown that 
Hefixpomatia agglutinin binds preferentially to melanoma and sarcoma cell lines in a 
manner that correlated with their ability to form pulmonary metastases in nude mice. In 
this study other lectins including wheat germ. agglutinin, Concanavalin A, peanut 
agglutinin and Ulex europeus I failed to show a similar correlation with pulmonary 
mestatases (Kjonniksen et al. 1994). 
The association of two lectins Phaseolus vulgaris leucagglutinin and Helix pomatia 
agglutinin with the formation of metastases led one group to investigate whether these 
lectins were recognising different oligosaccharides on a common metastasis-related 
glycoconjugate. However, the difference in the staining patterns observed with these two 
lectins in sections of breast cancer and breast cancer cell lines suggests that these lectins 
recognise oligosaccharides on different glycocojugates (Mitchell et al. 1998). 
In order to investigate whether enhanced Helix pomatia agglutinin binding in breast 
cancer was due to over-expression of a single or group of glycoproteins, Schumacher el 
al investigated Helirpomatia agglutinin binding in seven metastatic breast cancer cell 
lines. Analysis of the isolated membrane glycoproteins; from these cell lines on Western 
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blots suggested that, in fact several different membrane glycoproteins bound Helix 
pomatia agglutinin (Schumacher et al. 1995). However, one 55kDa glycoprotein, 
identified by protein sequencing to be a human immunoglobulin subclass A has been 
identified which binds Helix pomatia agglutinin in cancer but not benign tissue (Streets et 
aL 1996). 
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2.1 Central Hypothesis 
In this study, serum and tumour samples were collected from women with primary 
operable breast cancer and controls. Serum samples were used to measure androgen 
levels (dehydroepiandrostene sulphate, androstenedione and testosterone levels) using 
conventional ELI SA techniques. As "crosstaW' occurs between steroid hormone and 
growth factor pathways in breast (and prostate) cancer, it was proposed to measure 
cerbB-2 levels using a lectin ELISA format. This technique was chosen as a lectin ELISA 
for cerbB-2 had previously been developed in our laboratory, which showed encouraging 
results as a diagnostic test for breast cancer. 
Elevated levels of serum androgens in postmenopausal women and reduced levels of 
serum androgens in premenopausal women with breast cancer have been reported by 
several recent studies though there is disagreement on the significance of levels of 
different androgens. On the basis of these observations and the results of cell line studies 
it has been proposed that androgens may have a role in the aetiology of breast cancer by 
stimulating growth of hormone-dependent breast cancer in postmenopausal women and 
inhibiting the growth of hormone-dependent breast cancer in premenopausal women 
(Adams 1998). 
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In order to test this hypothesis, in the present study, the levels of three androgens 
dehyroepiandrosterone sulphate, androstenedione and testosterone were measured in a 
sample of women with primary operable breast cancer and controls. Two further 
relationships, between serum androgen levels, body mass index and age have been 
investigated. 
Cell line studies have been performed to examine the effect of two androgens, 5a- 
dihydrotestosterone and 5-androstene-30,17p-diol, on the prolifemtion of hormone- 
dependent breast cancer cell lines MCF7 and T47D and the hormone-independent cell 
breast cancer cell line MDAMB231.5a-Dihydrotestosterone and 5-androstene-30,170- 
diol have been chosen as they are true androgen metabolites, which act at the tissue level 
in vivo (Rochefort et aL 1984). 
A flow cytometric technique has been used to investigate the effect of these androgens on 
DNA cell cycle analysis in 48-hour incubations and cell numbers in 9-day incubations. 
Cell line models have been set up to mimic the hormonal environment in pre and 
postmenopausal women in order to investigate mechanisms by which androgens may 
stimulate the proliferation of hormone-dependent breast cancer in postmenopausal and 
inhibit the proliferation of hormone-dependent breast cancer in premenopausal women. 
A positive correlation between breast cancer incidence throughout the world and 
nutritional status has been demonstrated (DeWaard 1969). Nutritional status has been 
reported to affect androgen production and metabolism and therefore it has been 
60 
Chapter 2 Central Hypothesis 
proposed that androgens are implicated in the development of "Westem-environmentar' 
type breast cancer (Adams 1977). In order to investigate this hypothesis a correlation 
between serum androgen levels and body mass index has been sought. Secondly, a 
correlation between serum androgen levels and age has been investigated, as it has been 
proposed that although serum androgen levels fall with age in healthy women they are 
independent of age in women with breast cancer (Adams 1998). 
Flow cytometry is an established method for the determination of cell surface (Loken et 
aL 2000), cytoplasmic and nuclear antigens (Larson 2000). Multiparameter flow 
cytometry enables the simultaneous determination of expression of several antigens on 
tumour specimens. Flow cytometric methods for the determination of oestrogen receptor 
alpha (Brotherick et aL 1995), oestrogen receptor beta (Girdler et aL 2001) and epidermal 
growth factor receptor expression (Brotherick et aL 1994) have been established in our 
laboratory. In the present study a flow cytometric method for the determination of 
androgen receptor expression in breast cancer has been described. 
A correlation between androgen receptor expression, determined by flow cytometry and a 
more established technique, inummohistochemistry, has been investigated. In order to 
investigate the clinical significance of androgen receptor expression in breast cancer, 
androgen receptor expression has been correlated with existing prognostic markers 
Bloom Richardson grade (Bloom et aL 1957) and lymph node status (Fisher et aL 1978). 
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Oestrogen receptor expression in breast cancer has been found to increase with age 
(Elwood et aL 1980). Expression of steroid hormone receptors is regulated by their 
ligands, by a mechanism known as "negative autoregulation". In order to determine 
whether negative autoregulation determines androgen receptor expression in breast 
cancer in vivo a correlation between androgen receptor expression and serum 
dehydroepiandrosterone, androstenedione and testosterone levels have been investigated. 
In addition, an association between androgen receptor expression and age has been 
investigated. 
In the present study, in addition to androgen receptor expression, oestrogen receptor 
alpha and epidermal growth factor receptor expression has been determined. Flow 
cytometric methods for the determination of oestrogen receptor alpha (Brotherick et al. 
1995) and epidermal growth factor receptor (Brotherick et aL 1994) in breast cancer have 
previously been established in our laboratory. The relationship between androgen 
receptor, oestrogen receptor and epidermal growth factor receptor expression has been 
examined. 
The rational for investigating an association between androgen receptor and epidermal 
growth factor expression was that crosstalk occurs between steroid receptor and growth 
factor receptor pathways in breast (and prostate) cancer (Nicholson et aL 1999). An 
inverse correlation has been reported between oestrogen receptor expression and 
epidermal growth factor expression in breast cancer (Walker et aL 1999), though a 
relationship between androgen receptor and epidermal growth factor expression has not 
hitherto been investigated. 
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Materials and Methods 
The role of androgens in breast cancer 
In the following study Western Blotting was performed by Susan Cook in the Department 
of Surgery, immunohistochemistry by staff in the Department of Pathology. Flow 
cytometry was done mostly by the author under supervision of Susan Stamp and Dr Brian 
Shenton in the Department of Surgery and ELISA under the supervision of Dr David 
Cook in the Department of Clinical Biochemistry. 
3.1 Principles of Flow Cytometry 
Flow cytometry is a technique for making rapid measurements on particles or cells as 
they flow in a fluid stream one by one through a sensing point. A flow cytometer consists 
of a fluidic system, which delivers particles in suspension to a point intersected by a laser 
beam. This incident light is scattered by cells passing through the detection point as well 
as exciting fluorescent dyes bound to the cells. This scattered and fluorescent light is 
collected by photodetectors, which convert the photon pulses to electrical signals. 
On passing through the laser beam several physical processes take place diffraction, 
absorption, refraction and reflection of incident light. Diffraction is of significance close 
to the optical axis and is closely related to the size of the cell passing through the laser 
beam. Low-angle scattered light is focused onto a photoelectric diode. This signal is 
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referred to as forward angle light scatter (FALS). At higher angles, refraction and 
reflection become increasingly important. These processes result from structural features 
of the cell such as granularity and surface convulsions and are referred to as side scatter 
(SS) (Carter el al. 2000). These processes are illustrated in the following figure. 
High angle scatter: 
Reflection & refraction. 
Coll structure. 
Low angle scatter: 
Dift'rection. Coll size. 
Laser 
Direct boom stop. 
Light 
Fluorescence at longer 
wavelengths. 
Intrinsic 
(autofluoreseence) 
and extrinsic. 
Figure 3.1: Diffraction, absorption, refraction and reflection of incident laser light by 
particles passMg through a fluidic system (from hoy@cfac. uk) 
3.2 Use of fluorescent probes in flow cytometry 
The name laser is an acronym for "light amplification by stimulated emission of 
radiation". Laser light produces coherent radiation at discreet wavelengths. Fluorescence 
occurs when a molecule excited by light of one wavelength, returns to the unexcited state. 
Together with light scatter, fluorescence is the major parameter measured by flow 
cytometry. Fluorochromes such as fluorescein and phytoerythrin covalently linked to 
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antibodies can be used to measure antigen expression in cell populations. Propidium 
iodide, which binds DNA, can be used to gain information on cell cycle. 
There is a range of fluorescent molecules used in flow cytometry. The most commonly 
used is fluorescein isothiocyanate (FITC), which emits green light on excitation at 
488nm. The isothiocyanate group links the fluorescein molecule to lysine residue on a 
protein molecule. 
The ability to detect fluorescence simultaneously with two or more compounds 
fluorescing simultaneously at different wavelengths enables several parameters to be 
measured (multiparameter analysis). When a second label is required phycoerythrin 
(PE) is often chosen as it is also excited at 488mn but emits orange light, which can 
easily be distinguished from the green fluorescence of fluorescein (Ormerod 2000). 
3.3 Optics 
The optical configuration for the simultaneous measurement of light scatter and 
fluorescence is illustrated below. The forward collection lens gathers light from 
approximately I to 20 degrees off the laser beam light. Separation of the mixture of 
scattered and fluorescent light emitted from cells is achieved with an arrangement of 
dichroic mirrors and band pass filters. Bandpass filters transmit light of the desired 
wavelength over a narrow band. 
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The dichroic mirrors are placed at 45 degrees to the incident beam. The first mirror 
reflects light below a given wavelength (500nm) towards the side scatter detector. Longer 
wavelengths pass on to the second mirror, which again reflects light below a given 
wavelength (560nm) via a band pass filter to a detector. In this way light emitted from 
different fluorochromes is detected by a series of photomultiplier tubes (Carter et al. 
2000). 
Laseqs) 
Basic Optics of a Flow Cytometer 
(An automated fluorescent microscope) 
Dichroic mirrors 
2 
Cell 431 
Collecvon Band Pass Filters Lenses 
Photo- 
Scatter + multiplier A> 
Low & High 4j, 91p.. tubes angle 
Figure 3.2: Optics of flow cytometer (from hoy@cfac. uk) 
3.4 Interpretation of the signal: the dot-plot and histogram 
A current is generated in photomultiplier tubes by incident light. The amplitude of which 
is proportional to the number of photons reaching the photomultiplier tube. The output 
signal from the photomultipier tube is then passed on to a pre-amplifier. After that 
logarithmic amplification may take place. 
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Logarithmic amplification amplifies weak signals, compresses strong signals and 
J 
normalises data, which is skewed torwards lower values. The final step is conversion of I 
the current pulse to a digital signal, which takes place in the analog-to-digital converter Jý 
ýADC). These digital signals are displayed on a 1024-channel scale. 
With linear amplification a 1000-fold difference in signal intensity can be displayed on I I 
the 1024-channel scale. However, logarithmic amplification allows a 10,000-fold 
difference in signal intensity to be displayed on the 1024-channel scale. The relationship iiý 
between input and output voltages for a logarithmic amplifier is illustrated in figure 3.4. 
The continuous voltage analog signal is translated into a discrete scale by the analog-to- 
digital converter. This scale is divided into 1024 elements of I OmV. In order to 
meaningfully interpret this data it is displayed most commonly in two forms a frequency 
histogram or dot-plot. 
The frequency histogram is a direct graphical representation of the number of events 
occurring for each channel of the ADC. The dot-plot is a plot of the output from one 
ADC against the output from another. In this manner, populations of cells can be 
distinguished on dot-plots and statistical analyses carried out by setting boxes or 
polygons around regions of interest (gating). The antigen expression on a particular 
population of cells for instance, can be measured by limiting the analysis to the 
population within a certain gate (Carter et aL 2000). Examples of histograms and dot- 
plots are shown in figure 3.4. 
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3.5 Measurement of antigen expression by flow cytometry 
Information provided by light scatter and immunofluorescence enables the identification 
of cell populations within a heterogeneous mixture of cells. Having identified the cell 
population of interest, fluoresecent probes conjugated to antibodies directed against cell 
surface, cytoplasmic or nuclear antigens are used to determine antigen expression on a 
particular population (Larson 2000) (Loken et aL 2000). 
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Figure 3.3: Histogram and dot plot of CD3 and CD8 expression on a population of 
lymphocytes (from hoy@cfac. uk) 
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Figure 3.4: Channels/linear/log amplification (from hoy@cfac. uk) 
If intracellular antigens are analysed, it is necessary to permeabilise the cell in order that 
the antibodies can reach the appropriate target antigen, without allowing the antigen to 
leak out of the cell. This is usually achieved by incubation with a combination of fixative 
(paraformaldehyde) and a detergent (triton). 
3.6 Growth Medium 
Full medium consisted of Dulbecco's modified Eagle medium (DMEM) with 1000mg/L 
glucose and without sodium pyruvate (GIBCO Life Technologies, Paisley, UK) was 
supplemented with 10% heat-inactivated fetal calf serum (Sigma, Poole, UK), I% L- 
glutamine (GIBCO) and 0.5% Gentamycin (GIBCO). Stripped Medium consisted of 
DMEM with 1000mg/L glucose and without phenol red or sodium pyruvate (GIBCO) 
was supplemented with 10% charcoal/dexti-an treated foetal calf serum (HyClone, Perbio 
Science UK Ltd, Cheshire, UK), 1% L-glutamine (GIBCO) and 0.5% Gentamycin 
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(GIBCO). Phenol red was omitted from the stripped medium as it has been shown to have 
oestrogenic properties and produces a fluorescent signal, which interferes with the flow 
cytometric analysis. 
3.7 Cell Lines 
All cell lines were routinely cultured in DMEM full medium and grown in 75cm 3 flasks 
(Coming Ltd, High Wycombe, UK) at 370C in a humidified atmosphere containing 5% 
C02 in air. Cells were passaged every 34 days when they had grown to 90% confluence 
The breast cancer cell lines used were all epithelial cells, which grow as monolayers. 
They were the MCF7 cell line (European Collection of Animal Cell Cultures ECACC, 
Salisbury, Wiltshire, UK), which was established in 1970 from a pleural effusion 
obtained from a 69 year-old female (Soule et aL 1973): the T47D cell line (ECACC) 
which was established in 1974 from a 54 year old female with an infiltrating ductal 
carcinoma of the breast (Keydarl et aL 1979): the MDA-MB-231 cell line (ECACC) 
which was established in 1973 from the pleural effusion of a 51 year old female (Cailleau 
et aL 1974): and the SKBR3 cell line (American Type Tissue Culture Collection ATCC, 
Manassas, Virginia, USA) which was established from the pleural effusion of a 43 year 
old female. 
To passage cell lines, culture medium was decanted from the flasks and the cells washed 
with 2ml of Ix tr)Tsin-EDTA (GIBCO) at 37'C to remove any residual fetal calf serum 
(FCS). A further 8ml of Ix trypsin-EDTA was added to the flask and incubated for 
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approximately 5 minutes at 37'C until all the cells were detached. The trypsin-EDTA was 
inactivated by addition of I OmI full medium and decanted into a3 OmI universal 
centrifuge tube (Bibby Sterilin Ltd, Staffordshire, UK). The recovered cells were pelleted 
by centrifugation at 10OOrpm for 5 minutes. The cell pellets were either resuspended in 
full medium and split into flasks or retained in the pellet for cryopreservation (see below). 
Cryopreservation of all cell lines was routinely carried out at an early stage of passage, 
freezing medium contained 80% full medium, 10% FCS (Sigma) and 10% dimethyl 
sulfoxide DMSO (Sigma). Approximately 5xI 06 cells were pelleted by centrifugation, 
resuspended in I ml of freezing medium and transferred into cryogenic vials (Coming, 
USA). To control the rate of freezing cryogenic vials were initially frozen for 4 hours at - 
80'C before transfer to liquid nitrogen for long-tenn storage. 
Reculture of cryopreserved cells was achieved by rapid thawing of the frozen cell 
suspension at 37C and re-suspension in full medium. Cells were washed by 
centrifugation at 10OOrpm for 5 minutes to remove the DMSO, resuspended in fresh full 
culture medium and transferred to culture flasks. 
3.8 Clinical Material 
Patients were recruited to this study from the Breast Unit at the Royal Victoria Infirmary, 
Newcastle upon Tyne over a 2-year period. Venous blood was taken from women with 
confirmed primary operable breast cancer on or preceding the day of operation. Venous 
blood was also collected from women in whom breast cancer had been excluded, as 
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controls who attended the diagnostic breast clinic. All venous blood samples were 
centrifuged at 2500rpm for 5 minutes the serum was removed and stored at -80*C until 
analysed. 
Tumour samples were taken in the operating theatre immediately after excision of the 
breast cancer. A Bard MagnumTm (C. R. Bard Inc, Covington, USA) biopsy instrument 
was used to obtain core biopsies from palpable breast tumours. Core biopsies were snap 
frozen in liquid nitrogen and stored at -80'C until analysed. Ethical permission had been 
granted for this study, and all patients recruited had given their informed consent to tissue 
and serum collection. 
3.9 Titration of Antibodies 
All antibodies were titrated to determine their optimum concentration for use. For the 
titration of the biotinylated androgen receptor antibody (DAKO, Cambridge, UK) 
LNCap, a prostate cancer cell line known to express the androgen receptor (Horoszewicz 
et aL 1983) was used as a positive control and DU145, a prostate cancer cell line which 
does not express the androgen receptor (Stone et aL 1978) was used as a negative control. 
For the titration of phycoerythrin (PE) conjugated epidermal growth factor receptor 
EGFR monoclonal antibody (BD Pharminogen, San Diego, USA) the MCF7 cell line, 
which is known to express EGFR (Chrysogelos et aL 1994) was used as a positive control 
and lymphocytes were used as a negative control. The titration of biotinylated oestrogen 
receptor alpha antibody (DAKO, Cambridge, UK), which follows a similar method 
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outlined below, has previously been established in our laboratory and is described by 
Girdler (Girdler 2002). 
Cultured cells were harvested from the flasks and pelleted by centrifugation. The cell 
pellet was resuspended to form a single cell suspension and incubated with I% 
parafortnaldehyde (BDH Chemicals, Poole, UK) for 30 minutes at 4*C. The cell 
suspension was centrifuged for 5 minutes at 25OOrpm and resuspended in 0.025% triton 
(BDH Chemicals, Poole, UK) to give a final concentration of 1%106 cells/ml. Increasing 
amounts of biotinylated androgen receptor antibody (I td, 21d, 3111 and 5111) or PE 
conjugated EGFR (2.5W, 5gl, l0gl, 201d and 30gl) were incubated with 100gl aliquots of 
cell suspension for 30 minutes at 4'C. Cells were washed with 2ml of isoton (Becton 
Dickinson), centrifuged at 2500rpm for 5 minutes and resuspended in I 00gl of isoton. To 
those cells labelled with biotinylated androgen receptor antibody 21d of streptavidin 
phycoerythrin strep-PE (BD Biosciences, San Jose, USA) were added and incubated for 
30 minutes at 40C. The cell suspension was washed as above and resuspended in 2501d of 
isoton. Finally analysis was performed on a FACScan (Becton and Dickinson) using 
LYSYS 11 software with pre-stored settings. The medians of the FL2 histogram obtained 
were plotted against the different dilutions of antibody and the optimum dilution of 
antibody was selected as the point where the titration curve reached a plateau and the 
negative control remained at a low level. 
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1 
3.1 Preparation and Staining of Tumour Samples and cell lines 
Froz 
I 
en tumour samples were allowed to thaw out before being dissected into small pieces 
and disaggregated by passing through a wire mesh of approximately 501im. diameter 
(Boots Pharmaceuticals Ltd, Nottingham, UK) to form a single cell suspension in isoton. 
To reduce clumping further, cells were then passed through a 531tm nylon mesh 
(Lockertex, Warrington, UK) and the resulting cell suspension centrifuged at 1000rpm. 
zor: ) minutes. The supernatant was discarded and the cell pellet was resuspended in 2mls 
oil I-/o paraformaldehyde. Following incubation at 4(C for 20 minutes, this cell 
swpension was washed and centrifuged as above, and the cell pellet resuspended in 
1 
0.025% triton 
I 
IOOILI of the resulting fixed and permeabilised cells were aliquoted into FACS tubes (BD 
Labware, New Jersey, USA). To these aliquots primary antibody was added at the 
optimal quantity determined by titration, mixed thoroughly on a vortex mixer (Fisons 
Scientific, Loughborough, Leicestershire) and incubated for 30 minutes at 4C. The 
Pr7ary antibodies used were biotinylated androgen receptor antibody, biotinylated 
oestrogen receptor alpha antibody, and phycoerythrin conjugated epidermal growth factor 
re r body. 
Following incubation with primary antibody, the cell suspension was washed and 
centrifuged as above, and resuspended in 1001d of isoton. At this stage, 2111 of I 
strePtavidin phycoerythrin was added to the cells labeled with biotinylated antibodies and 
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5gl of fluorescein isothiocyanate conjugated cytokeratin antibody CK-FITC (Novocastra, 
Newcastle upon Tyne, LIK), an antibody which is directed towards cytokeratins 8 and 18 
(Ferrero el al. 1990), was incubated with each aliquot for 30 minutes at 4'C. Following 
washing with 2ml isoton and centrifugation as above, the fixed, permeabilised and 
stained cells were resuspended in 250pl of isoton and were now ready for analysis. 
Ile following controls were also performed for each sample; unlabelled cells, cells plus 
21d of streptavidin phycoerythrin, cells plus 5pl of fluorescein isothiocyanate conjugated 
cytokeratin antibody. Controls ensured that compensation was correctly adjusted to 
minimize interference between FITC and PE signals. Analysis was performed on a 
Becton Dickinson FACScan using LYSYS 11 software with pre-stored settings. 
The preparation and staining of cell lines for determination of antigen expression follows 
a similar method to that described above for the titration of antibodies. Cultured cells 
were harvested from the flasks and pelleted by centrifugation. The cell pellet was 
resuspended to form a single cell suspension and incubated with I% paraformaldehyde 
(BDH Chemicals, Poole, UK) for 30 minutes at 40C. The cell suspension was centrifuged 
for 5 minutes at 2500rpm and resuspended in 0.025% triton (BDH Chemicals, Poole, 
UK) to give a final concentration of IxI 06cells/ml. 
Primary antibody, biotinylated androgen receptor or biotinylated oestrogen receptor 
alpha, were then added at the optimum quantity determined by titration to I OOpI aliquots 
of this cell suspension. Cytokeratin antibody was not required when labeling cell lines, as 
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they are a homogenous population of epithelial cells. Following incubation for 30 
minutes with primary antibody, the cell suspension was washed with isoton and 
centrifuged at I OOOrpm. The cell pellet was then resuspended in I OOgI of isoton, 2 gl of 
streptavidin phycoerythrin was added and the cell suspension incubated for 30minutes at 
4'C. Following further washing and centrifugation the fixed, permeabilised and stained 
cells were resuspended in 250gI of isoton and analysed on a Becton Dickinson FACScan 
using LYSYS 11 software with pre-stored settings. 
3.11 Data Analysis & Quantification of Fluorescence 
Data analysis on samples on the FACScan was performed using LYSYS 11 software. 
Events were gated on a CK-FITC (fluorescence- 1) against PE (fluorescence-2) dot plot to 
distinguish cytokeratin positive cells from non-epithelial cells. Cytokeratin positive cells 
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Figure 3.5: Dot plot of fluorescence- I against fluorescence-2 to distinguish cytokeratin 
positive (i. e. epithelial) from non-epithelial cells 
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Fluorescence-2 (i. e. PE) histograms for streptavidin-PE, unlabeled cells and androgen 
receptor, oestrogen receptor alpha and EGFR labelled cells were generated for events 
falling within the RI gate. The median fluorescence intensity was determined from these 
fluorescence-2 histogrwns. 
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Figure 3.6: Fluorescence-2 histogram of cytokeratin positive cells 
Analysis of antigen expression on tumour samples and cell lines by the above methods 
generates a fluorescence-2 histogram with a median measured in the arbitrary units of 
median fluorescent intensity. This fluorescence can be quantified into absolute units of 
molecules of equivalent fluorochrome (MEF) using fluorescent microbead standards. 
Spherotec RCP50 beads were used to standardise the arbitrary units of median 
fluorescence intensity obtained on the cytometer into absolute units of molecules of 
equivalent fluorochrome. The beads were run using the same instrument settings 
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determined for cell line or tumour samples on FACScan and analysed using LYSYS 11 
software. 
Beads were gated as singlets on a dot plot of FSC against SSC and fluorescence-2 
histograms were generated from the gated events. The number of molecules of equivalent 
fluorochrome of the beads was obtained by the manufacturer spectrophotometrically, 
with reference to solutions containing known phycoerythrin molecules of fluorescence. 
These values were as follows 425,1131,3765,11628,34589,128918 and 294760. 
Figure 3.7: Fluorescence-2 histogram of Spherotec RCP50 beads 
A regression line of median fluorescent intensity against molecules of equivalent 
fluorocrome (i. e. phycoerythrin) was generated using Tallycal software (DAKO, 
Cambridge, UK) for the bead populations. From the regression equation the number of 
molecules of equivalent fluorochrome for the phycoerythrin labelled cell lines was 
extrapolated. 
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Figure 3.8: Regression curve of DAKO fluorospheres using Tallycal software: 
X-axis = log [bead calibration number] number of molecules of equivalent 
fluorochromeY-axis = log [median fluorescent intensity of fluorescence-2 histogram]. 
The following equation can thus be generated from which the antigen expression of 
tumour samples or cell lines can be quantified y=4.06 x+ 104.06 
Unlabeled cells and cells incubated with streptavidin-PE have a background fluorescence 
which does not reflect antibody binding to antigens expressed by the tumour cells. The 
number of molecules of equivalent fluorochrome was therefore determined for unlabelled 
cells and cells labelled with streptavidin-PE. In order to obtain the antigen expression the 
number of molecules of equivalent fluorochrome for cells incubated with streptavidin-PE 
was subtracted from the value obtained from cells stained with biotinylated androgen or 
oestrogen receptor antibody and streptavidin-PE. Likewise, the number of molecules of 
equivalent fluorochrome was determined for unlabeled cells and subtracted from the 
number of molecules of equivalent fluorocrome obtained for cells labeled with 
phycoerythrin conjugated EGFR antibody. 
79 
Chapter 3 Materials andMethods 
3.12 Staining and Analysis of DNA 
The DNA content of a cell shown as a cycle detennined by flow cytometry provides 
information on aneuploidy (i. e. an abnormal amount of DNA) and gives a static estimate 
of the percentage of cells present in each phase of the cell cycle (i. e. Go/I, S, and G2M. 
Cell lines were used as an in vitro model to assess the effects of 5cc-DHT, androstenediol 
and 170-oestradiol on cell cycle and cell proliferation. The study of synchronous 
populations of cells allowed steroid induced changes in the cell cycle to be quantified. To 
achieve synchronous cell populations, cells were cultured in full medium and harvested 
when approximately 80% confluent. The cells were then pelleted by centrifugation and 
resuspended in stripped medium. Cells were seeded in 12-well culture plates (Coming) 
for cell cycle studies and 6-well plates (Coming) for proliferation studies. The cells were 
allowed to adhere to the wells for 24 hours. At this point, cell cycle analysis was 
determined by processing the cells from wellsý outlined below. The stripped medium was 
aspirated from the remaining wells and replaced with stripped medium supplemented 
with steroids. 
The following method was used to prepare and stain cell lines for DNA analysis. 
Cultured cells were harvested with I xtrypsin/EDTA and pelleted by centrifugation at 
2500rpm for 5 minutes. The cell pellet was resuspended in 350gl of full medium and 
incubated for 5 minutes at 37'C. I OOpI of 0.25mg/ml propidium. iodide PI (Sigma, Poole, 
UK) containing 5% triton X-100 (BDH Chemicals, Poole, UK) and 50pl of lmgIml 
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RNAse (Sigma, Poole, UK) was added to the cell suspension. Analysis was performed on 
a Becton Dickinson FACScan using LYSYS 11 software with pre-stored settings. 
Permeabilisation of the cell membrane with the detergent triton X- 100 was required to 
allow the dye propidium iodide access to the DNA. RNAse was required to remove RNA 
to which the propidium iodide would otherwise bind. Propidium. iodide is a nucleic acid 
dye, which intercalates between the bases in double stranded nucleic acids. When excited 
by a 488nm laser, propidium iodide fluoresces at 620nm, which can be detected by the 
fluorescence-2 or fluorescence-3 photornultiplier tubes. 
Data files were converted from HP to PC format using HP disk (Applied Cytometry 
Systems, South Yorkshire, UK). DNA data analysis was then performed using Multicycle 
(Phoenix Flow Systems, San Diego, USA). This software used algorithms to deconvolute 
the DNA histogram and fit a cell cycle model. The DNA was identified on a dot plot of 
fluorescence-2 area against fluorescence-2 width and gated to exclude doublet and triplet 
molecules. 
F 2-1 F-E-Sm- 1 
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Figure 3.9: Dot plot of fluorescence-2 area against fluorescence-2 width. DNA from cell 
lines is gated to exclude doublet, triplet etc. populations. 
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A fluorescence-2 histogram of these gated events displays the DNA profile, and 
Multicycle was then used to fit the three phases of the cell cycle and calculate the 
percentage of cells within each phase. A DNA histogram exhibiting more or less than one 
Go/, peak is classified as aneuploid (Ormerod 2000). 
Figure 3.10: Fluorecence-2 histogram of gated events from the above dot plot. 
Multicycle software is used to determine the percentage of cells in each stage of the cell 
cycle from this histogram. 
3.13 Cell proliferation studies 
To assess the effect of steroids on the proliferation of cultured cells, the following method 
was followed. Cultured cells were harvested from 6 well plates by I xtrypsin/EDTA and 
pelleted by centrifugation at 2500rpm for 5 minutes in falcon tubes. The cells were then 
resuspended in 350gl of stripped medium and incubated for 5 minutes at 37T. 40gl of 
lmg/mI propidium iodide (Sigma, Poole, UK) and lOpI of Flow Count Fluorospheres 
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(Coulter, Bedfordshire, UK) were added. Analysis was performed on a Becton Dickinson 
FACScan using LYSYS 11 software on pre-stored settings. 
The incubation step prior to adding propidium iodide was necessary, as harvesting with 
I xtrypsin/EDTA damages the cell membrane rendering the cell leaky to small molecules 
such as propidium iodide. The incubation step enabled the cells to repair the cell 
membrane allowing all viable cells to remain impenetrable to propidium Iodide. 
Therefore propidium iodide was excluded from viable cells with an intact cell membrane, 
but intercalated with DNA from dead cells with a leaky cell membrane. Flow count 
fluorospheres consist of I Opm polystyrene fluorescent particles in an aqueous solution at 
a known concentration per Vd. They are excited by laser light at 488nm and have a broad 
emission spectrum of 525nm-700nm. 
Cells were analysed on a dot plot of FSC against SSC and a RI gate set around cells to 
exclude debris and an R2 gate set on the fluorospheres. A dot plot of fluorescence- I 
against fluorescence-2 was constructed for all events within the RI and R2 regions. Dead 
cells took up propidium iodide staining with higher fluorescence-2 intensity, and 
therefore could be easily identified. Quadrants were set so that the upper left area 
contained the dead cells, the lower left area the live cells and the upper right area the 
fluorospheres. 
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Figure 3.11: Dot plot of forward scatter (FSC) against side scatter (SSC) of cell lines and 
fluorospheres (gated RI and R2 respectiVely). A dot plot of fluorescence- I against 
fluorescence-2 is illustrated for the cells gated RI and R2. Quadrants have been set to 
distinguish dead from live cells and fluorospheres. The number of live cells = number of 
events in lower left quadrant / number of events in upper nght quadrant x fluorospheres 
per jAl x volume of fluorospheres added to sample (ýtl) 
3.14 Western Blotting and sodium dodecyl sulphate polyacrylamide gel 
electrophoresis SDSPAGE 
Western blotting was used to confirm the specificity of the androgen receptor antibody. 
Cultured LNCap cells were harvested and pelleted by centrifugation at 180xg for 
5minutes. Approximately IX 106 cells were lysed with 0.5ml of lysis buffer containing 
0.125M Tris-HCI (BDH Chemicals, Poole, UK) at pH 6.8,2% sodium dodecyl sulphate 
SDS (BDH Chemicals, Poole, UK), 10% glycerol (Sigma-Aldrich, Poole, UK), 0.001% 
bromophenol blue (BioRad, Hemel Hempstead, UK) and 10% P-mercaptoethanol 
(Sigma-Aldrich, Poole, UK). Sodium dodecyl sulphate is a detergent, which denatures 
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proteins and P-mercaptoethanol aids in separating the polypeptide chains by breaking 
disulphide bonds, which maintain protein confirmations. 
The cell suspension was heated to 100'C for 5minutes to ftu-ther denature proteins and 
centrifuged for 5 minutes at 12,000xg to pellet any debris. Gel electrophoresis of the 
proteins was performed using SDS-polyacrylamide gels to separate proteins by molecular 
weight. Polyacrylamide gels were set up using a running gel consisting of 10% 
acrylamide: bis-acrylamide 29: 1 mix (Kramel Biotech, Cramlington, UK), 375mM Tris- 
HCI (BDH Chemicals, Poole, UK) at pH8.8,0.1 % sodium dodecyl sulphate (BDH 
Chemicals, Poole, LTK), 1% ammonium persulphate (Sigma-Aldrich, Poole, UK) and 1% 
tetramethylethylenediamine TEWD (Sigma-Aldrich, Poole, UK). TEMED catalyzed the 
formation of free radicals from ammonium persulphate, which caused the acrylamide and 
bis-acrylamide to polymerize to form a gel matrix, which could be used for sieving 
macromolecules. 
Having allowed the running gel to set, it was overlaid with a stacking gel (5% 
acrylamide: bis-acrylamide mix, 125mM Tris-HCI at pH6.8,0.1% SDS, I% ammonium 
persulphate and I% TENED). Gels were assembled in a pouring frame and having set 
were transferred to a running frame (Mini Protean II, Bio-Rad, Hemel Hempstead, LJK) 
containing electrophoresis buffer containing 25mM Tris, 190mM glycine (BDH 
Chemicals, Poole, UK) and 0.1% SDS. 20gl of cell lysates and 3ptl of Seeblue standards 
(Novex, Frankfurt, Germany) were loaded into preformed wells in the stacking gels. 
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Electrophoresis was carried out at 200V for 45-60 minutes in electrophoresis buffer. The 
negatively charged proteins migrating towards the anode and separating on the basis of 
polypeptide chain size. Following electrophoresis, the proteins were transferred to a 
Hybond-C nitrocellulose membrane (Amersham. Life Sciences Ltd, Amersham, UK) by 
electrophoresis at 30V for 16 hours in transfer buffer containing 25mM Tris HCI pH 8.3, 
150mM glycine and 10% methanol (BDH Chemicals, Poole, UK). 
Nitrocellulose membranes have a high binding capacity for proteins. Therefore it was 
important to block any non-specific protein binding sites before incubating the membrane 
with antibody. Membranes were immersed in blocking solution for I hour at room 
temperature containing 5% non-fat milk powder (Marvel, Merseyside, UK), 20mM Tris- 
HCI at pH 7.5, and 500mM NaCI (BDH Chemicals, Poole, UK) and washed with Tris- 
Tween solution (0.1% Tween-20,2OmM Tris-HCI, 500mM NaCI). 
Membranes were then transferred to primary antibody solution containing androgen 
receptor mouse anti-human monoclonal antibody (Dako, Cambridge, UK), 0.05% 
skimmed milk protein and Tris-Tween solution, wrapped in cellophane, heat sealed and 
incubated for I hour at room temperature on a rotating wheel. To remove any unbound 
primary antibody, the membrane was washed twice for 5 minutes with Tris-Tween 
solution and incubated with secondary antibody solution containing I in 500 horse radish 
peroxidase conjugated mouse immunoglobulin HRP-lgG (Dako, Cambridge, UK) in Tris- 
Tween solution containing 0.05% non-fat milk powder for I hour with agitation. 
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Unbound secondary antibody was removed by two washes for 5 minutes in Tris-Tween 
solution, followed by a wash for 10 minutes in Tris buffer solution. A chemiluminescence 
system (ECL Plus, Amersham Life Sciences Ltd) was used to HRP conjugated secondary 
antibody and signals were visualised by exposure to X-ray film. 
3.15 Immunohistochernistry of LNCap cells with androgen receptor 
antibody (AR441) 
Immunobistochemistry of LNCap cells was performed to confirm that the androgen 
receptor antibody AR441 bound to antigen on sections of a cell line known to express 
androgen receptors (Horoszewicz et aL 1983). Preparation of a cellblock from the 
cultured LNCap cells was as follows. Cells were harvested from flasks with 3MM 
ethylenediaminetetraacetic acid EDTA (Sigma-Aldrich, Poole, UK), pelleted into 15ml 
Falcon tubes at 1700xg for 5 minutes. The supernatant was decanted the pellet fixed by 
incubation with 4% formalin (Sigma-Aldrich, Poole, UK) in phosphate buffer solution at 
pH 7.0 for I hour at room temperature. All but I ml of the fixative was decanted, the 
block loosened with a gentle tap on the bench and removed with forceps. 
This cellblock was then processed by hand by sequential 30 minute incubations with 
increasing concentrations of ethanol (70%, 95%, 100% and 100%), followed by 
incubation with xylene for 30 minutes and 60 minutes and finally wax twice for 60 
minutes, before embedding the block. 
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Sections were cut from the cellblock and pre-treated with 0.5% hydrogen peroxide 
solution (BDH Chemicals, Poole, UK) in methanol (BDH Chemicals, Poole, UK) for 
10minutes and rinsed with running tap water prior to pressure-cooking sections for 
antigen retrieval. Pressure-cooking was performed in 1.5L of citrate buffer containing 
21g citric acid monohydrate powder, 140m. M of 2MNaOH (BDH Chemicals, Poole, UK), 
I OL of distilled water at I OOT for 2 minutes. 
Sections were then rinsed in cold water, transferred to 0.005M Tris buffer solution TBS 
(BDH Chemicals, Poole, UK) for 5 minutes, and covered with normal rabbit solution 
NRS (Sigma-Aldrich, Poole, UK) for 10 minutes. Incubation with primary antibody 
solution containing I in 75 mouse anti-human androgen receptor monoclonal antibody 
AR441 (Dako, Cambridge, UK) was then undertaken for 30 minutes. Following 
incubation with primary antibody, the sections were rinsed twice with TBS and incubated 
for 30 minutes with secondary antibody- biotinylated rabbit anti-mouse antibody RAM 
(DAKO, Cambridge, UK) diluted I in 500 in normal rabbit serum. 
Sections were again rinsed twice for 5 minutes in TBS, excess removed, before 
incubation with I in 100 tertiary antibody, streptavidin-biotin-peroxidase (DAKO, 
Cambridge, UK) in normal rabbit serum for 30 minutes. Sections were rinsed twice in 
TBS for 5 minutes; peroxidase activity was then developed, by incubating the sections for 
5 minutes in diaminobenzidine tetrahydrochloride DAB solution (Sigma-Aldrich, Poole, 
UK). DAB solution was prepared by mixing 0.2ml of a solution containing a 10mg DAB 
tablet (Sigma-Aldrich, Poole, UK) in I Omls TBS at pH 7.6 to 0.2mls, of a solution 
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containing 30vol hydrogen peroxide (BDH Chemicals, Poole, UK) in 5.8mls of distilled 
water., 
Following incubation with DAB, sections were rinsed under running tap water for 10 
minutes, counterstained with haemotoxylin, mounted in DPX (CellPath) and visualised 
under a microscope. 
3.16 Immunohistochemistry of paraffin sections of breast tumours with 
androgen receptor antibody AR441 
Sections were pre-treated with 0.5 % solution of hydrogen peroxide in methanol for 10 
minutes, washed in running tap water and rinsed in 0.005M tris buffered solution (TBS) 
pH 7.6 for 5 minutes. Sections were then incubated with normal rabbit serum diluted I in 
10 with tris buffered solution for 10 minutes, excess serum was removed and replaced 
with primary antisera containing aI in 200 dilution of the androgen receptor monoclonal 
antibody AR441 (DAKO) in normal serum for 30 minutes. After two further 5 minute 
rinses with tris buffered solution, sections were then incubated with secondary antiserum 
containing aI in 500 dilution of biotinylated rabbit anti-mouse antibody in normal rabbit 
serum for 30 minutes. Sections were rinsed again with tris buffered solution, as above, 
prior to incubation for 30 minutes with tertiary antiserum, which contained I p] 
streptavidin, I Id biotinylated horseradish peroxidase and I OOILI of normal rabbit serum. 
After two further 5 minute rinses with tris buffered solution peroxidase activity was 
developed by a 5-minute incubation with diaminobenzidine tetrahydrochloride solution 
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(DAB). Sections were then rinsed in running tap water, conterstained with haematoxylin, 
mounted in DPX and visulaised under a microscope. 
3.17 Measurement of serum androstenedione, DHEAS and testosterone 
Serum was collected pre-operatively from women presenting with primary operable 
breast cancer on or preceding the day of surgery. Controls were taken from the diagnostic 
breast clinic from women presenting with breast symptoms, in whom the diagnosis of 
breast cancer had been excluded. Patients on exogenous oestrogens were excluded from 
the study. Blood samples were spun at 2,500 rpm for 5 minutes and the serum decanted 
and frozen at -70'C until analyzed. Serum DBEAS, androstenedione and cortisol were 
measured using ELISA kits (DRG Diagnostic% The limit of detection defined as the 
steroid concentration corresponding to the mean absorbance of 20 replicates of the zero 
standard minus 2 standard deviations, and the intraassay and interassay coefficients of 
variation for these kits are summarized in the following table. 
Lowest detectable 
limit 
Intra assay 
coefficient of 
variation % 
Inter assay 
coefficient of 
variation % 
DHEAS 0.02microg/ml 2.13-5.07 2.96-8.67 
I Androstenedione 0.043ng/ml 2.79-6.30 5.95-8.09 
1 Cortisol 2.5ng/ml 3.98-4.70 4.96-9.59 
Table 3.1: Specifications of senun androgen kits 
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Materials and Methods 
A lectin ELISA for cerbB-2/HER-2 
4.1 Lectin ELISAs 
The lectin-based methods summarised above are not suitable for the investigation of a 
large number of clinical specimens. Lectin-based assays using the familiar sandwich 
ELISA technology in mult1well plates have been developed for this purpose. Pekelharing 
et al first described a lectin-enzyme immunoassay for the measurement of transferrin 
sialovariants (Pekelharing et al. 1987). 
By replacing the immobilized or enzyme-linked antibody with a lectin a heterologous 
lectin-enzyme immunoassay to study the glycosylation of glycoprotems is constructed. 
The sandwich consists of a lectin and an antibody. Only glycoprotein that meets two 
conditions is measured. It must be the right protein to be bound by the antibody and have 
the relevant glycan structure to bind the lectin (Pekelharing et al. 1987). 
Antibody Lectin 
Protein 
Colour 
Solid Phase Change 
Figure 4.1: Lectin ELISA 
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Two configurations are possible, both of which have drawbacks. If the lectin is 
immobilised, it may bind glycans of other glycoproteins in the sample, which compete 
with the molecule of interest for the available binding sites. This may strongly influence 
the results and reduce the sensitivity of the method. On the other hand, when an antibody 
is used as a capture molecule, care must be taken to ensure that the antibody is not 
binding to the same determinant as that reacting with the lectin (Turner 1992). 
Both types of assay bear the risk of binding of the lectin to the carbohydrate determinants 
of the immunoglobin used as an antibody: IgG contains 5% carbohydrate, IgM 12% and 
IgA 7.5%. This may cause elevated binding in the absence of sample (Pekelharing et aL 
1987). 
Lectin ELISAs have subsequently been reported for the investigation of serum 
glycoproteins in a variety of diseases. Madiyalakan et al reported a lectin ELISA for the 
determination of CAI 25 antigen in ovarian cancer patients using an anti-CAI 25 
monoclonal antibody in the solid phase and 125 I-labelled wheat germ agglutinin in the 
liquid phase. A moderate correlation was found between the dual monoclonal antibody 
sandwich assay and lectin ELISA for CAI 25 in this study. The sensitivity of the lectin 
ELISA was higher than the conventional ELISA, though the specificities were 
comparable. This suggested that a lectin could potentially improve the diagnostic utility 
to detect ovarian cancer (Madiyalakan et aL 1996). 
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Parker et al developed a lectin ELISA for the diagnosis of pancreatic cancer, in which a 
lectin wheat germ agglutinin was bound to the solid phase and an anti-mucin antibody 
CAM17.1 and peroxidase-tagged antibody in the liquid phase were used as a detection 
system. The sensitivity and specificity of this assay compared with conventional 
radioinimunoassay for another mucin antigen CAI 9-9 (Parker et aL 1992). 
4.2 Blotinylation of synthetic p185 peptide 
A synthetic p 185 peptide (Cambridge Research Biochemicals Ltd, Cheshire, UK), which 
consists of the following sequence of amino acids, Pro-Glu-Ser-Phe-Asp-Gly-Asp-Pro- 
Ala-Sec-Asn-Thr-Ala-Pro-Leu-Glu-Pro-Cys was biotinylated by the following method. 
This sequence of amino acids forms part of the extracellular domain of BER-2. This 
synthetic peptide was used as the antigen against which the monoclonal antibody OM- II- 
954 (Genosys; Biotechnologies) was raised. 
150gg of p185 peptide was dissolved in O. Iml of OAM phosphate buffer solution O. lM 
NaP04 (BDH Chemicals, Poole, UK) to give a pl. 85 solution of 1500pg/ml. 
Molecular weight p 185 peptide = 2150 
Therefore the concentration of pl. 85 solution = 1500/2150 = 0.7 gmol/L 
2ml of EZ-linIJm NHS-LC biotin (Perbio Science, Cheshire, UK) was dissolved in l2pl 
of dimethyl sulfoxide DMSO (Sigma-Aldrich, Poole, UK) and 188pl of deionised water 
to give an EZ-linkTm solution of I Omg/ml. 
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Molecular weight of EZ-linkTm = 556.8 
Therefore the concentration of EZ-IinkTm solution = 10/556.8 = 17.9 Itmol/L 
To give a 10: 1 ratio of EZ-Iink7m: p 185 solution 
X= 10 x 0.7/18 = 0.39 mls of EZ-finOm need to be added per ml of p185 protein 
or, 19.5 pl EZ-liným to 501A of p185 solution. 
Therefore, 50gl of p185 solution and 19.5gl of EZ-IinkTm solution were vortexed and 
incubated for 4 hours at 4'C. The biotinylated p 185 peptide was separated from the 
excess biotin molecules by eluting the mixture through a 6x I cm column containing 
sephadex G-25 (Sigma-Aldrich, Poole, UK) with 0.0 1M phosphate buffer solution. I ml 
fractions were collected following elution with this buffer. 
4.3 Capture of biotinylated synthetic p185 by cerbB2 antibody OM-11-964 
Carbonate buffer: 0.1 M NaC03/NaHCO3 (BDH Chemicals, Poole, UK), pH 9.6 
PBS-Tween solution: OAM NaP04 (BDH Chemicals, Poole, UK), 0.10/oTween-20 
(Pharmacia, Uppsala, Sweden), pH 7.4 
Tris-Tween solution: OAM TrisHCI (BDH Chemicals, Poole, UK), 0.1% Tween-20, pH 
7.6 
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Immulon 4 microtiter plates (Dynex Technologies, Chantilly, USA) were incubated 
overnight with I 00gl of I in 1000 OM 11 -954 (Genosys Biotechnologies) in carbonate 
buffer at 4*C, washed x3 with PBS-Tween solution and slapped dry. 
I 00gl dilutions of biotin pl 85 in I% bovine serum albumin BSA (Sigma-Aldrich, Poole, 
UK) PBS-Tween solution were added per well and incubated overnight at 4'C, washed 
x6 with Tris-Tween solution and slapped dry. 
I 00gl of I in 2000 streptavidin alkaline phosphatase (Sigma-Aldrich, Poole, UK) in I% 
BSA Tris-Tween solution was added per well and incubated for 2 hours at room 
temperature, then washed x6 with Tris-Tween solution and slapped dry. 
I 00pl of BCIP substrate (KP Laboratories, Maryland, USA) was then added per well, and 
the absorbance was read on a vmax Idnetic microplate reader (Molecular Devices) at 
620nm. 
4.4 Competition between unconjugated syntheic p185 and blotinylated 
synthetic p185 for binding to cerbB2 antibody (OM-11-954) 
I 00ptl of I in 1000 OM- 11-954 in carbonate buffer was added per well and incubated 
ovemight at 4*C. Wells were washed x3 with PBS Tween solution and slapped dry. 
Dilutions of unconjugated synthetic p 185 in I% BSA PBS Tween were prepared. 
50gl of biotinylated synthetic p185 containing 800ng of protein in 1% BSA PBS Tween 
and 50pl of unconjugated synthetic p185 containing 0-15OOng of protein were added per 
well and incubated overnight at rC. Wells were washed x6 with TrisTween solution and 
100gi of I in 1000 streptavidin alkaline phosphatase in 1% BSA Tris Tween solution was 
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added per well and incubated for 2 hours at room temperature. Wells were then washed 
x6 with Tris-Tween solution and slapped dry. 100gl of BCIP substrate (KP Laboratories, 
Maryland, USA) was then added per well, and the absorbance was read on a vmax Idnetic 
microplate reader (Molecular Devices) at 620nm. 
4.5 Preparation of Zabrecky Lysate of SKBR3 cells 
Lysis Buffer: I OmM NaPO4 (BDH Chemicals, Poole, UK), 140mM NaCl (BDH 
Chemicals, Poole, UK), 1% Triton X-100 (BDH Chemicals, Poole, UK), 2.5ml Trasylol 
(Bayer), 0.1% sodium dodecyl sulphate (BDH Chemicals, Poole, UK), I% sodium 
deoxycholate (BDH Chemicals, Poole, UK) and I m. M phenylmethylsulfonylfluoride 
(Sigma-Aldrich, Poole, UK) 
Preparation of a SKBR3 cell lysate follows the method described by Zabrecky (Zabrecky 
et aL 199 1) and is as follows. The SKBR3 cell line was chosen as it has been shown to 
express high levels of HER-2 protein (Leitzel et aL 1992). 
5001d of SKBR3 cells were removed from storage in liquid nitrogen, thawed and 250pl 
aliquots; were transferred to I ml Eppendorf tubes. The cells were then centrifuged at 
13,000rpm for 15minutes at 4'C to from a cell pellet. The supernatant was decanted and 
the pellet resuspended by vortexing in lysis buffer (described above). This cell suspension 
was incubated for 30minutes at 40C, centrifuged for 20minutes at 13,000rpm and the 
supernatant decanted into I ml Eppendorf tubes. This supernatant was re-centrifuged for 
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10minutes at 13,000rpm and 25pl aliquots added to lOOAI of buffer containing 50mM 
BEPES (Sigma-Aldrich, Poole, UK), 140mM NaCI (BDH Chemicals, Poole, UK), 0.1% 
Triton X- 100 (BDH Chemicals, Poole, UK), at pH 7.5. These 125 gI aliquots; of Zabrecky 
lysate were stored at -800C. 
4.6 Binding of OMI 1-954 with Zabrecky Lysate of SKBR3 cells 
This experiment was undertaken to demonstrate that the OMI 1-954 antibody, used as the 
capture antibody in the lectinELISA, bound to p185 protein coated to wells incubated 
overnight with Zabrecky lysate of SKBR3 cells. Medium from the SKBR3 cells, obtained 
after centrifiiging the cell suspension in the first step of the preparation of Zabrecky 
lysate was also investigated to establish whether this contained any shed p 185 protein. 
The IHER-2 protein content of the Zabrecky lysate of SKBR3 cells was also measured 
using cerbB-2 kits (Oncogene Science). 
Immulon 4 microtitre plates were incubated overnight at 4'C with 100 gl of Zabrecky 
lysate or medium of SKBR3 cells diluted in carbonate buffer, washed 3x with PBS- 
Tween solution and slapped dry. 100pl of I in IOOOOMII-954 in I% BSA PBS-Tween 
solution was added per well, incubated overnight at 4'C, washed x6 with Tris-Tween 
solution and slapped dry. I OOpI of I in 1000 alkaline phosphatase conjugated anti-mouse 
IgG (Sigma-Aldrich, Poole, UK) in I% BSA Tris-Tween solution was added per well and 
incubated overnight at 40C. After washing x6 with Tris-Tween solution and slapping the 
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wells dry, I 00ptl of BCIP was added and absorbance was read at timed intervals on a 
vmar kinetic microplate reader (Molecular Devices) at 620nm. 
4.7 Binding of wheat germ agglutinin to complex carbohydrates 
Fetuin, a heavily glycosylated glycoprotein was used to check that the lectin used in the 
assay, wheat germ agglutinin, binds to glycoconjugate. 3mgIml fetuin in phosphate buffer 
solution was diluted to a final concentration of 30gg/ml. Immulon 4 plates were coated 
overnight at 4*C with 100ptl dilutions of 30pglml fetuin in carbonate buffer, washed x6 
with PBS-Tween solution and slapped dry. I OOpI of I in 1000 biotin conjugated wheat 
germ agglutinin b-WGA (Vector) in I% PBS-Tween was added per well, incubated 
overnight at 4*C, washed x6 with Tris-Tween solution and again slapped dry. Finally, 
wells were incubated with I 00ptl of I in 1000 streptavidin alkaline phosphatase (Vector) 
in 1% BSA Tris-Tween solution for 2hours, at room temperature, washed x6 with Tris- 
Tween solution, slapped dry and I OOgI of BCIP added per well. Absorbance was read at 
timed intervals on a vmax kinetic microplate reader (Molecular Devices) at 620nm. 
4.8 The HER-2/cerbB-2 lectin ELISA 
Having established by the above methods that the capture antibody OMI 1-954 binds 
p 185 the extracellular domain of HER-2, the Zabrecky lysate of SKBR3 cells contains 
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the BER-2 protein and that OMI 1-954 binds to this protein, and the wheat germ 
agglutinin binds to complex carbohydrates, the next step was to construct the HER-2 
lectin ELISA. 
Immulon 4 microtitre plates were incubated overnight at 40C with 100 pl of I pgIml 
OM 11-954 in carbonate buffer, then washed x3 with PBS-Tween and slapped dry. I 00pl 
of SKBR3 Zabrecky lysate diluted in I% BSA PBS-Tween was added per well, 
incubated overnight at 4*C, washed x6 with PBS-Tween and slapped dry. I 00gl of I in 
1000 biotinylated wheat germ agglutinin in I% BSA PBS-Tween was added per well, 
incubated overnight at 4'C, washed x6 with Tris-Tween solution and slapped dry. 
Finally, after 2 hours incubation at room temperature with I 001d of I in 1000 streptavidin 
alkaline phosphatase in I% BSA Tris-Tween, followed by further washing in Tris-Tween 
solution and slapping dry, I 00pl of BCIP was added and absorbance was read at 620nm 
at timed intervals, as above. 
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Results and discussion 
Serum androgens levels in breast cancer 
All patients were recruited to this study between August 2000 and July 2002 from the 
Breast Unit at the Royal Victoria Infirmary, Newcastle upon Tyne. Cases had confirmed 
primary operable screen-detected or symptomatic breast cancer. Controls were recruited 
from the diagnostic breast clinic and had a variety of benign breast disorders. The case 
and control groups had a similar mean, median and range of ages. This data is 
summarized in the following table. 
Number Age Range Median Age Mean Age 
Premenopausal case 23 33-51 46 44.7 
Premenopausal control 25 34-52 46 44.8 
Postmenopausal case 58 48-80 63 63.1 
Postmenopausal control 37 48-86 62 63.0 
Table 5.1: Sample demographics DHEAS and androstenedione 
Number Age range Mean age Median age 
Premenopausal 21 33-51 45.0 47.5 
case 
Premenopausal 22 34-52 45.0 46 
control 
Postmenopausal 51 46-86 63.0 63 
case 
Postmenopausal 41 48-88 63.0 64 
control 
Table 5.2: Sample demographics serum testosterone 
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Results 
5.1 Relationship between serum androstenedione, DHEAS and testosterone 
levels in women with breast cancer and controls 
In this study serum androstenedione levels were significantly correlated with DHEAS in 
women with breast cancer (p<0.0001, r2=0.54) and controls (p<0.0001, r2--0.58). Serum 
testosterone levels were correlated with androstenedione, in women with breast cancer 
(p=0.0024, r2=0.14) and controls (p=0.000 1, r2=0.24) and DHEAS in women with breast 
cancer (p=0.02, ? --0.07) and controls (p<0.0001, i2=0.30). This data is illustrated in the 
following graphs and tables. 
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Serum JDHEASJ versus 
Destosterone] In women with 
breast cancer 
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Figure 5.1: Serum testosterone versus DHEAS and androstenedione 
Testosterone 
Case Control 
DHEAS p=0.02 2<0.0001 
r'=0.07 r'=0.30 
Androstenedione p!:: 2.0O)A p=0.0001 
r'=0.14 r'=0.24 
Table 53: Results of linear regression analysis of serum testosterone against DHEAS 
and androstenedione for women with breast cancer and controls 
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Androstenedione 
Case Control 
DHEAS R<0.0001 R<0.0001 
x'=0.54 r--0.56 
Table 5.4: results of linear regression analysis of serum DHEAS against androstenedione 
for women witli breast cancer and controls 
5.2 Relationship between serum androstenedione, DHEAS and testosterone 
levels and age in women with breast cancer and controls 
In the control group of this study, we observed a decline in serum DHEAS levels with 
increasing age. The association between serum DHEAS and age in the control group was 
significant (linear regression p--0.006) though the correlation was low (r--0.09). 
Likewise serum testosterone levels were found to decline with age, the association 
between serum testosterone and age was significant (linear regression p=0.006) but again 
the correlation coefficient was low (r2--0.09). Serum androstenedione levels also fell with 
age in the control group, though the association between serum androstenedione and age 
was not significant (linear regression p=0.08). 
The association between age and serum adrenal androgen levels in women with breast 
cancer was significant Oinear regression p=0.003) but again the correlation was low 
(r 2 =0.1). Serum testosterone levels also fell with age, though the association between age 
and serum testosterone levels in women with breast cancer failed to reach significance 
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Oinear regression p=0.07). The relationship between serum adrenal androgen levels and 
age are demonstrated in the following graphs. 
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Figure 5.2: Relationship between serum androstenedione, DHEAS and age in women 
with breast cancer and controls 
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Serum Testosterone levels 
versus age In patients with 
breast cancer 
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Figure 5.3: Relationship between serum testosterone levels and age in women with 
breast cancer and controls 
Testosterone DHEAS Androstenedione" 
Case R2 0.05 0.1 0.09 
P value 0.07 0.003 0.006 
Control R2 0.09 0.1 0.05 
P value 0.009 0.003 0.08 
Table 5.5: Relationship between serum testosterone, DHEAS and androstenedione levels 
and age in women with breast cancer and controls 
105 
Chapter 5 Resu Its and Discussion 
5.3 Serum androstenedione, DHEAS and testosterone levels in women with 
breast cancer and controls 
Next the serum levels of androstenedione, DHEAS and total testosterone in pre and 
postmenopausal women with breast cancer and control groups were compared. Both 
mean and median serum DHEAS levels were elevated in postmenopausal women with 
breast cancer. However, although the difference in median serum DHEAS between 
postmenopausal women with breast cancer and controls was significant (Mann-Whitney 
test p=0.03 8), the difference between mean serum DHEAS just failed to reach 
significance (t test p=0.056). No difference was observed in serum DHEAS levels 
between premenopausal women with breast cancer and controls. Serum androstenedione 
levels were not found to differ between women with breast cancer and controls in either 
premenopausal or postmenopausal groups. 
Although mean serum testosterone levels were higher in both pre and postmenopausal 
women with breast cancer than controls the difference between the means failed to reach 
significance in either group. Serum DHEAS, androstenedione and testosterone levels in 
premenopausal and postmenopausal women with breast cancer and controls are 
illustrated in the following table and graphs. 
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Serum Median ng/ml Mean ng/ml Standard 95% 
[androstenedionel error of mean Confidence 
interval 
Premenopausal 1.47 1.73 0.22 1.30-2.19 
case 
Premenopausal 1.36 1.89 0.34 1.19-2.59 
control 
Postmenopausal 1.2 1.42 0.13 1.17-1.67 
case 
Postmenopausal 1.16 1.37 0.12 1.12-1.62 
control 
Table 5.6: Androstenedione cases and controls 
Serum JDHEASJ In 
Serum [DHEAS] In 
premenopausal cases and postmenopausal cases and controls controls 
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Figure 5.4: DHEAS and androstenedione cases versus controls 
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Serum JDHEASJ Median Mean Standard 95% 
microg/ml microg/ml error of mean Confidence 
interval 
Premenopausal 1.22 1.65 0.24 1.14-2.16 
case 
Premenopausal 1.1 1.50 0.21 1.06-1.94 
control 
Postmenopausal 1.15* 1.28 0.10 1.09-1.48 
case 
Postmenopausal 0.8* 0.99 0.11 0.77-1.21 
control 
Table 5.7: serum DHEAS cases and controls 
serum testosterone 
premenopausal cases and 
controls 
1.. 
U- 
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Figure 5.5: Serum testosterone cases and controls 
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Serum Median Mean Standard 95% 
[testosteronel ng/ml ng/ml error of the Confidence 
mean Intervals 
Premenopausal 0.60 0.63 0.06 0.50-0.75 
case 
Premenopausal 0.47 0.55 0.05 0.45-0.66 
control 
Postmenopausal 0.50 0.52 0.03 0.46-0.59 
case 
Postmenopausal 0.45 0.46 0.03 0.39-0.52 
control 
Table 5.8: serum testosterone cases and controls 
5.4 Relationship between serum androstenedione, DHEAS and testosterone 
levels and body mass index 
An association between serum adrenal androgen levels and body mass index was sought. 
No significant association was found between serum DBEAS and body mass index in 
women with breast cancer (linear regression p=0.87, r2=0.00) or controls (linear 
regression p=0.198, r2=0.036). Likewise senun androstenedione was not associated with 
body mass index in either women with breast cancer (linear regression p=0.97, r2=0.00) 
or controls (linear regression p=0.7 1, r2--0.00). These results suggest that serum adrenal 
androgen levels are independent of body mass index, and are illustrated in the following. 
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Serum landrostenedlonel 
versus body mass Index pre, 
and postmenopausal women 
with breast cancer 
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Figure 5.6: Relationship between serum androstenedione, DHEAS and testosterone 
levels and body mass index 
Testosterone DHEAS Androstenedione 
Case 0.04 0.00 0.00 
Control P value 0.20 0.87 0.97 
Case Rz 0.09 0.036 0.71 
Control P value 0.04 0.198 0.00 
Table 5.9: Relationship between serum androstenedione, DHEAS and testosterone levels 
and body mass index 
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5.5 Relationship between serum androgens and stress 
Adrenal androgens are secreted in response to changes in ACTH as part of the pituitary- 
adrenal axis (Parker et al. 1980). As serum was taken from women with breast cancer on 
or preceding the day of surgery we investigated whether pre-operative anxiety may have 
contributed to the elevated adrenal androgen levels observed in women with breast 
cancer. Cortisol is a steroid, which is also secreted by the adrenal cortex in response to 
changes in ACTH levels accompanying trauma, infection, surgery and emotional 
disturbance (James 1984). Serum cortisol levels were therefore measured and plotted 
against serum DHEAS. The absence of an association between serum cortisol and 
DHEAS suggests that serum DHEAS levels are truly elevated in postmenopausal women 
with breast cancer and are not spuriously raised due to the stress response. The following 
graph illustrates that serum DHEAS were independent of serum cortisol. 
Relationship betAaen serum 
[DHEAS] and (corbsoQ In breast 
cancercases 
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P-0.89 
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Figure 5.7: Relationship between serum DHEAS and cortisol levels 
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Discussion 
5.6 Sources of androgens in women 
We have mentioned previously that androgens are derived from the adrenal cortex and 
ovary. The adrenal secretes primarily DHEA, DHEAS and androstenedione, but also 
smaller amounts of testosterone (Longcope 1986). Adrenal androgens, in addition to 
cortisol and aldosterone are secreted by the adrenal cortex in response to changes in 
serum adrenocorticotrophin hormone (ACTH) concentrations. This mechanism is referred 
to as the pituitary adrenal axis (Parker et al. 1980). Because of the selective increase in 
adrenal androgen levels observed at the adrenarche and the apparent dissociation between 
adrenal androgen and cortisol levels in fasting, obesity, anorexia nervosa, surgical stress 
and aging, the existence of an adrenal androgen stimulating hormone (AASH) has been 
postulated (Parker el aL 1980). However, the evidence for the existence of a separate 
trophic hormone for adrenal androgens is not conclusive and it has been suggested that 
prolactin may fulfill this role (Adams 1985). 
In premenopausal women the ovary secretes testosterone, androstenedione and DHEA 
under action of luteinising hormone (Longcope 1986). Ovarian adrenal androgen 
secretion varies during the menstrual cycle. Testosterone and androstenedione reach a 
peak at mid-cycle whereas ovarian DHEA secretion is constant throughout the menstrual 
cycle (Abraham 1974). In postmenopausal women the ovary continues to secrete 
androstenedione and testosterone (Longcope 1986). 
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When we consider the contribution each organ makes to the serum levels of androgens, 
the situation is more complex. Studies of androgen concentrations in ovarian and adrenal 
veins have shown that DHEAS is secreted only by the adrenal gland. DHEA is produced 
mainly in the adrenal cortex. However small amounts are secreted in the ovary in 
premenopausal women (Longcope 1986). 
The ovary and adrenal cortex contribute equally to serum androstenedione levels except 
at the midcycle in premenopausal women when the ovarian contribution is twice that of 
the adrenal (Abraham 1974). In a recent study of postmenopausal women Dorgan et al 
have found that both the ovaries and adrenal cortex also contribute equally to the elevated 
serum androstenedione levels found with breast cancer (Dorgan et aL 2001). 
The major source of testosterone is the peripheral conversion of androstenedione. 
However, despite androstenedione secretion varying with the menstrual cycle, serum 
testosterone levels remain stable. In addition to peripheral conversion of androstenedione 
the ovary and adrenal also contribute equally to serum testosterone levels (Longcope 
1986). 
On the other hand neither the adrenal nor the ovary contributes significantly to the 
production of androstenediol or 5alpha dihydrotestosterone, they can therefore be 
considered as end-points in the metabolism of androgens (Longcope 1986). 
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In practice, DHEAS, DHEA and androstenediol are often referred to as "adrenal" 
androgens, though this term only strictly applies to DHEAS. Testosterone is often 
referred to as ovarian androgen, though this term is strictly incorrect, as it arises from 
both the ovary and adrenal. Rochefort and Garcia (Rochefort et aL 1984) classify 
androgens into three groups: androgens with high afflinity for the androgen receptor 
(5alpha-dihydrotestosterone and testosterone); androgens which are converted to 
oestrogens by the aromatase enzymes (androstenedione and testosterone); and those of 
adrenal origin (DHEAS, DHEA and androstenediol), which have affinity for the 
oestrogen receptor. 
5.7 Relationship between serum androstenedione, DHEAS and testosterone 
levels In women with breast cancer and controls 
The correlation we observed between serum androgen levels are in agreement with those 
of Phillips et al who showed that serum androstendione, DBEAS and testosterone were 
correlated in healthy women (Phillips 1996). As outlined above the adrenal cortex 
secretes androgens in response to ACTH and the ovary secretes androgens in response to 
luteinising hormone. These two systems are independent Therefore a high correlation 
coefficient and level of significance between serum androgen levels suggests a common 
source of secretion. 
Androstenedione and DHEAS are highly correlated in both women with breast cancer 
and controls. This suggests that androstenedione and DHEAS are predominantly secreted 
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from the adrenal cortex in women with breast cancer and controls. The differences 
observed between coffelation coefficients for serum testosterone versus DBEAS and, to a 
lesser extent, androstenedione in women with breast cancer compared to controls 
suggests that testosterone and/or androstenedione are derived from a more heterogeneous 
source in women with breast cancer than controls. 
5.8 Relationship between serum androstenedione, DHEAS and testosterone 
levels and age In women with breast cancer and controls 
A significant negative correlation has been reported between serum adrenal androgen 
levels and age (Labrie et aL 1997) (Orentreich et aL 1984) (Sulcova et aL 1997). Serum 
levels of DHEA and DHEAS reach a peak in early adulthood and decline thereafter 
(Sulcova et al. 1997). A concomitant decrease in cortisol, another adrenal cortical steroid 
secreted in response to ACTH does not occur with aging (Bonney et al. 1984). The 
reason for the age-related decline in DHEA and DHEAS levels has been attributed to 
alterations in the zona reficularis of the adrenal gland, whereas the reduction in serum 
androstenedione with aging is probably due to reduced ovarian secretion after the 
menopause (Parker et aL 2000). 
Few studies have commented on a relationship between serum adrenal androgens and age 
in women with breast cancer. In contrast to the age invariance of serum adrenal androgen 
levels described by Zumoff et al (Zumoff 1981), both serum DHEAS and 
androstenedione declined with age in women with breast cancer in this study. 
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Serum testosterone levels have also been shown to decrease with increasing age 
(Bancroft et aL 1996), in agreement with the findings of the present study. Serum total 
testosterone levels are unaffected during the menopausal transition (Burger et al. 2000). 
SHBG levels fall as a result of the menopause, and this leads to a rise in free testosterone 
levels in postmenopausal women (Burger et aL 2000). 
5.9 Serum androstenedione, DHEAS and testosterone levels in women with 
breast cancer and controls 
The finding of a raised serum DHEAS in postmenopausal women with breast cancer 
compared to controls is in agreement with the fmdings of other groups (Cauley 1999) 
(Dorgan 1997) (Gordan 1990) (Zeleniuch-Jacqotte 1997) (Secreto 1991) (Zumoff 1981). 
DBEAS is secreted almost exclusively by the adrenal cortex (Longcope 1986). Elevated 
levels of DHEAS measured in postmenopausal women with breast cancer suggest 
increased adrenal androgen secretion, and supports a role for adrenal androgens in the 
aetiology of breast cancer. It has been proposed that in postmenopausal women adrenal 
androgens stimulate the proliferation of hormone-responsive breast cancer by interaction 
of a product of DHEAS metabolism, androstenediol with the oestrogen receptor (Adams 
1998). Furthermore, after the menopause almost all oestrogens are synthesized in 
peripheral tissues from precursor steroids of adrenal origin (Labrie 199 1). The 
importance of DBEAS is suggested by the findings that among the androgens only 
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DBEAS had oestrogenic activity at physiological concentrations on breast cancer cell 
lines (LeBail et aL 1998). 
No significant difference in serum androstenedione levels between postmenopausal 
women with breast cancer and controls was observed in this study, though other groups 
have found elevated androstenedione levels in postmenopausal women who developed 
breast cancer (Cauley 1999) (Secreto 199 1) (Dorgan et aL 200 1). 
No significant differences were observed in serum DIMAS and androstenedione levels 
between premenopausal women with breast cancer and controls. This is in agreement 
with the findings of Helzlsouer et al (Helzlsouer 1992) for DBEAS but contradicts those 
of Zumoff and Bulbrook (Zumoff 1981) (Bulbrook 1986). Our findings do not therefore 
support a role for adrenal androgens in the development of premenopausal breast cancer. 
However, fewer numbers of premenopausal women in this study and failure to control for 
all potential variables discussed below may have affected our results. 
The present study observed that although mean serum testosterone levels were elevated in 
premenopausal and postmenopausal women with breast cancer no significant difference 
was found between serum testosterone levels between women with breast cancer and 
controls. The results of other groups suggest that serum testosterone levels are elevated in 
premenopausal and postmenopausal women with breast cancer (Malarkey 1977) (Sauter 
2002) (Zeleniuch-Jacqotte 1997) (Cauley 1999) (Hill 1985) (Secreto 1991) (Thomas 
1997). The failure of this study to find significantly elevated serum testosterone levels in 
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women with breast cancer may be a reflection of the size of the group studied or failure to 
control for the variables outlined below. 
One further factor might have to the failure to observe a difference in serum androgen 
levels between these groups. This was the observation that serum androgen levels have 
been reported to be elevated in women with benign breast disease (Parlati et al. 1992; Lee 
et aL 1999; Mady et aL 2000). As controls for this study were taken from the one-stop 
breast clinic, a high proportion would have had benign breast disease. 
Several factors have been reported to affect androgen levels include cigarette smoking 
(Baron et aL 1995), diurnal variation (Nicolau et aL 1984), body mass index (Kirschner 
et aL 1982), menstrual cycle (Abraham 1974) and exogenous oestrogens (Kraemer et aL 
2001). 
5.10 Relationship between serum androstenedione, DHEAS and 
testosterone levels and body mass Index 
A strong correlation between the degree of obesity and serum oestrogen levels in 
postmenopausal women is established (Kirschner et aL 1982) (Cauley et aL 1989). This 
is consistent with the fact that aromatization of androgens occurs primarily in adipose 
tissue CLongcope 1986). However, the relationship between serum androgens and 
adiposity is less straightforward. 
118 
Chapter 5 Results and Discussion 
An increased production of adrenal androgens and excretion of 17-ketosteroids has been 
found in obese subjects (Glass et al. 198 1) (Adams 1985). In addition obesity is 
associated with decreased sex hormone binding globulin levels and consequently an 
elevated free testosterone levels, which may explain the increased incidence of 
amenorrhoea and hirsutism reported in obese patients (Glass et al. 1981). 
Studies investigating an association between serum adrenal androgen levels and obesity 
suggest that serum androstenedione (Kirschner et aL 1982) (Cauley et aL 1989) and 
DHEAS (Williams et aL 1993) (DePergola et al. 199 1) (Baffet-Connor et al. 1996) levels 
are independent of body mass index. These results are supported by the observations of 
the present study. However, an inverse association has been reported between serum 
DHEA levels and obesity (Field et aL 1994) (DePergola et al. 1991) (Barret-Connor et al. 
1996) (Tchernof et aL 1995). 
In premenopausal women, Kirschner et al found no significant difference between 
plasma androstenedione levels in obese women compared to controls; but reported that 
the production, metabolic clearance rate, and aromatization of androstenedione was 
significantly higher in obese women (Kirschner et aL 1982). Two other groups have 
failed to find a correlation between serum DBEAS levels and body mass index in 
premenopausal women (Williams et aL 1993) (DePergola et al. 1991). However serum 
DBEAS levels have been shown to be associated with truncal distribution of body fat in 
women (Williams et aL 1993) (Barret-Connor et aL 1996). Likewise, in men and 
119 
Chapter 5 Results and Discussion 
postmenopausal women no association between androstenedione levels (Cauley et aL 
1989), DHEAS (Barret-Connor et aL 1996) and obesity has been reported. 
However, an inverse association between serum DHEA and body mass index has been 
reported in premenopausal women (DePergola et al. 199 1) and postmenopausal women 
(Barret-Connor et aL 1996). In addition, DBEA has been found to have anti-obesity 
properties in rodents (Williams 2000) and to be inversely associated with body mass 
index in men (Field et aL 1994) (Tchernof et aL 1995). 
No clear association between serum total testosterone and obesity in women has been 
demonstrated (Kirschner et aL 1982). However, obesity is associated with decreased 
serum sex hormone binding globulin (SHBG) levels, and consequently elevated free 
testosterone levels (DePergola et aL 1991). This finding may explain the increase in 
menstrual disturbance and hirsutism reported in obese women (Kirschner et aL 1982). 
The relationship between adrenal androgens and obesity may therefore be similar to that 
between cortisol and obesity. Normal plasma cortisol levels are maintained in obesity as 
the enhanced production is balanced by an accelerated metabolism of cortisol (Glass et 
al 198 1). In the same way serum adrenal androgen levels are normal in obesity, though 
production, metabolism and urinary excretion may be increased. 
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5.11 Relationship between serum androgens and stress 
Surgical stress has been reported to induce a marked and sustained increase in adrenal 
androgen secretion (Batrinos 1999). In the present study no association between 
preoperative serum levels of DHEAS and cortisol in women undergoing surgery has been 
demonstrated. The lack of correlation between serum DBEAS and cortisol levels may be 
due to the relatively large pool of DHEAS in the serum, which masks an elevation in 
serum DHEAS due to episodic secretion (Rosenfeld et aL 1975). In addition these results 
suggests that the elevated DHEAS levels we have observed in postinenopausal women 
with breast cancer are not due to emotional stress in the pre-operative period. 
5.12 Serum androgens and smoking 
The anti-oestrogenic effect of cigarette smoking particularly evidence that smoking 
reduces the risk of endometrial cancer (Lesko et aL 1985) has stimulated interest in the 
possible effect of smoking on steroid hormones. Several studies have reported that 
smokers have elevated levels of androstenedione (Longcope et aL 1988) (Cauley et al. 
1989) (Khaw et al. 1988) (Baron et aL 1995) (Field et aL 1994) and DHEAS (Khaw et aL 
1988) (Baron et aL 1995) (Field et aL 1994). Other studies have reported that serum 
DBEAS levels did not differ between smokers and non-smokers (Key et aL 1991). The 
association between androgens and smoking appears to be restricted to adrenal 
androgens, as those studies which have measured sertun testosterone levels have not 
found them to differ between smokers and non-smokers (Longcope et aL 1988) (Khaw et 
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al. 1988). The mechanism of the association between smoking and elevated adrenal 
androgen levels is unknown. However, Baron et al noted that smoking caused not only an 
elevation of adrenal androgen levels but a generalized disturbance in adrenal cortical 
hormone levels (Baron et al. 1995). 
5.13 Diurnal variation In serum androgens 
Adrenal androgens are secreted by the adrenal cortex, along with cortisol in response to 
changes in ACTH and are a component of the pituitary-adrenal axis (James 1984). Over a 
24-hour period plasma DIHEA and androstenedione levels vary synchronously and 
episodically with cortisol secretion in response to pulsatile changes in ACTH secretion 
(Rosenfeld et aL 197 1). Although DHEAS is also secreted in response to ACTH, serum 
levels do not vary synchronously with other adrenocortical hormones. This may be due to 
the relatively long half-life of DBEAS and therefore the large pool of DHEAS in the 
serum, which masks an elevation in DBEAS levels, due to episodic secretion. Serum 
DBEAS levels are thus less labile than other adrenocortical. hormone, however, a diurnal 
variation in DHEAS secretion has been described (Nicolau et aL 1984) with a maximum 
level during the day and a minimum at night (Jones et aL 1987). Though other studies 
have failed to find evidence for a diurnal variation in serum DBEAS levels over a 24- 
hour period (Garde et aL 2000). A diurnal variation in serum testosterone levels has also 
been demonstrated (Nicolau et aL 1984). Testosterone is also secreted episodically (West 
et aL 1973) though peaks do not occur synchronously with cortisol. 
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5.14 Summary 
Controls in this study have been matched for age. Patients on exogenous oestrogens have 
been excluded. Controls have not been matched with respect to cigarette smoking, body 
mass index and time of venepuncture. Failure to control for these factors, for the reasons 
outlined above may have affected our findings. However, few of the studies investigating 
serum androgens in breast cancer have matched cases and controls for all of these factors, 
apart from age. 
In conclusion, these findings show an elevated sennn DHEAS level in postmenopausal 
women with breast cancer. No difference was observed in senun androstenedione levels 
between postmenopausal women with breast cancer and controls. Nor were levels of 
either adrenal androgen different between premenopausal women with breast cancer and 
controls. Mean testosterone levels were non-significantly raised in both premenopausal 
and postmenopausal women with breast cancer. These results, in conjunction with those 
reported by other groups (Gordan 1990; Dorgan 1997; Zeleniuch-Jacqotte 1997; Cauley 
1999) suggest a role for DHEAS in the aetiology of postmenopausal breast cancer. 
However the failure to find any differences in androstenedione or testosterone levels in 
this group and a difference in DBEAS levels that was onlyjust significant at the 5% level 
in postmenopausal women does not exclude the possibility that these results could have 
occurred by chance. 
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Mechanisms for an action for DBEAS are discussed in chapter 8: in an oestrogen- 
depleted environment DHEAS stimulates the proliferation of hormone-dependent breast 
cancer via its metabolite 5-androstene-30,170-diol or via aromatisation to 170-oestradiol. 
Serum adrenal androgens have been implicated in the aetiology of "Western- 
environmental" breast cancer. It has been postulated that dietary factors or body mass 
index may account for differences in adrenal androgens observed in western women. This 
study has demonstrated that serum androgen levels are independent of body mass index 
in a sample of western women with breast cancer. 11is suggests that body mass index has 
no effect on serum androgen levels. 
Finally this study has shown that serum androgen levels decline with increasing age in 
women with breast cancer, as they do in controls. This contradicts previous studies, and 
suggests there is no fundamental difference in the age-related decline in androgen 
production between women with breast cancer and healthy women. 
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Results and Discussion 
Androgen receptor expression in primary operable breast cancer 
6.1 Titration of androgen and epidermal growth factor receptor antibodies 
Titration of the biotinylated mouse anti-human androgen receptor antibody (DAKO, 
Cambridge, UK) against the androgen receptor positive and negative prostate cancer cell 
lines LNCap and DuI54 is illustrated in the following figure. This indicates that the 
titration curve reaches a plateau, while the control remained low, at a concentration of 3 pI 
of androgen receptor antibody per 105 cells. Therefore 3gl of androgen receptor antibody 
was used in subsequent experiments to determine the androgen receptor expression in 
breast turnours. Likewise, the titration curve of the phycoerythin. conjugated epidermal 
growth factor antibody against MCF7 cells and lymphocytes reaches a plateau at 20gl of 
antibody per 105 cells, indicating that this quantity of antibody was optimal. 
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Figure 6.1: Androgen and epidermal growth factor receptor antibody titration curve 
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6.2 Western blotting of LNCaP lysate with androgen receptor antibody 
(AR441) 
In order to confirm the specificity of the androgen receptor antibody Western blotting of 
a lysate of LNCap cells was performed as described above. Using the AR441 androgen 
receptor antibody as a probe a transcript at II OkDa, which corresponds to the molecular 
weight of the androgen receptor was detected. This is illustrated in the following figure. 
These results illustrate that the AR441 antibody detects a protein of molecular weight 
I lOkDa, which corresponds to the molecular weight of the androgen receptor (van Laar 
el al. 1989). 
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Figure 6.2: Western blot of LNCaP lysate with the AR441 androgen receptor antibody 
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6.3 Immunohistochernistry of LNCaP cells with androgen receptor antibody 
(AR441) 
Immunohistochernistry demonstrated after counterstaming with haernatoxylin that both 
LNCap cell nuclei and cytoplasm stained positively for androgen receptors. Cell nuclei 
stained more intensely than the cytoplasm. This suggests that the androgen receptor are 
localised predominantly to the cell nucleus. Immunopositive cell nuclei staining varied 
with some cells showing intense staining and others faint or no staining. The results of 
immunohistochemistry are demonstrated in the following figure. 
40. 
Figure 6.3: Immunohistochemistry of LNCaP cells using AR441 androgen receptor 
antibody 
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6.4 Immunohistochernistry of paraffin sections of breast turnours with 
androgen receptor antibody (AR441) 
ImmunohistochemiStry of paraffin sections of breast tumours demonstrated variable 
levels of androgen receptor expression. Androgen receptors were predominantly located 
in the nucleus, but cytoplasmic staining was present. Figures 6.4-6 illustrate breast 
tumour sections, which stained strongly, moderately and weakly for androgen receptor 
expression. 
AL 
Vim_ 
Figure 6.4: Paraffin section of breast turnour demonstrating strong stammg for androgen 
receptor expression 
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Figure 6.5: Paraffin section of breast tumour demonstrating moderate staining for 
androgen receptor expression 
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Figure 6.6: Paraffin section of breast tumour demonstrating weak staining for androgen 
receptor expression 
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Breast sections were graded for the intensity with which they stained for androgen 
receptor expression (1=weak, 2=moderate, 3=strong) and the percentage of positively 
staining cells. These figures were added to arrive at a number termed a "quickscore' 
(Detrie et aL 1995). 
Androgen receptor expression determined by flow cytometry, which was expressed in 
units of molecules of equivalent fluorochrome, was plotted against the quickscore and 
intensity of androgen receptor staining determined by immunohistochemistry. In order to 
determine whether any correlation existed between these methods, linear regression 
analysis was perfonned. Figures 6.7 and 6.8 illustrate that no correlation occurred 
between immunohistochemical and flow cytometric methods for androgen receptor 
expression. 
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Figure 6.7: Androgen receptor expression determined by flow cytometry versus 
androgen receptor "quickscore"' and intensity by immunohistochemistry. Note the 
tumours with a quickscore of "0" have been omitted from the graph and statistical 
analysis. 
6.5 Androgen receptor expression of breast turnours 
Eighty-six percent of breast turnours, in this study were found by flow cytometry to 
express the androgen receptor. This level of androgen receptor expression in breast 
cancer is in agreement with reported studies of androgen receptor expression by ligand- 
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binding assay (Lea et al. 1989) (Soreide et al, 1992) and immunohistochemistry (Isola 
1993) (Kuenen-Boumeester et aL 1992). 
In addition the level of androgen expression observed was higher than the oestrogen 
receptor alpha expression, which was found to be 80%, and confirms previous reports 
that the androgen receptor is the most frequently expressed steroid receptor in breast 
cancer (Lea el al. 1989). 
The level of expression of androgen receptor in the sixty-three breast turnours analyzed is 
illustrated in figure 6.8. 
Histogram of androgen receptor 
expression of 63 breast turnours 
determined by flow cytometry 
12 
= 20 0 
15 
0 10 
5 
E JITI U-0 
Z0 Qý RFI (Z§l 461 461 
40 
cy 
Androgen receptor expression molecules of 
equivalent fluorochrome 
Figure 6.8: Androgen receptor expression in sixty-three primary operable breast cancers 
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6.6 Androgen receptor is co-expressed with oestrogen receptor alpha In 
breast cancer 
A plot of androgen receptor expression against oestrogen receptor alpha in the 43 breast 
tumours analyzed demonstrates that there is a significant correlation between androgen 
receptor and oestrogen receptor alpha expression (linear regression r2--0.30, p<0.0001). 
Previous studies have found a similar association between androgen and oestrogen 
receptor expression in breast cancer (Isola 1993) (Lea et al. 1989) (Soreide et aL 1992). 
Though the reason for co-expression of steroid receptors in breast cancer is unknown. 
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Figure 6.9: Androgen receptor versus oestrogen receptor alpha expression in breast 
cancer 
6.7 Androgen receptor expression increases with age 
Androgen receptor expression was observed to increase with increasing age. The 
association between breast tumour androgen receptor expression and age reached 
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significance but the correlation co-efficient was low (linear regression p--0.02, r2--0.08). 
This is illustrated in the following figure. 
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Figure 6.10: Androgen receptor expression versus age in breast cancer 
Steroid receptor levels are regulated by their ligands. Adaption by up regulation of the 
receptor apparatus to compensate for the declining supply of sex steroids observed in 
advancing age has been proposed as an explanation for the increase in steroid hormone 
receptor expression observed in breast cancer (Lea et al. 1989). It has been demonstrated 
in chapter 5 that serum androgen levels decline in women with breast cancer. In order to 
further examine the hypothesis that negative autoregulation determines breast tumour 
androgen receptor expression in vivo we measured serum testosterone, 
dehydroepiandrosterone sulphate and androstenedione in these patients, and a correlation 
between tumour androgen receptor expression and serum androgen levels was sought. 
Breast tumour androgen receptor expression increased with decreasing serum levels of 
DBEAS and androstenedione, and the association between tumour androgen receptor 
expression and serum DBEAS was approaching significance, though the correlation co- 
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efficient was low (linear regression, p=0.08, r2=0.08). However, breast tumour androgen 
receptor expression appeared to be independent of serum testosterone levels (linear 
regression p=0.94, i2=0.00). This data is illustrated in the following figures. 
Tumour Androgen Receptor 
TumourAndrogen Expression expression versus serum 
versus serum JDHEASJ [Androstenedionel 
c 
400DO- 40DOO- 
' D0 -4 30000- rL 0 
p U0.08 
2 
8 30000- 2! 
XX p =0.18 X 
ir 20000- 
_0.08 r. ; X 01 
20000- 
r2.0 
. 05 
-C 
0 
10000 10000 
0 12345 
0 
34 
serum IDHEASI microgiml serum land rostenedlonel ngtrid 
Tumour androgen receptor 
expression versus serum 
testosterone In primary 
operable breast cancer 
p =O. 94 0 
2, rI. ' 1- 
10000 20000 30000 40000 
Tumour androgen receptor 
expression molecules of 
fluorescencelcell 
Figure 6.11: Tumour androgen receptor expression versus serum DBEAS, 
androstenedione and testosterone 
136 
Chapter 6 Results and Discussion 
6.8 Androgen receptor expression versus turnour grade, lymph node status 
and Nottingham Prognostic Index 
Tumour androgen receptor expression was compared against the established prognostic 
markers, Bloom-Richardson grade (Bloom et aL 1957), lymph node status (Fisher et aL 
1978) and Nottingham Prognostic Index. This data is presented in the following tables 
and figures. 
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Figure 6.12: Androgen receptor status versus tumour grade, lymph node status and 
Nottingham Prognostic Index in breast cancer 
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Mean androgen receptor expression increased with tumour grade suggesting that 
androgen receptor expression is a marker of poor prognosis. A statistically significant 
difference was observed between these groups (Kruskal-Wallis p=0.01). No difference in 
mean androgen receptor expression was observed between axillary lymph node positive 
and negative groups (Mann-Whitney p=0.84). No association was observed between 
androgen receptor expression and Nottingham Prognostic Index. 
6.9 Expression of androgen receptor and epidermal growth factor receptor 
are positively correlated In breast cancer 
We investigated whether an association between epidermal growth factor receptor 
expression and androgen receptor expression occurs in breast cancer. A positive 
correlation between epidermal growth factor receptor and androgen receptor expression 
in breast cancer in the present study (linear, regression, p=0.0 I r2=0.13) illustrated in the 
following figure suggests a functional interaction between androgen receptor and the 
epidermal growth factor receptor pathways in breast cancer. 
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Figure 6.13: Androgen receptor versus epidermal growth factor receptor expression 
Discussion 
6.10 
A flow cytometric method for the determination of androgen receptor 
expression in breast cancer 
We report here a novel method for the determination of androgen receptor expression in 
primary operable breast cancer by flow cytometry. The observations that androgen 
receptor expression, determined by this method occurs in 86% of breast tumours and is 
co-expressed with oestrogen receptor alpha are in agreement with previous studies 
investigating androgen receptor status in breast cancer (Lea et aL 1989) (Soreide et aL 
1992) (Isola 1993) (Kuenen-Boumeester et aL 1992) (Allegra et al. 1979). 
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Flow cytometry is an established method for the determination of surface, cytoplasmic 
and nuclear antigen expression (Loken et al. 2000) (Larson 2000). In our laboratory, flow 
cytometric methods for the determination of oestrogen receptor alpha (Brotherick et al. 
1995), oestrogen receptor beta (Girdler et al. 2001) and epidermal growth factor receptor 
(Brotherick et al. 1994) in breast tumour specimens have been established. 
An increasing number of prognostic and predictive factors in breast cancer have now 
been described (Slooten et aL 200 1). In addition to providing information on DNA ploidy 
and S-phase fraction (Ormerod 2000) the use of flow cytometry to measure cell surface 
and cytoplasmic antigen expression provides a rapid, reliable and objective method for 
the simultaneous determination of multiple parameters in breast cancer. 
There was however no coffelation between immunohistochemical and flow cytometric 
methods for the determination of androgen receptor expression. Both methods have 
disadvantages. Immunohistchemistry has become established as a routine method for the 
determination of antigen expression on clinical specimens. Flow cytometry is not used in 
r outine clinical practice to measure antigen expression, however its capability to 
simultaneously measure the expression of several antigens on clinical specimens suggests 
a clinical utility. 
Immunohistochemistry used a subjective detennination of the intensity of antigen 
expression plus the percentage of positive cells to arrive at a "quickscore". Whereas, flow 
cytometry determined the number of antigen molecules expressed per cell. This figure 
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was not arrived at entirely objectively, as the placing of gates around cytokeratin positive 
cells (see figure 3.5) on a dot plot of fluorescence-I against fluorescence-2 was 
subjective. This "gating" did affect the final measurement as antigen expression was 
determined on cells within the gate, and the cytokeratin population was not always so 
easily distinguished as those shown in figure 3.5. 
Immunohistochemistry has the advantage of directly visualizing tumour cells. Flow 
cytometry measured antigen expression on cytokeratin-positive (i. e. epithelial) cells. This 
assumes that all the cytokeratin-positive cells in the sample were tumour cells. This may 
not be the case, particularly as core biopsies of palpable breast tumours, were used in this 
study. Immunohistochemistry of paraffin-embedded sections of breast turnours 
demonstrated that epithelial cells in normal breast tissue also frequently stained positively 
for androgen receptor expression. The inability of flow cytometry to distinguish 
cytokeratin-positive tumour cells from normal epithelial cells may have influenced the 
results presented in this chapter and contributed to the lack of correlation with 
immunohistochemistry. 
Interestingly, previous flow cytometric methods, developed in our laboratory, for 
epidermal growth factor receptor and oestrogen receptor alpha both correlated with 
ligand-binding assays (Brotherick et aL 1994) (Brotherick et aL 1995). Ligand-binding 
assays, which have been superseded by immunohistochemistry in routine clinical 
practice, also have the disadvantage of not showing the cellular distribution of antigen 
expression. 
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6.11 The association between tumour androgen receptor status, lymph 
node status, grade and Nottingham Prognostic Index 
The present study has reported a significant association towards increasing androgen 
receptor expression with higher grade. This observation is at odds with previous studies, 
which have found androgen receptor expression to be associated with low grade and 
favorable prognosis in breast cancer (Isola 1993) (Kuenen-Boumeester et aL 1996) 
(Bryan et aL 1984) (Langer et al. 1990). 
No significant difference in androgen receptor expression was observed between lymph 
node positive and negative breast cancers. Few studies have examined the relationship 
between androgen receptor expression and lymph node metastases. Kuenen-Boumeester 
et at reported no association between the presence of lymph node metastases and 
androgen receptor status (Kuenen-Boumeester et aL 1996), whereas Soreide, et al found a 
positive correlation between androgen receptor expression and the presence of axillary 
metastases (Soreide et al. 1992). 
Androgen receptor is co-expressed with oestrogen receptor alpha in breast cancer 
(Kuenen-Boumeester et aL 1992) (Isola 1993) (Lea et al. 1989) (Allegra, et aL 1979). The 
reason why steroid hormone receptors should be co-expressed in breast cancer is not 
established. Oestrogen receptor expression in breast cancer is correlated with 
differentiated tumours, response to endocrine therapy and improved survival (Hawkins et 
aL 1980). As androgen receptors are co-expressed with oestrogen receptors in breast 
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cancer, one may expect androgen receptor expression to be also correlated with improved 
outcome. 
However, Lea et al found that androgen receptors are expressed as the sole steroid 
receptor in 25% of breast cancer metastases (Lea et al. 1989). This suggests that during 
the de-differentiation of hormone receptor positive to hormone receptor negative tumours 
androgen receptor is the last steroid receptor to be lost. It is for this reason that we may 
expect androgen receptor expression to be associated with a more aggressive phenotype 
than oestrogen receptor alpha expression. 
6.12 Breast tumour androgen receptor expression and serum androgen 
levels 
Negative autoregulation of steroid receptor expression by their own ligand is a 
phenomenon common to the steroid receptor family of transcription factors and may 
reflect a homeostasis mechanism modulating hormone signals towards a steady state. It is 
a complex process, which is incompletely understood but is regulated at the level of 
transcription and by post-transcriptional processes. 
Upregulation of ARmRNA in vivo has been reported on androgen withdrawal in rat 
ventral prostate, epididymis, seminal vesicle, kidney and brain and in vitro in the prostate 
cancer cell line LNCaP (Quarmby et aL 1990). However, regulation of ARmRNA differs 
between androgen responsive tissues, downregulation of ARmRNA occurs on treating 
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LNCaP and the breast cancer cell lines T47D, NENU23 and EFM19 with androgens 
(Wolf et aL 1993) (Krongrad et aL 199 1) (Hackenberg et aL 1992). Whereas, levels of 
ARmRNA in genital skin fibroblasts are unaffected by androgens (Krongrad et aL 1991) 
and upregulation of ARmRNA occurs in the prostate cancer cell lines DU145 and PO 
(Dai et aL 1996) by incubation with androgens. 
Regulation of AR protein expression by androgen has also been reported to vary in a 
tissue specific manner. Downregulation of AR mRNA has been reported to coincide with 
a rise in AR protein expression in LNCaP on treatment with androgen due to increased 
translational efficiency or stabilisation of the receptor protein (Krongrad et aL 1991). 
However, other groups did not observe an upregulation of AR protein expression under 
these conditions, but found prolonged incubation of the LNCaP with androgen led to a 
functional inactivation of the androgen receptor (Wolf et aL 1993). However, 
downregulation of ARmRNA is accompanied by a fall in AR protein expression on 
treating mammary cancer cell lines with androgen (Hackenberg et al. 1992). 
The regulation of androgen receptor expression in vivo is complicated by the finding that 
oestrogens, and to a lesser extent progestins, may also downregulate AR protein 
expression in MCF7 cells by an oestrogen receptor mediated mechanisms (Stover et al. 
1987). Autoregulation of oestrogen receptor expression in breast cancer has also been 
demonstrated and is reviewed by Martin et al (Martin et al. 1994). Autoregulation, has 
also been described for glucocorticoid receptors (Okret et al. 1986) and the progesterone 
receptors (Read et al. 1988). 
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Evidence from in vivo studies of ER protein expression in human breast tumours has 
established that ER protein expression increases with age (Elwood et aL 1980) (McCarty 
et aL 1983). Studies, which have investigated an association between serum oestrogen 
levels and tumour ER protein expression, have reported a negative correlation (Nagai et 
aL 1979) (Theve et aL 1978). These results provide strong evidence for negative 
autoregulation of ER protein expression in breast tumours; in vivo. Only one study has 
investigated an association between serum adrenal androgens and oestrogen receptor 
expression in breast cancer. This reported that serum DHEAS levels were non- 
significantly higher in patients with oestrogen receptor positive breast tumours (Skinner 
et aL 1984). 
The observation that breast tumour androgen receptor expression increased with age is 
consistent with previous fiiidings (Lea et aL 1989). In addition, it has been demonstrated 
in chapter 5 that serum androgen levels decline with patient age in women with breast 
cancer. Few studies have sought a correlation between serum androgen levels and 
androgen receptor expression. Langer et al found no correlation between serum DHEAS, 
serum testosterone levels and tumour androgen receptor expression and a positive 
correlation between serum androstenedione and tumour androgen receptor expression in 
61 women with breast cancer, though he had difficulty interpreting these findings (Langer 
et aL 1990). 
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The results of the present study have not showed a significant correlation between serum 
androgen levels and tumour androgen receptor expression in women with primary 
operable breast cancer. However, a trend towards increasing tumour androgen receptor 
expression with decreasing serum DHEAS levels was observed. 
DBEAS is quantitatively the most important steroid hormone in the circulation and is 
metabolized to androgenic metabolites such as testosterone and 5alpha- 
dihydrotestosterone, oestrogenic androgens such as androstenediol and via aromatase 
enzymes to oestrogens (Rochefort et aL 1984). DBEAS could therefore give rise to a 
variety of steroids, which could regulate the expression of androgen receptor expression 
in breast cancer cell lines in vitro. 
The finding of an inverse correlation between serum DHEAS and androgen receptor 
expression, though not reaching significance, suggests DBEAS is a determinant of 
androgen receptor expression in breast cancer. The observation that serum DHEAS levels 
decline with age and breast tumour androgen receptor levels rise with age suggests that 
negative autoregulation is the mechanism underlying this observation. 
In contrast, tumour androgen receptor expression appeared to be independent of serum 
total testosterone levels. This finding is surprising as testosterone and its metabolite 
5alpha-dihydrotestosterone have high afflinity for the androgen receptor, and have been 
shown to regulate androgen receptor expression in breast cancer cell lines in vitro 
(Hackenberg et aL 1992). However, testosterone is bound in the circulation to sex 
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hormone binding globulin and albumin, only the unbound fraction is biologically active 
(Brooks 1984). Serum total testosterone has been measured in this study. It would 
therefore be necessary to measure free testosterone levels in order to investigate further 
an association between serum testosterone levels and androgen receptor expression in 
breast tumours. 
6.13 Androgen receptor and epidermal growth factor receptor expression in 
breast cancer 
This is the first study, which has examined a relationship between androgen receptor 
expression and epidermal growth factor expression in human breast cancer. As outlined 
above crosstalk between oestrogen receptor and epidermal growth factor pathways has 
been demonstrated to occur in breast cancer (Nicholson et al. 1999). Likewise crosstalk 
between androgen receptor and epidermal growth factor pathways has been demonstrated 
in prostate cancer (Culig 1994). The androgen receptor clearly has a very different role in 
breast cancer than prostate cancer. Though it has been speculated that crosstalk occurs 
between androgen receptor and growth factor pathways in breast cancer (Brys 2000), 
there is no evidence to substantiate this at present. 
The results of the present study suggest that a functional interaction between epidermal 
growth factor and androgen receptor. This implies that crosstalk between androgen 
receptor and epidermal growth factor receptor-pathways. However, these results have to 
be interpreted with caution. Firstly there are only small numbers in this study, secondly 
147 
Chapter 6 Results and Discussion 
we have used a novel technique i. e. flow cytometry to measure steroid and growth factor 
expression and thirdly an association between oestrogen receptor and epidermal growth 
factor was demonstrated, though previous results have demonstrated an inverse 
association between these antigens in breast cancer (Walker et aL 1999). Further 
investigation of this area will require in vitro studies to establish whether crosstalk occurs 
between growth factor and androgen receptor pathways in breast cancer. This should help 
us further understand the role of the androgen receptor in breast cancer. 
6.14 Summary 
The results of a flow cytometric method for the determination of androgen receptor 
expression in breast cancer are presented in this chapter. Western blotting demonstrates 
that the androgen receptor antibody AR441 detects a protein of molecular weight II OkDa 
corresponding to the androgen receptor. Immunohistochemistry of the androgen receptor 
positive prostate cancer cell line LNCap demonstrates positive nuclear staining for 
androgen receptors. Immunohistochemistry of parrafin sections of breast tumours show 
staining for androgen receptor expression. A clinical utility for the determination of 
antigen expression by flow cytometry is suggested by its capability to determine the 
expression of several antigens simultaneously. However, no correlation was observed 
between androgen receptor expression determined by immunohistochemistry and flow 
cytometry. The disadvantages of each method and possible causes for the failure to 
observe a correlation have been discussed. Androgen receptor expression increased with 
patient age and a trend towards increasing tumour androgen receptor expression with 
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decreasing serum androgen levels provides evidence for negative autoregulation of 
androgen receptor expression in vivo. In the present study androgen receptor expression 
was found to increase with increasing Bloom Richardson grade. This suggests that 
androgen receptor expression is a marker of poor prognosis. The lack of an association 
between androgen receptor expression and lymph node status suggests that androgen 
receptor is not important in the process of metastasis. Co-expression of androgen receptor 
and oestrogen receptor alpha confirms results of previous studies. A positive correlation 
between androgen receptor expression and epidermal growth factor expression suggests a 
functional interaction between these pathways in breast cancer and warrants further 
investigation. 
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Results and Discussion 
The growth effects of 5a-dihydrotestosterone and 5-androstene-30,170-diol 
on MCF7, T47D and MDAMB231 breast cancer cell lines 
Results 
7.1 Analysis of steroid hormone receptor expression of breast cancer cell 
lines 
The cell lines used in this study, namely MCF7, T47D and MDAIMB231 were chosen as 
they express different levels of steroid receptors (Horwitz et aL 1978). MCF7 cells have 
been reported to express high levels of estrogen receptors and moderate levels of 
androgen receptors (Horwitz et aL 1975). Whereas T47D cells have been reported to 
express moderate levels of androgen and oestrogen receptors and MDAMB231 cells are 
steroid receptor negative (Horwitz et aL 1978). 
The steroid receptor expression of the cell lines used in the present study has been 
determined using a flow cytometric technique. Flow cytometry is an established 
technique for the determination of cytoplasmic and nuclear antigens (Larson 2000). 
Methods for the determination of oestrogen receptor alpha (Brotherick et aL 1995) have 
been established in our laboratory. Methods for the determination of androgen receptor 
expression in breast cancer are described in the materials and methods section. The 
steroid receptor profile is illustrated in the following figure. 
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Androgen receptor and oestrogen receptor alpha 
expression of MCF7, T47D and MDAMS231 cell 
lines determined by flow cytometry 
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Figure 7.1: Androgen and oestrogen receptor alpha expression of MCF7, T47D and 
MDAMB231 cell lines 
7.2 Analysis of DNA cell cycle during forty-eight hour incubation of MCF7, 
T47D, and MDA231 with Sct-dihydrotestosterone +/- faslodex 
MCF7, T47D and MDA231 breast cancer cell lines were incubated over 48 hours with a 
range of concentrations of 5a-dihydrotestosterone. The percentage of cells in each phase 
of the cell cycle GO/ I, S and G2/M was determined at 0,24 and 48 hours as outlined in 
the matenals and methods section above. 
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MCF7 cells were incubated with a range of concentrations of 5cc-dihydrotestosterone 
from physiological (I 0-9M to 10-8M concentrations) to pharmacological levels (I 0-7M to 
10-6K. 
The following figure illustrates that pharmacological levels of 5cc-dihydrotestosterone 
resulted in a fall in the percentage of cells in GO/I and a rise in the percentage of cells in 
S phase within 24 hours. These findings would be interpreted as a stimulation of 
proliferation. Likewise, 10'2M 5cc-dihydrotestosterone stimulated the proliferation of 
MCF7 cells, whereas 10-9M 5ec-dihydrotestosterone did not affect proliferation over a 48 
hour period. The effect on the progression of all breast cancer cells to G2/M was less 
consistent. 
Similar results were obtained with T47D cells. Pharmacological doses of 5(x- 
dihydrotestostcrone stimulated the proliferation of T47D cells over 48 hours, however, 
physiological doses did not affect the proliferation of this cell line. Again the effect on 
progression of cells to G2/M was inconsistent. On incubating the MDA231 cell lines with 
10-9M to 10-6M 5cc-dihydrotestosterone and 5-androstene-30,170-diol which express low 
or zero aniounts of oestrogen receptors, no significant effect on proliferation was 
observed. These results are illustrated below. 
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MCF7 and T47D cell lines were incubated with 5a-dihydrotestosterone and the anti- 
oestrogen 10-6M faslodex. The percentage of cells in each phase of the cell cycle GO/I, S 
and G2/M was detennined at 0,24 and 48 hours, as previously. The following figures 
demonstrate that the proliferation of MCF7 cells by 5a-dihydrotestosterone was inhibited 
by faslodex confirming that 5a-dihydrotestosterone stimulates proliferation in the MCF7 
cell line via interaction with the oestrogen receptor. However, faslodex failed to inhibit 
the proliferation of T47D cells, suggesting that 5alpha dihydrotestosterone stimulates 
proliferation in T47D cell line via a pathway other than the oestrogen receptor. 
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Figure 7.2: O/oMCF7 cells in GO/1, S and G2/M on incubation with I 0-'M to I 01M 5a- 
dihydrotestosterone (abbreviations: nDHT =I 0-'M 5ct-dihydrotestosterone, ETOH 
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Figure 7.4: I/oMDA231 cell lines on incubation with 10-9m to 10 -6 M 5ct- 
dihydrotestosterone and 5-androstene-3p, 17p-diol (abbreviations: DHT-n =I O-n M 5ot- 
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dihydrotestosterone, ADIOL-n =I O'M 5-androstene-3 0,170-diol, ETOH = 0.0 1% 
ethanol) 
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Figure 7.5: O/oMCF cells in GO/I on incubation with 10-9M to I 0"('M 5a- 
dihydrotestosterone and I 0-'(N4 faslodex (abbreviations: nDHT =I O'M 5ot- 
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Figure 7.6: O/oMCF cells in S phase on incubation with 10-9M to 10 _6 M 5(X- 
dihydrotestosterone and I 0"6M faslodex (abbreviations: n. DHT =I O'M 5ct- 
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7.3 Cell proliferation of MCF7 and T47D cell lines during 9-day incubation 
with 5cc-dihydrotestosterone 
MCF7 and T47D cells were incubated for 9 days with physiological levels of 5cc- 
dihydrotestosterone and 170-oestradiol (10-9M). The following figures illustrate that 
physiological levels of 5(x-dihydrotestosterone inhibit the baseline and oestrogen-induced 
proliferation of MCF7 and T47D breast cancer cell lines. 
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Figure 7.8: Proliferation of MCF7 and T47D breast cancer cell lines during 9-day 
incubation with physiological levels of 5(x-dihydrotestosterone and 170-oestradiol 
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(abbreviations: nDHT = 10'M 5a-dihydrotestosterone, e2 = 170-oestradiol, ETOH = 
0.01% ethanol) 
7.4 Analysis of DNA cell cycle during forty-eight hour incubation of MCF7 
and T47D cell lines with 5-androstene-30,170-diol +I- faslodex 
MCF7 and MDA231 breast cancer cell lines were incubated over a 48 hour period with 
physiological levels of 5-androstene-30,17p-diol (10-9M to 10-6M) . The percentage of 
cells in each phase of the cell cycle GOA, S and G2/M was determined at 0,24 and 48 
hours as outlined in the materials and methods section above. 
The following figures illustrate that both physiological and pharmacological levels of 5- 
androstene-3p, 17p-diol resulted in a fall in the percentage of cells in GO/I and a rise in 
the percentage of cells in Sphase at 24hours. Again the progression of cells to G2/M was 
less consistent. It can be interpreted from these results that physiological levels of 5- 
androstene-30,170-diol stimulate the proliferation of MCF7 cell line. In addition, 
stimulation increased up to a concentration of I OOnM 5-androstene-3 0,170-diol, but no 
additional stimulation was observed at greater concentrations. No significant affect on 
proliferation of the MDA231 cell line was observed. 
On co-incubating MCF7 cells with 5-androstene-30,170-diol and faslodex it can be seen 
from the following figures that faslodex completely inhibits the stimulatory affect of 
physiological doses of 5-androstene-30,170-diol and partially inhibits the stimulation of 
pharmacological doses of 5-androstene-3p, 17p-diol. 
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Figure 7.9: I/oMCF7 cells in GO/I, S phase and G2/M during 48hour incubation with 10- 
6 to 10-9M 5-androstene-3p, 17p-diol (abbreviations: ADIOLn = 10'M 5-androstene- 
30,17p-diol, ETOH = 0.01% ethanol) 
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Figure 7.10: O/oMCF7 cells in GO/I during 48hour incubatiOn with 5-androstene-30,170- 
diol and faslodex (abbreviations: ADIOLn = 10'M 5-androstene-30,17p-diol, ETOH = 
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Figure 7.11: I/oMCF7 cells in GO/ I during 48hour incubation with 5-androstene-3 0,170- 
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7.5 Cell proliferation of MCF7 and T47D cell lines after 6 day incubation with 
physiological levels of 5-androstene-30,170-diol and 170-oestradiol 
MCF7 and T47D cell lines were incubated for 8 days with physiological levels of 
oestradiol and 5-androstene-30,170-diol. Cell numbers were determined after 6 and 8 
days by the methods outlined above. As illustrated in the following figure, physiologIcal 
levels of 5-androstene-30,170-diol stimulated baseline and inhibited oestrogen-induced 
proliferation of MCF7 and T47D cells. 
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Figure 7.12: Proliferation of MCF7 and T47D cell lines after 8 days and 6 days 
incubation with physiological levels of 170-oestradiol and 5-androstene-30,170-diol 
(abbreviations: ADIOLn =I 0-'M 5 -androstene-3p, I 7p-diol, ETOH = 0.0 1% ethanol, e2 
= 170-oestradiol) 
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Discussion 
As outlined in the introduction several studies have published results, which implicate 
androgens in the aetiologY of breast cancer. Epidemiological studies have established that 
serum androgens are elevated in postmenopausal women who develop breast cancer 
(Cauley 1999) (Dorgan 1997) (Gordan 1990) (Zeleniuch-Jacqotte 1997) and subnormal 
in premenopausal women who develop breast cancer (Bulbrook 1986) (Helzlsouer 1992). 
Our understanding of the mechanism of action of androgens however has been hindered 
by the findings that androgens are metabolically inter-related and they can inhibit or 
stimulate the proliferation of hormone-dependent breast cancer through different 
mechanisms. This action depends on the nature of the androgen, its concentration, the 
hormone receptor profile of the breast cancer and the endocrine status of the patient 
(Adams 1998). 
The metabolism of androgens is illustrated below. Androgens are metabolised: 
(a) By the sulfatase enzymes to 5-androstene-30,170-diol a metabolite with high afflinity 
for the oestrogen receptor 
(b) Via androstenedione and testosterone to 5(x-dihydrotestosterone which has high 
affinity for the androgen receptor 
(c) By the aromatase enzymes to oestrogens. 
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The ovary and the adrenal cortex both contribute to circulating levels of androgens. 
However neither produce significant quantities of either 5a-dihydrotestosterone or 5- 
androstene-30,170-diol, which may therefore be considered true metabolites, which act at 
tissue level (Longcope 1986). 
Dehydroepiandrosterone Sulphate 
Dehydroepiandrosterone 10 4-Androstenedione 
Oestrone 
5-Androstene-30,170-diol Testosterone rp 
Oestradiol 
Oestrogen 5cc-Dihydrotestosterone Androgen Receptor 10 Receptor 
30-Androstanediol 3a-Androstanediol 
Figure 7.13: The Metabolism of Androgens (Rochefort et aL 1984) 
In the present study we have therefore examined the actions of 5ot- dihydrotestosterone 
and 5-androstene-30,170-diol on breast cancer cell lines. In general it appears that 
androgen receptor mediated mechanisms in breast cancer inhibit growth. The mechanism 
of this action is unknown. However, recently it has been suggested that this affect may be 
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mediated by the production of one or more proteins, which prevent entry of the target cell 
into the cell cycle. These proteins have been termed androcyclone Il (Szelei et aL 1997). 
The aim of the present study was therefore to examine the affects of 5-androstene- 
30,170-diol and 5a-dihydrotestosterone on cell cycle and proliferation using a flow 
cytometric technique. The hormone-dependent cell lines MCF7 and T47D have been 
examined as well as the hormone-independent cell line MDA23 1. 
7.6 Actions of 5(x-dihydrotestosterone on proliferation of breast cancer cell 
lines 
5cc-Dihydrotestosterone, an androgen with high affinity for the androgen receptor and 
low affinity for the oestrogen receptor (Rochefort et aL 1984) has also been shown to 
have anti-oestrogenic activity at physiological levels in the MCF7 cell line (MacIndoe 
1981). As outlined in the introduction, physiological levels of 5cc-dihydrotestosterone 
inhibit the proliferation of T471), ZR751 and NTW23 breast cancer cell lines via an 
interaction with the androgen receptor (Poulin et aL 1986) (Biffell 1995) (Hackenberg et 
al. 1991). Although 5(x-dihydrotestosterone stimulates the proliferation of MCF7 and 
MDAMB453 cell lines at physiological levels this may be due to the activation of 
androgen receptor-independent pathways by active metabolites with oestrogenic activity 
(Hall et al. 1994) (Biffell 1995). At pharmacological levels, 5et-dihydrotestosterone has 
been shown to stimulate the proliferation of MCF7 cells via the oestrogen receptor (Zava 
1978) (Lippman 1976). 
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This study has observed that over 8-9 day incubations physiological concentrations of 
5a-dihydrotestosterone inhibit the proliferation of MCF7 and T47D cell lines. 
Physiological levels of 5a-dihydrotestosterone have previously been reported to either 
stimulate (Biffell 1995) (Hackenberg et al. 1988) or not afTect (Zava 1978) the 
proliferation of MCF7 cells and inhibit the proliferation of T47D breast cancer cells via 
an androgen receptor mediated mechanism (Birrell 1995). 
MCF7 cells have been shown metabolise 5ot-dihydrotestosterone to androstane-3ct, 170- 
diol, an androgen with oestrogenic properties (Roy 1992). This may account for the 
stimulatory affect of 5a-dihydrotestosterone observed in MCF7 cells, in contrast to the 
inhibitory action of 5ec-dihydrotestosterone observed in other breast cancer cell lines 
(Roy 1992) (Birrell 1995). The MCF7 cell line used in this study has been passaged 
several hundred times. It is not known how this affects glucuronyltransferase activity. It 
may be that repeated passages result in downregulation or loss of glucuronyltransferase 
expression in MCF7 cells, which may account for the inhibitory affect of physiological 
concentrations of 5a-dihydrotestosterone observed in this study. 
In addition to the inhibition of MCF7 and T47D cell lines demonstrated in this study, 5ot- 
dihydrotestosterone has been observed to inhibit the oestrogen-induced proliferation of 
MCF7 and T47D cell lines. These findings are consistent with previous studies on MCF7 
(Maclndoe 1981) and ZR751 cell lines (Poulin 1988) by a mechanism, which is mediated 
via the androgen receptor. 
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Over 48 hours 10-9M 5ot-dihydrotestosterone does not affect the progression of MCF7 or 
T47D cells through the cell cycle. Likewise 10-8M 5a-dihydrotestosterone does not affect 
the proliferation of T47D cells during OVCT 48 hour incubation, however, 10-8M 5(x- 
dihydrotestosterone stimulates the proliferation of MCF7 cells via an oestrogen receptor 
mediated mechanism. 
The phases of the cell cycle are illustrated below. The quiescent cell is in the GO phase of 
the cell cycle. On the initiation of division the cell moves into GI phase and produces 
proteins required for DNA replication. Replication of DNA takes place in the S phase, by 
the end of which the DNA content of the cell has doubled. At this point the cell enters G2 
phase followed by mitosis (M phase) during which the cell divides. Following cell 
division the cell either returns to the quiescsent state (GO phase) or if cell division is to be 
sustained to G1. 
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Figure 7.14: Phases of the cell cycle 
Cell cycle progression in breast cancer is regulated by a series of cyclin-dependent 
kinases and cyclin-dependent kinase inhibitors (Grana et al. 1995) (Hunter et al. 1994). 
These proteins control the transition through checkpoints between different cell cycle 
states occurring, for example, at the initiation of DNA replication (S phase) and cell 
division (mitosis). Androgens have been shown to upregulate expression of the cyclin- 
dependent kinases CDK2 and CDK4 and downregulate expression of the cyclin- 
dependent kinase inhibitor CKlpl6 in the androgen-dependent prostate cancer cell line 
LNCaP. Thereby stimulating the cell to enter S phase of the cell cycle and enhancing 
proliferation (Lu et al. 1997). Androgen regulation of another cyclin-dependent kinase 
inhibitor p27 is also of importance in prostate cancer (Macri et al. 1999). 
How androgens regulate cellular proliferation in breast cancer remains poorly understood. 
Szelei el al using a synthetic non-metabolised androgen R 1881 and MCF7 cells 
transfected with androgen receptor observed these MCF7-AR I cells were arrested in 
GO/Gl phase of the cell cycle after 24hours incubation with androgen. It was postulated 
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that this affect was due to androgens inducing the synthesis of a gene product, termed 
androcyclone-II, which prevented entry of target cells into the cell cycle (Szelei et al. 
1997). 
In the present study, despite 5a-dihydrotestosterone inhibiting the proliferation of MCF7 
and T47D breast cancer cell lines over longterm incubations no affect on progression of 
cells through the cell cycle was observed over 48 hours. These findings are consistent 
with those of Poulin et al and Birrell et al who observed that the inhibitory actions of 5(x- 
dihydrotestosterone on breast cancer cell lines were not observed until 6 days incubation 
with androgen (Birrell 1995) (Poulin 1988). Further studies are necessary to determine 
how androgens affect the growth of breast cancer via the androgen receptor, and in 
particular whether they affect the expression of cyclin-dependent kinases and cyclin- 
dependent kinase inhibitors in breast cancer cell lines. 
The present study demonstrates that pharmacological levels of 5cc-dihydrotestosterone 
stimulate MCF7 and T47D cells to enter the S phase and enhance proliferation. In MCF7 
cells this action is blocked by co-incubation with faslodex implying an oestrogen receptor 
mediated mechanism, consistent with previous observations (Zava 1978) (Lippman 
1976). Faslodex does not block this action in T47D cells, suggesting an alternative 
pathway is involved in mediating the proliferation of T47D cells by pharmacological 
levels of 5(x-dihydrotestosterone. 
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7.7 The actions of 5-androstene-30,170-diol on the proliferation of breast 
cancer cell lines 
The oestrogenic actions of androgens are established and are the subject of a review by 
Rochefort and Garcia (Rochefort et aL 1984). Much attention has centred on 5- 
androstene-30,170-diol, an androgen termed "hermaphrodiol" due to its relatively high 
affinity for the oestrogen and androgen receptor (Poortman et al. 1975) (Adams 1998). 5- 
Androstene-30,170-diol induces the secretion of a 46K oestrogen-dependent protein and 
stimulates the proliferation of MCF7 (Adams et aL 1981) (Hackenberg 1993) (Boccuzzi 
et aL 1992) and ZR751 (Poulin et aL 1986) breast cancer cell lines at physiological 
concentrations. This action has subsequently been demonstrated to occur via a direct 
interaction with the oestrogen receptor (Maggiolini et aL 1999). 
In addition to its oestrogenic actions, at physiological levels 5-androstene-30,170-diol 
antagonises the oestrogen-induced proliferation of MCF7 cells by an androgen receptor 
mediated mechanism (Boccuzzi et aL 1992) (flackenberg 1993). 
5-Androstene-30,170-diol is formed by peripheral conversion of DHEA, which is in 
equilibrium with DHEAS thus providing a buffer to maintain levels of its metabolites 
(Longcope 1986). In conbwt to 5-androstene-30,170-diol, DHEA has a very low and 
DBEAS a negligible affinity for the oestrogen receptor (Rochefort el aL 1984). However, 
DBEAS and DHEA have both been shown to stimulate the proliferation of hormone- 
dependent breast cancer cell lines, the former at physiological levels (Adams et aL 1981) 
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(LeBail et al. 1998) and to be elevated in the serum of postmenopausal women who 
develop breast cancer (Cauley 1999) (Dorgan 1997) (Gordan 1990). 
The mechanism of action of DHEAS was unknown. However recently, it has been shown 
that sulfatase inhibitors block the DBEAS-stimulated growth of MCF7 cells (Billich et al. 
2000). This suggests that the mitogenic affect of DHEAS on breast cancer cell lines is 
mediated via its metabolism to 5-androstene-30,17p-diol, rather than aromatisation of its 
metabolites androstenedione and testosterone to oestrogens. This pathway is of clinical 
significance as it enables the ongoing stimulation of hormone-dependent breast cancers 
by adrenal androgens in patients on aromatase inhibitors. 
The interim findings of the Arimidex, Tamoxifen, alone or in Combination (ATAC) trial 
(Baum 200 1) demonstrate that aromatase inhibitors are superior to tamoxifen as the 
adjuvant therapy for postmenopausal women with breast cancer. In light of these findings 
the evidence-base for the routine use of aromatase inhibitors in clinical practice is 
currently being established (Winer et al. 2002). The properties of 5-androstene-30,170- 
diol are therefore of particular significance and it is timely therefore to examine the 
effects 5-androstene-30,170-diol on breast cancer growth. 
Several previous studies have reported that 5-androstene-30,170-diol stimulates the 
proliferation of hormone-responsive breast cancer cell lines via interaction with the 
oestrogen receptor at physiological levels (Adams et aL 1981) (Poulin et aL 1986) 
(LeBail et aL 1998) (Boccuzzi et aL 1992) (Ilackenberg 1993) (Maggiolini et aL 1999). 
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The present study demonstrates that within 24 hours 5-androstene-30,170-diol stimulates 
MCF7 cells to enter S phase of the cell cycle thereby enhancing cell proliferation. 
Furthermore, this affect was blocked by co-incubation with faslodex, confirming that this 
action is mediated via the oestrogen receptor. 
5-Androstene-30,170-diol is a steroid, which has affinity for both the oestrogen and 
androgen receptor and has therefore been tenned "hermaphradiol" (Poortman et aL 1975) 
(Adams 1998). Consistent with its affinity for the androgen receptor, the present study 
confirms previous findings demonstrating that 5-androstene-30,170-diol like 5a- 
dihydrotestosterone inhibits the oestrogen-induced proliferation of hormone-dependent 
breast cancer cell lines (Boccuzzi et aL 1992) (Boccuzzi et aL 1994) (flackenberg 1993). 
7.8 Implications for the role of androgens In breast cancer 
Androgens are metabolised to substrates, which inhibit (5ot-dihydrotestosterone) or 
stimulate (5-androstene-30,17p-diol, oestrogens) the proliferation of hormone-dependent 
breast cancer cells at physiological levels. The net affect of androgens in vivo seems 
likely to be a balance between the stimulatory and inhibitory affects of their metabolites. 
The findings by several groups that serum androgens are elevated in postmenopausal 
women who develop breast cancer suggest that the net activity in vivo is stimulatory. In 
premenopausal women, the hormonal milieu is rich in ovarian oestrogens. In the present 
study both 5a- dihydrotestosterone and 5-androstene-30,170-diol antagonise the 
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oestrogen-induced proliferation of breast cancer cells. Elevated levels of androgens in 
premenopausal women by antagonising the oestrogen-induced proliferation of hormone- 
dependent breast cancer may therefore protect against the development of breast cancer. 
This mechanism may underlie the observations of Bulbrook et al and others that 
premenopausal women who develop breast cancer have subnormal androgen levels 
(Bulbrook 1986). 
The observation that 5-androstene-30,170-diol stimulates the proliferation of hormone- 
dependent breast cancer cell lines at physiological levels has implications for patients on 
aromatase inhibitors, as this pathway provides a mechanism for the ongoing stimulation 
of hormone-dependent breast cancer. Evidence that this pathway may have importance in 
vivo is suggested by a recent study. This found that elevated serum 
dehydroepiandrosterone sulphate levels predict breast cancer progression in 
postmenopausal women on aromatase inhibitors (Morris et aL 2001). 
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Results and Discussion 
A lectin ELISA for the cerbB-2 oncoprotein 
Results 
Following the development of a lectin ELISA for the cerbB2 oncoprotein, which showed 
encouraging results in a pilot study as an assay for the diagnosis of breast cancer (Cook et 
al. 1999), serum was collected from women with breast cancer and controls, and steps , 
were taken to re-establish the assay in vitro. It was the intention to apply the assay to test 
serum taken from women with primary operable breast cancer and controls, expanding 
the results of the pilot study. 
In order to re-establish the assay in vitro it was necessary to demonstrate that each step of 
the assay was functioning satisfactorily i. e. cerbB2 antigen was captured by antibody 
(OM-1 1-954) and lectin (wheat germ agglutinin) bound carbohydrate. Having established 
that these steps were working a lysate was prepared from a breast cancer cell line SKBR3 
known to express high levels of the cerbB2 protein (Leitzel et aL 1992). The cerbB2 
lectin ELISA was performed on this lysate. Modifications were then carried out including 
the addition of human serum, to investigate different aspects of the assay. 
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8.1 Biotinylation of a synthetic pl 85 peptide (OP-1 1-3549) 
A synthetic peptide OP- 11-3 549 (Cambridge Research Biochemicals Ltd, Cheshire, UK) 
consisting of an eighteen peptide sequence, which forms part of the extra-cellular domain 
of cerbB2 which was used as the antigen for producing the monoclonal antibody OM- II- 
954 (Genosys Biotechnolgies, Cambridge, UK) was biotinylated as outlined in materials 
and methods. 
The following graph illustrates the optical density of I ml fractions collected after passing 
a mixture of synthetic p185 peptide OP-11-3549 and EZ-IinkTm MHS-LC biotin through 
sephadex beads. Optical density was detennined using a spectrophotometer and reflects 
the protein content of the fraction. 
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Figure 8.1: Gel filtration of synthetic p185 peptide (OP-11-3549) and NHS-LC biotin 
through sephadex beads 
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It was likely that the biotin-pl 85 was contained in the fractions with the highest optical 
density i. e. the first and third fractions. In the following experiment both fractions were 
therefore tested to investigate which contained the biotin-p 18 5. 
8.2 Capture of biotinylated synthetic p185 peptide OP-11-3549 by 
monoclonal antibody to cerbB2 (OM-1 1-954) 
This experiment was performed to demonstrate that the monoclonal antibody used in the 
cerbB2 lectin ELISA, OM-1 1-954 bound cerbB2 protein and would therefore capture this 
antigen when applied to the serum samples. Following the steps outlined in the materials 
and methods section the first and third fractions obtained above by gel filtration were 
investigated. No response was obtained with the first fraction, but the third fraction 
showed an increase in absorbance with higher concentrations of biotin pl 85. This is 
illustrated in the following figure. 
Figure 8.2: Capture of biotin synthetic p 185 by cerbB2 monoclonal antibody OM- 11-954 
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It was assumed that all the synthetic biotm p 185 was contained in the third fraction, 
giving a final concentration of about 75pg/ml of synthetic p 185. 
Furthermore, a competition experiment was performed to confirm that unlabelled 
synthetic p185 competes with biotinylated synthetic pl 85 for antibody binding sites. 
Following the method outlined in the materials and methods section, the following results 
were obtained. These demonstrate that competition between unconjugated synthetic p 185 
and biotinylated synthetic p 18 5 does occur. 
Competition between unconjugated 
and blotinylated synthetic p185 for 
binding to cerbB2 antibody OM-11-964 
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Figure 8.3: Competition between unconjugated synthetic p 185 and biotinylated synthetic 
p 185 for binding to OM- 11-954 antibody 
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8.3 Binding of lectin (wheat germ agglutinin) to glycoprotein 
In the first step of the lectin ELISA antigen is captured by the monoclonal antibody OM- 
11-954. In the second step lectin binds to carbohydrate expressed on the surface of the 
cerbB2 protein. In order to test whether the lectin used in this assay, wheat germ 
agglutinin, binds carbohydrate, fetuin a heavily glycosylated glycoprotein was used. 
Following the steps outlined in materials and methods increasing concentrations of fetuin 
were incubated with biotinylated wheat germ agglutinin. The followmg figure illustrates 
that biotinylated wheat germ aggutinin binds fetuin, and should therefore bind to 
glycoconjugates expressed on the surface of captured cerbB2 antigen. 
Binding of biotinylated wheat germ 
agglutinin to fetuin 
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Figure 8.4: Binding of biofinylated wheat germ agglutinin to fetum 
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8.4 Binding of monoclonal antibody OM-1 1-954 to extra-cellular domain of 
cerbB2 in a lysate of SKBR3 cells 
A lysate to be used as a standard against which serum samples could be compared was 
prepared by a method outlined in materials and methods from a breast cancer cell line, 
SKBR3, known to express high levels of cerbB2 (Leitzel et aL 1992). In order to test that 
the antibody OM- 11-954 bound to cerbB2 in SKBR3 lysate, an experiment was 
performed in which antibody was incubated with dilutions of SKBR3 lysate immobilised 
in the solid phase, see section 4.5 in materials and methods. The following figure 
illustrates that a substantial quantity of receptor was present in the lysate. 
Binding of cerbB2 antibody OM41-964 
to SKBR3 Zabrecky lysate and 
medium 
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Figure 8.5: Binding of cerbB2 protein from SKBR3 lysate and medium by cerbB2 
antibody OM-1 1-954 
The response levels off at a SKBR3 lysate, dilution of 1150. Failure of the signal to 
increase at higher concentrations of lysate may be due to steric hindrance or saturation of 
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the plastic. It can also be seen that the medium in which the SKBR3 cells were cultured 
does not contain significant quantities of the cerbB2 antigen. 
8.6 A lectin ELISA for cerbB2 
Having demonstrated that the monoclonal antibody OM-1 1-954 binds to a synthetic 
cerbB2 protein and to a protein from a lysate of SKBR3 cells, and that biotinylated wheat 
germ agglutinin binds to carbohydrate groups on the heavily glycosylated glycoprotein 
fetum. The different components of the lectin ELISA were put together as outlined in 
materials and methods. The following figure illustrates that a good response was 
achievable with increasing absorbance occurring up to a lysate dilution of 1/20. 
Lectin ELISA of Zabrecky lysate after 
40 mins incubation with BCIP 
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Figure 8.6: Lectin ELISA for cerbB2 usmg SKBR3 lysate 
Various aspects of the assay were then determined. The effect to the response of the assay 
of adding human serum was investigated. This was done to simulate the serum samples, 
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in which non-specific proteins in the serum by competing for binding of cerbB2 antigen 
to antibody and lectM may interfere with steps in the assay. The lectin ELISA was 
performed as outlined above, but the lysate contained 15% human serum taken from one 
of the investigators. The following figure illustrates that serum does suppress the 
response of the assay. 
The effbct of 150/6 human serum on the 
response of the Lectin ELISA 
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Figure 8.7: Lectin ELISA for cerbB2 using SKBR3 lysate +/- 15% human serum 
Different concentrations of lectin (wheat germ agglutinin) were used to investigate 
whether this would enhance the response of the assay. The cerbB2 lectin ELISA was 
therefore performed as described in the materials and methods, but I/ 100,1/200 and 
1/500 dilutions of biotinylated wheat germ agglutinin were used. The following figures 
show that higher concentrations of wheat germ agglutinin will enhance the response of 
the assay, however on addition of 15% human serum to the lysate a flat response curve 
was obtained. 
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CerbB2 lectin ELISA comparing effect 
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Figure 8.8: Lectin ELISA for cerbB2 using different concentrations of wheat germ 
agglutinin +/- 15% human serum 
Lectins, though they have specificity for particular sugars, will bind to glycoconjugates 
expressed by non-specific proteins present in the serum. It is probable that the high 
response observed on increasing the concentration of lectin is due to wheat germ 
agglutinin binding to non-specific serum proteins, absorbed to the well, or antibody. 
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Using a higher concentration of wheat germ agglutinin will therefore decrease the 
specificity of the assay when applied to the serum samples. 
8.6 Inter-assay variation 
The results presented above were obtained at different times during the research project 
and imply a functioning assay. Considerable difficulties were encountered in reproducing 
these results. It was finally concluded that there were fundamental problems with the 
assay. The experiments upon which this conclusion was drawn are outlined below. 
The following graphs illustrate the response of the cerbB2 lectin ELISA on three separate 
occasions on lysates extracted in the laboratory from SKBR3 cells and a SKBR3 pellet 
(Oncogene Research Products). This shows there is a considerable variation in the 
perfonnance of the assay. The extent of this inter assay variation would preclude the 
clinical use of the cerbB2 lectin ELISA. 
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Figure 8.9: Comparison of cerbB2 lectin ELISA performed on three separate occasions 
on SKBR3 lysates 
It was then decided to determine how much cerbB2 protein was present in the collected 
lysates that had been extracted from SKBR3 cells. For this purpose an Oncogene Science 
Research Products cerbB2 ELISA was used. This shows that the lysate extracted from the 
SKBR3 pellet contained a considerable quantity of cerbB2 antigen, however with one 
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exception, the lysates extracted from SKBR3 cells grown in the laboratory contained little 
cerbB2 protein. 
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Figure 8.10: Oncogene Science Research Products cerbB2 ELISA of collected lysates 
In vlew of these results a comparison of the cerbB2 lectin, ELISA of the collected lysates 
was perfonned. This illustrates that there was no correlation between the response of the 
cerbB2 lectin ELISA and the quantity of cerbB2 protein present in the lysate. The lysate 
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prepared from a SKBR3 cell pellet contains significantly more cerbB2 protein than the 
other lysates yet doesn't give a higher response in the cerbB2 lectin ELISA. 
The lectin ELISA measures the carbohydrate expressed on the surface of proteins bound 
to the capture antibody rather than quantity of protem present. The lack of correlation 
between the response of the lectin ELISA and conventional ELISA was therefore not an 
entirely unexpected result, though other studies have reported significant correlations 
between these two types of assay (Madiyalakan et al. 1996). 
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Figure 8.11: CerbB2 lectin ELISA of collected lysates 
Lysates were then prepared from using 4-5 x number of cerbB2 cells in the hope that they 
contain more cerbB2 protein. Two different extraction methods were compared. These 
were the Zabrecky method described above and a commercial protein extraction kit 
(Pierce, USA). The following figures demonstrate that these lysates contained significant 
amounts of cerbB2 protein. 
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Figure 8.12: Oncogene Science cerbB2 ELISA of lysates extracted by Zabrecky and 
Pierce methods 
The cerbB2 lectin ELISA was performed on these lysates as described in materials and 
methods, though for comparison capture antibody was omitted from one strip of wells. 
The following graph illustrates that this did not change the response observed. 
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Figure 8.13: CerbB2 lectln ELISA +/- capture antibody 
A similar cerbB2 lectin ELISA was then performed using a variety of cerbB2 antibodies 
instead of OM- 11-954, including Ab-5 and Ab-7 (Oncogene Science, USA) and Ab-3, 
Ab-19 and Ab-21 (Abcam, USA). The response using these antibodies to capture the 
cerbB2 antigen were similar to those illustrated above i. e. a similar response curve was 
obtained when the capture antibody was omitted from the cerbB2 lectin ELISA. 
Finally, it has been reported that repeated freeze-thaw cycles and the length of time 
specimens are stored may affect the conformation of glycoprotems. Thompson et al ma 
study of sera from ovanan cancer patients reported that abnormal forms of alpha-l- 
proteinase inhibitor could not be extracted from fresh sera by the lectin lotus 
letrogonolobus unless specimens had been subjected to repeated cycles of freezing and 
thawing. Thompson el al also attributed discrepancies between the measurement of 
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abnormal forms of alpha- I -proteinase inhibitor between this and previous studies to the 
length of time specimens were stored Prior to analyses (Thompson el al. 1990). 
In the current study, the protein concentration in the lysates required to achieve a given 
response in the cerbB-2 lectin ELISA was much higher than that employed by Bustamam 
el al (Bustamam 1998). The affect of subjecting the serum sample to repeated freeze thaw 
cycles was therefore examined. The cerbB-2 lectin ELISA was performed on a fresh 
serum sample and a sample from the same patient subjected to 10 freeze thaw cycles. 
The steps outlined in section 4.7 in the materials and methods section were followed, 
however wells were incubated overnight at 4'C with I 00gl of aI in 10 dilution of serum 
in 1% BSA PBS-Tween instead of SKBR3 Zabrecky lysate. The following figure 
demonstrates that repeated freeze thaw cycles did not alter the response from the cerbB-2 
lectin ELISA. 
CerbB-2 lectin ELISA of serum 
subjected to ton freeze thaw cycles 
compared to fresh serum 
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Figure 8.14: CerbB-2 lectin ELISA on a sennn sample to investigate the affect of 
repeated freeze-thaw cycles 
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8.7 Discussion: A lectin ELISA for cerbB2 
The cerbB2 lectin ELISA was established by BustamamAA et al as a means of detecting 
the extracellular domain of cerbB2 in the serum, at a time when only one antibody to the 
extracellular domain was commercially available (Bustamam 1998). This necessitated 
that a lectin was used as a probe in the second part of the antibody-lectin sandwich to 
detect the cerbB2 extracellular domain (p 185) bound to antibody. 
The assay was investigated quite extensively including competition experiments to 
confirm the specificity of the assay, see figure 82 in Bustamam's PhD thesis (Bustamam 
1998). These experiments demonstrated that a synthetic p 185 protein competed with 
lysate protein for antibody binding sites. These experiments were repeated in the present 
study and imply that the antibody was successfully capturing cerbB2 protein. 
In the pilot study, the effect of performing the assay in the presence of human serum was 
investigated. It was decided that the response from the cerbB2 lectin ELISA was 
optimum in about 20% human serum. However, in the presence of 20% human serum 
approximately half the response of the cerbB2 lectin ELISA was due to the addition of 
serum, see figure 98 in Bustainam's PhD thesis (Bustamam 1998). This affect was 
attributed to non-specific serum glycoproteins absorbed to the plastic. These results 
should have alerted the investigators to question the suitability of the assay for use on 
clinical samples. 
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Bustainam et al did not perform any experiments to assess the reproducibility of the 
assay. The present study has demonstrated a wide variation in the response from the assay 
performed on different occasions on the same SKBR3 lysate. The results presented above 
demonstrate that each step of the assay functions satisfactorily and that a lysate has been 
successfully extracted that contains sufficient quantities of cerbB2 protein. The final 
experiment demonstrates the response from the cerbB2 lectin ELISA does not reflect 
glycosylation of cerbB2, but glycosylation of non-specific proteins present in the lysate 
absorbed to the sides of the wells, albeit the protein concentration in these lysates was 
much higher than that employed by Bustamam. et al (Bustamam 1998). Rebeski et al have 
reported on unacceptable background caused by non-specific protein adsorption to 
immunoassay plates using ELISAs concluding that this could be a factor in the 
development and application of ELISAs (Rebeski et aL 1999). 
The difficulties that have been encountered in this study may be attributed to the extent 
and variation of glycosylation of cerbB2 and the nature of lectins. Several lectin ELISAs 
have been published which have reported low coefficients of inter-assay variation 11.2% 
(Parker et aL 1992), <5% (Madiyalakan et aL 1996) and 16.4% (Nagata et aL 199 1). 
Madiyalakan et al reported a correlation between the lectin ELISA and conventional two- 
site antibody sandwich for the determination of CA-125 in the serum of patients with 
ovarian cancer (Madiyalakan et aL 1996). These studies have investigated proteins, 
which are heavily glycosylated. Parker et al measured a mucin, a group of molecules, 
which are heavily glycosylated (Kim et aL 1996) and Nagata. et al measured 
carcinoembryonic antigen (CEA), which is known to comprise of 50% carbohydrate 
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(Nagata et aL 1991). In contrast little is known about the extent and nature of 
glycosylation of cerbB2. 
Thompson et al have reported that abnormal forms of alpha- I -proteinase inhibitor present 
in the sera of women with ovarian cancer could not be extracted by the lectin lotus 
tetrogonolobus unless samples had beeen stored for 6-9 years or artificially aged by being 
subject to repeated freeze-thaw cycles (Thompson et al. 1990). In the present study 
repeated freeze-thaw cycles did not affect the response of the cerbB-2 lectin ELISA (see 
figure 8.14), however the affect of the length of time for which samples were stored on 
the response of the lectin ELISA could not be excluded. 
SKBR3 cells were cultured in the same laboratory using similar experimental techniques 
in the present study and the pilot study. However, there was a time lapse of 34 years 
between studies. The nature and extent of glycosylation of glycoproteins may vary with 
time and repeated passage of cell lines. However, differences in the glycosylation of 
glycoproteins are difficult to quantify without lengthy and time-consuming techniques, 
which were out of the scope of this project. These factors may have contributed to the 
differences between performance of this assay in the present and pilot study. In addition, 
these factors presented difficulty in producing a reliable standard with known cerbB2 
protein and constant glycosylation against which the samples could be compared. 
Lectins have specificity for sugar groups present on glycoproteins (Walker 1989). 
However, when used in lectin ELISAs, they may bind to non-specific glycoproteins 
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adherent to the side of the wells. A conventional two-site double-antibody ELISA has 
capture and detection antibodies with specificity for the protein under investigation. This 
confers on them a high degree of reproducibility. In contrast the response from a lectin 
ELISA may vary to a greater extent on the presence of other non-specific proteins present 
in the sample to which the lectin binds. This may be overcome to an extent when the 
protein under investigation is heavily glycosylated, such as a mucin (Kim et aL 1996). 
The results from the present study do not support the use of lectin ELISAs for the 
measurement of cerbB2 in the serum of women with breast cancer. Results from the pilot 
study revealed shortcomings in the assay, which may have become apparent if the 
reproducibility of the assay had been investigated at this stage. Further investigation of 
this area should commence with an investigation of the nature and extent of glycosylation 
of cerbB2 using techniques such as mass spectroscopy or nuclear magnetic resonance 
analysis. 
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The Role of Androgens In Breast Cancer 
9.1 Central Hypothesis 
In this study, serum and tumour samples were collected from women with primary 
operable breast cancer and controls. Serum samples were used to measure androgen 
levels (dehydroepiandrostene sulphate, androstenedione and testosterone levels) using 
conventional ELISA techniques. As "crosstaW' occurs between steroid hormone and 
growth factor pathways in breast (and prostate) cancer, it was proposed to measure 
cerbB-2 levels using a lectin ELISA format. This technique was chosen as a lectin ELISA 
for cerbB-2 had previously been developed in our laboratory, which showed encouraging 
results as a diagnostic test for breast cancer. 
Elevated levels of serum androgens in postmenopausal women and reduced levels of 
seram androgens in premenopausal women with breast cancer have been reported by 
several recent studies though there is disagreement on the significance of levels of 
different androgens. On the basis of these observations and the results of cell line studies 
it has been proposed that androgens may have a role in the aetiology of breast cancer by 
stimulating growth of hormone-dependent breast cancer in postmenopausal women and 
inhibiting the growth of hormone-dependent breast cancer in premenopausal women 
(Adams 1998). 
In order to test this hypothesis, in the present study, the levels of three androgens 
dehyroepiandrosterone sulphate, androstenedione and testosterone were measured in a 
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sample of women with primary operable breast cancer and controls. Two ftu-ther 
relationships, between serum androgen levels, body mass index and age have been 
investigated. 
Cell line studies have been performed to examine the effect of two androgens, 5cc- 
dibydrotestosterone and 5-androstene-30,170-diol, on the proliferation of hormone- 
dependent breast cancer cell lines MCF7 and T47D and the hormone-independent cell 
breast cancer cell line MDAMB231.5cc-Dihydrotestosterone and 5-androstene-3p, 17p- 
diol have been chosen as they are true androgen metabolites, which act at the tissue level 
in vivo (Rochefort et aL 1984). 
A flow cytometric technique has been used to investigate the effect of these androgens on 
DNA cell cycle analysis in 48-hour incubations and cell numbers in 9-day incubations. 
Cell line models have been set up to mimic the hormonal environment in pre and 
postmenopausal women in order to investigate mechanisms by which androgens may 
stimulate the proliferation of hormone-dependent breast cancer in postmenopausal and 
inhibit the proliferation of hormone-dependent breast cancer in premenopausal women. 
A positive correlation between breast cancer incidence throughout the world and 
nutritional status has been demonstrated (DeWaard 1969). Nutritional status has been 
reported to affect androgen production and metabolism and therefore it has been 
proposed that androgens are implicated in the development of "Western-environmental" 
type breast cancer (Adams 1977). In order to investigate this hypothesis a correlation 
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between serum androgen levels and body mass index has been sought. Secondly, a 
correlation between serum androgen levels and age has been investigated, as it has been 
proposed that although serum androgen levels fall with age in healthy women they are 
independent of age in women with breast cancer (Adams 1998). 
Flow cytometry is an established method for the determination of cell surface (Loken et 
al. 2000), cytoplasmic and nuclear antigens (Larson 2000). Multiparameter flow 
cytometry enables the simultaneous determination of expression of several antigens on 
tumour specimens. Flow cytometric methods for the determination of oestrogen receptor 
alpha (Brotherick et aL 1995), oestrogen receptor beta (Girdler el aL 2001) and epidermal 
growth factor receptor expression (Brotherick et al. 1994) have been established in our 
laboratory. In the present study a flow cytometric method for the determination of 
androgen receptor expression in breast cancer has been described. 
A correlation between androgen receptor expression, determined by flow cytometry and a 
more established technique, immunohistochemistry, has been investigated. In order to 
investigate the clinical significance of androgen receptor expression in breast cancer, 
androgen receptor expression has been correlated with existing prognostic markers 
Bloom Richardson grade (Bloom et al. 1957) and lymph node status (Fisher et al. 1978). 
Oestrogen receptor expression in breast cancer has been found to increase with age 
ful 
kEtwood el al. 1980). Expression of steroid hormone receptors is regulated by their 
ligands, by a mechanism known as "negative autoregulation". In order to determine 
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whether negative autoregulation determines androgen receptor expression in breast 
cancer in vivo a correlation between androgen receptor expression and serum 
dehydroepiandrosterone, androstenedione and testosterone levels have been investigated. 
In addition, an association between androgen receptor expression and age has been 
investigated. 
In the present study, in addition to androgen receptor expression, oestrogen receptor 
alpha and epidermal growth factor receptor expression has been determined. The 
relationship between androgen receptor, oestrogen receptor and epidermal growth factor 
receptor expression has been examined. 
The rational for investigating an association between androgen receptor and epidermal 
growth factor expression was that crosstalk occurs between steroid receptor and growth 
factor receptor pathways in breast (and prostate) cancer (Nicholson et aL 1999). An 
inverse correlation has been reported between oestrogen receptor expression and 
epidermal growth factor expression in breast cancer (Walker et aL 1999), though a 
relationship between androgen receptor and epidermal growth factor expression has not 
hitherto been investigated. 
9.1 The role of androgens in breast cancer 
The investigation of the role of androgens in breast cancer has been divided into three 
sections. Firstly the serum levels of androgens in women with breast cancer and controls 
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have been measured. A correlation of serum androgen levels in women with breast cancer 
and controls with age and body mass index has been sought. The results presented above 
demonstrate that serum testosterone, androstenedione and DHEAS levels fall with 
increasing age, in both women with breast cancer and controls. These findings conflict 
with previous published data on the association between serum androgen levels and age, 
which suggested that serum androgen levels were independent of age in women with 
breast cancer (Zumoff 198 1). 
No association was demonstrated between serum androgen levels and body mass index in 
women with breast cancer or controls. These findings may have importance in the 
epidemiology of breast cancer. Obesity is implicated in the aetiology of breast cancer. 
The results of the present study demonstrate that serum androgen levels are independent 
of body mass index. Therefore the higher incidence of breast cancer in obese 
postmenopausal women is more likely to be due to higher serum oestrogen levels (Cauley 
et aL 1989) due to greater aromatisation of androgens in peripheral adipose tissue rather 
than a direct affect of body mass index on serum androgen levels. 
In this study, serum DHEAS levels were observed to be higher in postmenopausal 
women with breast cancer. This suggests a role for adrenal androgens in the aetiology of 
breast cancer in postmenopausal women. These results are supported by the cell culture 
experiments which demonstrated that 5-androstene-30,170-diol a metabolite of DHEAS 
stimulates the proliferation of hormone receptor positive breast cancer cell lines at 
physiological levels via an interaction with the oestrogen receptor. On the other hand, 5a- 
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dihydrotestosterone a metabolite of DBEAS with high affinity for the androgen receptor 
was found to inhibit the basal proliferation of hormone receptor positive breast cancer 
cell lines. Thus it is apparent that androgens are metabolized to steroids which may 
stimulate (5-androstene-30,170-diol, 170-oestradiol) or inhibit (5a-dihydrotestosterone) 
the growth of hormone dependent breast cancer. 
In longterm tissue culture both androstene-30,170-diol and 5a-dihydrotestosterone 
inhibited the oestrogen-induced proliferation of hormone receptor positive breast cancer 
cell lines. This suggests androgens may protect against breast cancer in premenopausal 
women. They are supported by the results of Bulbrook et al who measured urinary 
androgen metabolites in a sample of women on the island of Guernsey who subsequently 
developed breast cancer (Bulbrook 1986). In the present study, serum androgen levels did 
not differ between premenopausal women with breast cancer and controls. The results of 
this study do not entirely support a protective role against breast cancer for androgens in 
premenopausal women. However, fewer numbers in the premenopausal group and failure 
to account for the variables outlined above may have accounted for the failure to observe 
a difference between serum androgen levels in premenopausal women with breast cancer 
and controls. 
By using a flow cytometric technique, tissue culture experiments in this study have 
demonstrated for the first time the effect of androstene-30,170-diol and 5cc- 
dihydrotestosterone on DNA cell cycle in hormone receptor positive and negative breast 
cancer cell lines. Szelei et al demonstrated that androgens inhibit the proliferation of a 
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MCF7 breast cancer cell line transfected with an androgen receptor (Szelei et aL 1997). 
There was no effect on DNA cell cycle during forty-eight hour incubation of honnone 
receptor positive breast cancer cells with physiological levels of 5a-dihydrotestosterone 
in this study. However, longterm incubations demonstrate that 5a-dihydrotestosterone 
inhibits basal proliferation of hormone receptor positive cells after 6 days incubation. 
A flow cytometric method for the determination of androgen receptor expression in 
breast cancer has been established in this study. The potential for flow cytometry to 
simultaneously measure several antigens on tumour samples suggests a clinical utility for 
flow cytometry in the management of breast cancer. The level of androgen receptor 
expression and the co-expression of androgen receptors with oestrogen receptors in breast 
cancer demonstrated in this study are in agreement with previous immunohistochemical 
studies (Kuenen-Boumeester et aL 1992) (Isola 1993). Androgen receptor expression was 
shown to increase with age. Serum androgen levels declined with increasing age in 
women with breast cancer. Negative autoregulation of steroid receptor levels by their 
ligands is thought to be the phenomenon common regulating steroid receptor levels in 
tissues. The negative correlation between senun DHEAS, androstenedione and tumour 
androgen receptor expression demonstrated in this study supports this concept. 
Crosstalk between steroid receptor and growth factor pathways has been demonstrated to 
occur in both breast and prostate cancer. A correlation between androgen receptor and 
epidermal growth factor receptor expression was investigated in the present study as 
indirect evidence of a functionally important interaction between these receptors in breast 
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cancer. Expression of androgen and epidermal growth factor receptors was positively 
correlated in breast cancer specimens. This supports the concept of a functionally 
important interaction between these receptors in breast cancer. However, further work in 
this area, to establish the role of the androgen receptor in breast cancer is now indicated. 
9.2 A lectin ELISA for cerbB-2 I HER-2 
Bustamam et al have established a lectin ELISA for the determination of cerbB-2/ HER-2 
in our laboratory (Bustamarn 1998). Only one cerbB-2 antibody was available at this 
time, therefore a lectin was used to detect captured cerbB-2 antigen in the assay. Results 
from applying this assay to the serum of women with breast cancer and controls, 
suggested the assay had value as a diagnostic test for breast cancer. Despite cerbB-2/ 
HER-2 being over-expressed/ amplified in only 25-30% of breast cancers (Slamon et al. 
1987) it was hypothesized that as the assay did not measure cerbB-2 protein levels, but 
the glycosylation of cerbB-2/HER-2, it would be worthwhile investigating a larger 
sample of patients. 
Preliminary experiments to establish the assay in vitro uncovered fundamental problems 
with the assay that precluded its use on serum samples collected from patients with breast 
cancer. As discussed in chapter 8 these problems may relate to lectins and the 
glycosylation of cerbB-2/BER-2. Lectins have specificity for sugar groups expressed by 
complex carbohydrates. They are therefore able to bind to glycoconjugates expressed by 
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non-specific proteins present in the serum or lysate, which inevitably bind to the sides of 
the well during incubation stages of the assay. In addition lectins may bind directly to the 
sides of the wells. This phenomenon has been reported by Rebeski et al, who concludes 
that non-specific binding of lectins to immunoassay plates could be a serious impediment 
to development of lectin ELISAs as diagnostic assays (Rebeski et aL 1999). 
On review of experiments performed by Bustarnam et al it is apparent that non-specific 
binding of lectins occurred during establishment of the cerbB-2/HER-2 lectin 
ELISA. This phenomenon certainly occurred in the course of the present study. This is 
demonstrated by the final experiment in chapter eight, which demonstrated that omission 
of the capture antibody from the lectin ELISA did not affect the response. 
Secondly, problems were encountered with the production of a standard with constant 
glycosylation. It is unknown how storage or tissue culture conditions affect the 
composition and structure of complex carbohydrates expressed on the surface of antigens 
such as cerbB-2/HER-2. As lectin-ELISAs measure the glycosylation of proteins, rather 
than the quantity of protein present, this presents considerable difficulties for the 
production of a reproducible standard against which the serum samples can be compared. 
Thompson et al reported that artificially ageing samples by repeated freeze-thaw cycles 
and the length of time samples were stored affected the analysis of glycoproteins by 
lectins; (Thompson et aL 1990). Although in the present study repeated freeze-thaw cycles 
were not shown to significantly affect the response of the cerbB-2 lectin ELISA, 
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differences in response of the cerbB-2 lectin ELISA between this study the pilot study 
may be attributed to the length of time the samples were stored. 
Finally, the extent and nature of the glycosylation of cerbB-2/BER-2 is not known. 
Further work in this field should be directed at establishing the glycosylation of cerbB-2 
by techniques discussed in the introduction to this thesis. 
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